



STIC Search Report

Biotech-Chem Library

223

STIC Database Tracking Number: 185029

TO: Rei-Tsang Shiao
Location: rem/5A10/5C18
Art Unit: 1626
May 4, 2006

Case Serial Number: 10/780415

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

FOR OFFICIAL USE ONLY

ACCESS DB # 185029
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Robert (Bob) Shin Examiner #: 7952 Date: 4/12/06
Art Unit: 1626 Phone Number: 2-0707 Serial Number: 10/782,415
Location (Bldg/Room#): R619 (Mailbox #): 5A107 Results Format Preferred (circle): PAPER DISK

15C18

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:


Title of Invention: Bryla Middelod

Inventors (please provide full names): Sun et al.

Earliest Priority Date: _____

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



STAFF USE ONLY		Type of Search	Vendors and cost where applicable	
Searcher:		<input type="checkbox"/> NA Sequence (#)	<input type="checkbox"/> STN	<input type="checkbox"/> Dialog
Searcher Phone #:		<input type="checkbox"/> AA Sequence (#)	<input type="checkbox"/> Questel/Orbit	<input type="checkbox"/> Lexis/Nexis
Searcher Location:		<input type="checkbox"/> Structure (#)	<input type="checkbox"/> Westlaw	<input type="checkbox"/> WWW/Internet
Date Searcher Picked Up:		<input type="checkbox"/> Bibliographic	<input type="checkbox"/> In-house sequence systems	
Date Completed:		<input type="checkbox"/> Litigation	<input type="checkbox"/> Commercial	<input type="checkbox"/> Oligomer
Searcher Prep & Review Time:		<input type="checkbox"/> Fulltext	<input type="checkbox"/> Interference	<input type="checkbox"/> Score/Length
Online Time:		<input type="checkbox"/> Other	<input type="checkbox"/> Other (specify)	<input type="checkbox"/> Encode/Transl

THIS PAGE BLANK (USPTO)

=> d his ful

(FILE 'HOME' ENTERED AT 14:42:47 ON 04 MAY 2006)

FILE 'REGISTRY' ENTERED AT 14:42:57 ON 04 MAY 2006

L1 STR
L3 3704 SEA SSS FUL L1
L5 STR
L6 2769 SEA SUB=L3 SSS FUL L5

FILE 'HCAPLUS' ENTERED AT 14:59:49 ON 04 MAY 2006

L7 420 SEA ABB=ON PLU=ON L6
L8 361 SEA ABB=ON PLU=ON L7 AND PD=<MAY 18, 2002
L9 10 SEA ABB=ON PLU=ON L7(L) (?MEDIC? OR ?THERP? OR ?DRUG? OR
?PHARM?)
L10 45 SEA ABB=ON PLU=ON L7 AND (?MEDIC? OR ?THERP? OR ?DRUG? OR
?PHARM?)
L11 24 SEA ABB=ON PLU=ON L8 AND L10

FILE 'REGISTRY' ENTERED AT 15:03:04 ON 04 MAY 2006

L12 101616 SEA ABB=ON PLU=ON ANDROGEN OR ANDROGENS OR RECEPTOR OR
RECEPTORS

FILE 'HCAPLUS' ENTERED AT 15:08:05 ON 04 MAY 2006

L13 1866083 SEA ABB=ON PLU=ON L12 OR ?ANDROGEN? OR ?RECEPTOR? OR
?MODULAT? OR REGULAT?
L14 34 SEA ABB=ON PLU=ON L7 AND L13
L15 17 SEA ABB=ON PLU=ON L8 AND L14
L16 35 SEA ABB=ON PLU=ON L11 OR L15
D STAT QUE
D IBIB ABS HITSTR L16 1-35
SELECT HIT RN L16 1-35
L21 204 SEA ABB=ON PLU=ON SUN C/AU OR "SUN CHONG"/AU OR ("SUN CHONG
OING"/AU OR "SUN CHONG QING"/AU)
L22 73 SEA ABB=ON PLU=ON ("HAMANN L"/AU OR "HAMANN LAWERENCE G"/AU
OR "HAMANN LAWRENCE"/AU OR "HAMANN LAWRENCE G"/AU OR "HAMANN
LAWRENCE GERARD"/AU OR "HAMANN LAWRENCE H"/AU)
L23 43 SEA ABB=ON PLU=ON ("AUGERI DAVID"/AU OR "AUGERI DAVID J"/AU
OR "AUGERI DAVID JOHN"/AU)
L24 65 SEA ABB=ON PLU=ON BI Y ?/AU OR "BI YINGZHI"/AU
L25 90 SEA ABB=ON PLU=ON "ROBL J A"/AU OR ("ROBL JEFF"/AU OR "ROBL
JEFF A"/AU OR "ROBL JEFFREY"/AU OR "ROBL JEFFREY A"/AU OR
"ROBL JEFFREY ADAM"/AU)
L26 1397 SEA ABB=ON PLU=ON "HUANG YAN"/AU OR "HUANG YAN TING"/AU OR
HUANG Y/AU OR HUANG Y T?/AU
L27 787 SEA ABB=ON PLU=ON ("WANG TAMMY"/AU OR "WANG TAMMY C"/AU) OR
WANG T/AU OR WANG T C?/AU
L28 14 SEA ABB=ON PLU=ON ("HOLUBEC A"/AU OR "HOLUBEC ALEX"/AU OR
"HOLUBEC ALEXANDRA"/AU OR "HOLUBEC ALEXANDRA A"/AU OR "HOLUBEC
ALEXANDRA ANASTASIA"/AU OR "HOLUBEC ALEXEJ"/AU)
L29 27 SEA ABB=ON PLU=ON ("SIMPKINS L M"/AU OR "SIMPKINS LIGAYA"/AU
OR "SIMPKINS LIGAYA M"/AU)
L30 121 SEA ABB=ON PLU=ON "SUTTON J"/AU OR ("SUTTON J C"/AU OR
"SUTTON J CARL"/AU OR "SUTTON J CURTIS"/AU) OR "SUTTON
JAMES"/AU OR ("SUTTON JAMES C"/AU OR "SUTTON JAMES C JR"/AU OR
"SUTTON JAMES CLIFFORD JR"/AU)
L31 2508 SEA ABB=ON PLU=ON "LI JAMES"/AU OR "LI JAMES J"/AU OR LI
J/AU OR LI J J?/AU
L32 1 SEA ABB=ON PLU=ON (L21 AND L22 AND L23 AND L24 AND L25 AND
L26 AND L27 AND L28 AND L29 AND L30 AND L31) NOT L16

THIS PAGE BLANK (USPTO)

Shiao 10_780415-- History

L33 15 SEA ABB=ON PLU=ON (L21 AND (L22 OR L23 OR L24 OR L25 OR L26
OR L27 OR L28 OR L29 OR L30 OR L31)) NOT L16
L34 22 SEA ABB=ON PLU=ON (L22 AND (L23 OR L24 OR L25 OR L26 OR L27
OR L28 OR L29 OR L30 OR L31)) NOT L16
L35 10 SEA ABB=ON PLU=ON (L23 AND (L24 OR L25 OR L26 OR L27 OR L28
OR L29 OR L30 OR L31)) NOT L16
L36 7 SEA ABB=ON PLU=ON (L24 AND (L25 OR L26 OR L27 OR L28 OR L29
OR L30 OR L31)) NOT L16
L37 27 SEA ABB=ON PLU=ON (L25 AND (L26 OR L27 OR L28 OR L29 OR L30
OR L31)) NOT L16
L38 97 SEA ABB=ON PLU=ON (L26 AND (L27 OR L28 OR L29 OR L30 OR
L31)) NOT L16
L39 10 SEA ABB=ON PLU=ON (L27 AND (L28 OR L29 OR L30 OR L31)) NOT
L16
L40 2 SEA ABB=ON PLU=ON (L28 AND (L29 OR L30 OR L31)) NOT L16
L41 3 SEA ABB=ON PLU=ON (L29 AND (L30 OR L31)) NOT L16
L42 2 SEA ABB=ON PLU=ON (L29 AND L31) NOT L16
L43 52 SEA ABB=ON PLU=ON L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR
L39 OR L40 OR L41 OR L42
D STAT QUE L43
D IBIB ABS HITSTR L43 1-52

FILE 'REGISTRY' ENTERED AT 15:54:51 ON 04 MAY 2006

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2006 HIGHEST RN 882736-15-4
DICTIONARY FILE UPDATES: 3 MAY 2006 HIGHEST RN 882736-15-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCPLUS

THIS PAGE BLANK (USPTO)

Shiao 10_780415-- History

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 4 May 2006 VOL 144 ISS 19
FILE LAST UPDATED: 3 May 2006 (20060503/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

THIS PAGE BLANK (USPTO)

C~G3
@10 11O=C~O
12 @13 14O=C~C
15 @16 17C~O
@18 19Ak~C~G5
20 @21 22CH~G5
@23 24C~O~C~O~C
25 26 @27 28 29CH~G7
@30 31C=G8
@32 33

REP G1=(1-2) C
 VAR G2=CH/10
 VAR G3=AK/CB/13/16/18
 VAR G4=CH2/21/23/27
 VAR G5=AK/O/S/X/N
 VAR G6=CH2/30/32
 VAR G7=AK/CY
 VAR G8=O/S/N/C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

L6	2769 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L7	420 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
L8	361 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND PD=<MAY 18, 2002
L10	45 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (?MEDIC? OR ?THERP? OR ?DRUG? OR ?PHARM?)
L11	24 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 AND L10
L12	101616 SEA FILE=REGISTRY ABB=ON PLU=ON ANDROGEN OR ANDROGENS OR RECEPTOR OR RECEPTORS
L13	1866083 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 OR ?ANDROGEN? OR ?RECEPTOR? OR ?MODULAT? OR REGULAT?
L14	34 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND L13
L15	17 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 AND L14
L16	35 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 OR L15

=>
 =>

=> d ibib abs hitstr l16 1-35

L16 ANSWER 1 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:90045 HCAPLUS
 DOCUMENT NUMBER: 136:151436
 TITLE: Preparation of combinatorial libraries of N-arylsulfonyl-N-diazadioxobicyclooctyl amino acid

Shiao 10_780415

=> fil hcplus
FILE 'HCAPLUS' ENTERED AT 15:08:05 ON 04 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 4 May 2006 VOL 144 ISS 19
FILE LAST UPDATED: 3 May 2006 (20060503/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
=>

=> d stat que
L1 STR



REP G1=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L3 3704 SEA FILE=REGISTRY SSS FUL L1
L5 STR

amides as **drugs**
INVENTOR(S) : Lu, Shao-Po; Hebert; R. Normand
PATENT ASSIGNEE(S) : Lion Bioscience A.-G., Germany
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008227	A2	20020131	WO 2001-EP8322	20010718 <--
WO 2002008227	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2416654	AA	20020131	CA 2001-2416654	20010718 <--
EP 1301512	A2	20030416	EP 2001-960516	20010718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-621177 A 20000721
WO 2001-EP8322 W 20010718

OTHER SOURCE(S) : CASREACT 136:151436; MARPAT 136:151436
AB RZN(SO2R1)CHR2CONH₂ [I; R = (un)substituted Ph or CH₂Ph; R₁ =
2-methoxycarbonyl-3-thienyl, substituted Ph, etc.; R₂ = amino acid side
chain; Z = 1,3-diaza-2,4-dioxobicyclo[3.3.0]octane-3,6-diyl] were prepared
Data for antibacterial activity of I were given.


IT 393876-35-2P 393876-37-4P 393876-38-5P
393876-39-6P 393876-40-9P 393876-41-0P
393876-42-1P 393876-43-2P 393876-44-3P
393876-45-4P 393876-46-5P 393876-47-6P
393876-48-7P 393876-50-1P 393876-51-2P
393876-52-3P 393876-53-4P 393876-54-5P
393876-55-6P 393876-56-7P 393876-57-8P
393876-58-9P 393876-59-0P 393876-61-4P
393876-62-5P 393876-63-6P 393876-65-8P
393876-66-9P 393876-67-0P 393876-68-1P
393876-69-2P 393876-70-5P 393876-71-6P
393876-72-7P 393876-73-8P 393876-74-9P
393876-75-0P 393876-76-1P 393876-77-2P
393876-79-4P 393876-80-7P 393876-81-8P
393876-82-9P 393876-83-0P 393876-84-1P
393876-85-2P 393876-86-3P 393876-87-4P
393876-88-5P 393876-89-6P 393876-90-9P
393876-91-0P 393876-92-1P 393876-93-2P
393876-94-3P 393876-95-4P 393876-96-5P
393876-97-6P 393876-99-8P 393877-00-4P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study);
PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of N-arylsulfonyl-N-
diazadioxobicyclooctyl amino acid amides as **drugs**)

RN 393876-35-2 HCPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-37-4 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-38-5 HCAPLUS

CN Butanamide, 2-[[[(6S,7aS)-2-(3,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-39-6 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1*S*)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6*S*,7*a**S*)-hexahydro-1,3-dioxo-2-phenyl-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-40-9 HCAPLUS

CN Butanamide, 2-[(6*S*,7*a**S*)-hexahydro-2-(2-methoxyphenyl)-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-3-methyl-, (2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-41-0 HCPLUS

CN Propanamide, 2-[(6S,7aS)-hexahydro-2-(3-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-42-1 HCPLUS

CN Propanamide, 2-[(2,4-difluorophenyl)sulfonyl][(6S,7aS)-2-(2-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393876-43-2 HCPLUS

CN Butanamide, 2-[(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-

pyrrolo[1,2-c]imidazol-6-yl] [(3-fluorophenyl)sulfonyl]amino]-3-methyl-,
(2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-44-3 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-chlorophenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-45-4 HCAPLUS

CN Butanamide, 2-[(6S,7aS)-hexahydro-2-[(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-46-5 HCPLUS

CN 1H-Imidazole-4-propanamide, α -[[$(6S,7aS)$ -2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-47-6 HCPLUS

CN Cyclohexanepropanamide, α -[[$(3\text{-fluorophenyl})\text{sulfonyl}$] [$(6S,7aS)$ -hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-48-7 HCAPLUS

CN Pentanamide, 2-[(4-bromophenyl)sulfonyl][(6*S*,7*a**S*)-hexahydro-1,3-dioxo-2-(2,4,5-trimethylphenyl)-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl]amino]-4-methyl-, (2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-50-1 HCAPLUS

CN Pentanamide, 2-[(6*S*,7*a**S*)-2-(2-chlorophenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl][(2-fluorophenyl)sulfonyl]amino]-4-methyl-, (2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-51-2 HCAPLUS

CN Propanamide, 2-[(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-52-3 HCAPLUS

CN Butanamide, 2-[(3-fluorophenyl)sulfonyl][(6S,7aS)-hexahydro-1,3-dioxo-2-(2,4,5-trimethylphenyl)-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-53-4 HCAPLUS

CN Pentanamide, 2-[(4-bromophenyl)sulfonyl][(6S,7aS)-hexahydro-2-(3-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-54-5 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1*S*)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6*S*,7*aS*)-hexahydro-2-(4-methylphenyl)-1,3-dioxo-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-55-6 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1*S*)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6*S*,7*aS*)-hexahydro-2-(3-methylphenyl)-1,3-dioxo-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-56-7 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-57-8 HCAPLUS

CN 1H-Imidazole-4-propanamide, α-[[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-58-9 HCAPLUS

CN Propanamide, 2-[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(2,4-dichlorophenyl)sulfonyl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-59-0 HCAPLUS

CN Butanamide, 2-[(6S,7aS)-hexahydro-2-(3-methoxyphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][4-(trifluoromethyl)phenylsulfonyl]amino]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-61-4 HCAPLUS

CN Benzenepropanamide, α -[(*6S,7aS*)-hexahydro-1,3-dioxo-2-(2,4,5-trimethylphenyl)-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl] [[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-62-5 HCAPLUS

CN Cyclohexanepropanamide, α -[(6S,7aS)-2-(2-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-63-6 HCPLUS

CN Butanamide, 2-[(3-fluorophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[4-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-65-8 HCPLUS

CN 1H-Imidazole-4-propanamide, α-[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-66-9 HCAPLUS

CN Propanamide, 2-[[[(2,4-dichlorophenyl)sulfonyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-67-0 HCAPLUS

CN 1H-Imidazole-4-propanamide, α -[[[(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-68-1 HCAPLUS

CN Cyclohexanepropanamide, α -[(6*S*,7*aS*)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (*αS*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-69-2 HCAPLUS

CN Pentanamide, 2-[(2-cyanophenyl)sulfonyl][(6*S*,7*aS*)-hexahydro-2-(2-methoxy-5-methylphenyl)-1,3-dioxo-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl]amino]-4-methyl-, (2*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-70-5 HCAPLUS

CN Propanamide, 2-[(6S,7aS)-hexahydro-2-[4-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-71-6 HCAPLUS

CN Butanamide, 2-[(2-bromophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[2-methyl-6-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-72-7 HCAPLUS

CN Benzene propanamide, 4-chloro- α -[(4-chlorophenyl)sulfonyl][(6S,7aS)-2-(4-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-73-8 HCAPLUS

CN Propanamide, 2-[(6S,7aS)-hexahydro-2-(4-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-74-9 HCAPLUS

CN Pentanamide, 2-[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-75-0 HCAPLUS

CN Cyclohexanepropanamide, α -[[[4-bromophenyl)sulfonyl][(6*S*,7*aS*)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-76-1 HCAPLUS

CN 1*H*-Imidazole-4-propanamide, α -[[[(6*S*,7*aS*)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl][(4-fluorophenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-77-2 HCAPLUS

CN Butanamide, 2-[[[(6S,7aS)-2-(5-fluoro-2-methylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-79-4 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-80-7 HCPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-81-8 HCPLUS

CN Benzenepropanamide, α -[(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-82-9 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-83-0 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-2-(3-chlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-84-1 HCAPLUS

CN 1H-Imidazole-4-propanamide, α -[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-85-2 HCPLUS

CN 1H-Imidazole-4-propanamide, α -[[[(6S, 7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-86-3 HCPLUS

CN Propanamide, 2-[[[(6S, 7aS)-2-(2,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-87-4 HCPLUS

CN Propanamide, 2-[(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(2,4-dichlorophenyl)sulfonyl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-88-5 HCPLUS

CN Pentanamide, 2-[(6S,7aS)-hexahydro-2-(4-methoxyphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-89-6 HCAPLUS

CN Cyclohexanepropanamide, α -[[$(6S,7aS)$ -2-(3,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-90-9 HCAPLUS

CN Benzenepropanamide, α -[[$(6S,7aS)$ -2-(5-fluoro-2-methylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-(trifluoromethyl)phenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-91-0 HCAPLUS

CN Benzenepropanamide, α -[[[(6S,7aS)-2-(2,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-92-1 HCAPLUS

CN Cyclohexanepropanamide, α -[[[(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-93-2 HCAPLUS

CN Benzenepropanamide, α -[[[(6S,7aS)-2-[4-(dimethylamino)phenyl]hexahydro-
o-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-
(trifluoromethyl)phenyl]sulfonyl]amino]-, (α S)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 393876-94-3 HCAPLUS

CN 2-Thiophencarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-
2-oxoethyl][(6S,7aS)-hexahydro-2-[4-(1-methylethyl)phenyl]-1,3-dioxo-1H-
pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 393876-95-4 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,6-difluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-96-5 HCAPLUS

CN 1H-Imidazole-4-propanamide, α-[[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3,4-difluorophenyl)sulfonyl]amino]-, (αS)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-97-6 HCAPLUS

CN 1H-Imidazole-4-propanamide, α -[[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393876-99-8 HCAPLUS

CN Pentanamide, 2-[[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393877-00-4 HCPLUS

CN Cyclohexanepropanamide, α -[[[(3-fluorophenyl)sulfonyl][(6*S*,7*aS*)-hexahydro-2-[2-methyl-6-(1-methylethyl)phenyl]-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:26966 HCPLUS

DOCUMENT NUMBER: 136:290459

TITLE: New synergistic and selective herbicide compositions

AUTHOR(S): Anon.

CORPORATE SOURCE: UK

SOURCE: Research Disclosure (2001), 452 (Dec.), P2044
(No. 452061)

CODEN: RSDBB; ISSN: 0374-4353

PUBLISHER: Kenneth Mason Publications Ltd.

DOCUMENT TYPE: Journal; Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RD 452061		20011210		

PRIORITY APPLN. INFO.: RD 2001-452061 20011210
 AB New herbicidal compns. have been found which are suitable for controlling a broad range of weeds in cultures of useful plants, in particular wheat or corn. Both monocot and dicot weeds may be controlled with the use of these compns. The compns. are suitable for use on both unmodified crops and those that are either naturally herbicide tolerant or have been modified to be tolerant to one or both of the herbicides in the compns. The compns. contain, beside standard formulation materials such as diluents, surfactants or adjuvants, a mixture of active ingredients comprising (1) 2-(2'-nitro-4'-methylsulfonylbenzoyl)-1,3-cyclohexane dione (mesotrione) and (2) a herbicidally effective amount of at least one further co-herbicide selected from the group consisting of bromoxynil, fluthiacet-Me, EPTC, halosulfuron-Me, clopyralid, diflufenzoxypr, flumiclorac-pentyl, 2,4-D, bentazone, carfentrazone-Et, fluroxypyr, isoxaflutole, isoxachlortole, metosulam, sethoxydim, sulfentrazone, thifensulfuron-Me, cyanazine, fentrazamide, MCPA, MCPB, MCPP, mecoprop, metobenzuron, pethoxamid, profluazol and sulcotrione, isoxaflutole. The compns. can be used in a method for selectively controlling broadleaf weeds in useful plant cultures, in particular wheat or corn, which method comprises treating the useful plants, their seeds or a locus thereof at the same time or successively with mesotrione and the co-herbicide listed - above. The application rate is usually between 0.001 to 2.0 kg/ha of mesotrione, preferably from 0.005 to 1 kg/ha, and between 0.001 to 2.0 kg/ha of coherbicide, preferably 0.005 to 1 kg/ha. For application to the crops, the compns. of mesotrione with the co-herbicides may be applied together with the additives in formulations such as emulsion concs., brushable pastes, directly sprayable or dilutable solns., diluted emulsions, wettable powders, soluble powders, dusts, granules, or capsules. The compns. may also contain further additives such as stabilizers, antifoaming agents, viscosity modulators, as well as a safener, a further herbicide, a fungicide or an insecticide, or fertilizers or other active substances for achievement of special effects.

IT 406921-77-5, Mesotrione-profluazol mixture

RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
 (synergistic and selective herbicide compns. containing)

RN 406921-77-5 HCPLUS


CN Methanesulfonamide, 1-chloro-N-[2-chloro-4-fluoro-5-[(6S,7aR)-6-fluorotetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]phenyl]-, mixt. with 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione (9CI) (CA INDEX NAME)

CM 1


CRN 190314-43-3

CMF C13 H11 Cl2 F2 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 104206-82-8
CMF C14 H13 N 07 S

L16 ANSWER 3 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:12287 HCPLUS
 DOCUMENT NUMBER: 136:226294
 TITLE: Plasma **pharmacokinetics** and tissue distribution of a N-pyrrolo-[1,2-C]imidazolylphenyl sulfonamide in rats
 AUTHOR(S): Moghaddam, Mehran F.; Bogdanffy, Matthew S.; Brown, Alethia; Ford, Kim; Shalaby, Lamaat
 CORPORATE SOURCE: Nutrition and Health, DuPont, Newark, DE, USA
 SOURCE: Drug Metabolism and Disposition (2002), 30(1), 47-54
 CODEN: DMDSAI; ISSN: 0090-9556
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB TY029, an N-pyrrolo[1,2-c]imidazolylphenyl sulfonamide herbicide, controls economically important weeds through inhibition of protoporphyrinogen oxygenase. As partial satisfaction of **regulatory** requirements to establish safety and to aid in the interpretation of toxicol. bioassays, a rat metabolism study of TY029 was performed to define the **pharmacokinetics** and tissue distribution of this compound. Animals were exposed to single 50- and 2-mg/kg doses of [hydantoin-5-14C]TY029 by oral gavage. The tissue distribution studies revealed that generally greater than 5% of the oral dose was found in the carcass,

gastrointestinal tract, liver, and the whole blood when plasma microgram equivalent per g of TY029 was at maximum or at half of the maximum. However, these

concns. rapidly declined to negligible levels. By 96 h after the oral administration of [hydantoin-5-14C]TY029, the highest value reported for any one of the collected tissues was below 0.5% of administered dose. Therefore, neither TY029 nor its metabolites was sequestered in tissues to appreciable levels. The Cmax, Cmax/2, and area under the curve (AUCINF) obtained from the plasma **pharmacokinetics** suggested that in general single-dosed female rats absorbed and eliminated the test compds. faster than their male counterparts. Mass spectral evaluations of the plasma from single high- and low-dose male and female rats identified the plasma constituents related to the test compound. Although the parent mol. was present in all plasma samples, the three acidic metabolites were the predominant plasma metabolites in the high-dose groups. The overall plasma profile included TY029 and six metabolites.


IT 190314-68-2

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(plasma **pharmacokinetics** and tissue distribution of TY029 in rats)

RN 190314-68-2 HCAPLUS

CN Methanesulfonamide, 1-chloro-N-[2-chloro-4-fluoro-5-[(6S,7aS)-6-fluorotetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]phenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 190314-43-3, TY029

RL: PKT (Pharmacokinetics); BIOL (Biological study)
(plasma **pharmacokinetics** and tissue distribution of TY029 in rats)

RN 190314-43-3 HCAPLUS

CN Methanesulfonamide, 1-chloro-N-[2-chloro-4-fluoro-5-[(6S,7aR)-6-fluorotetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]phenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:10472 HCAPLUS

DOCUMENT NUMBER: 136:85827

TITLE: Preparation of methanoimidazopyridinones, methanoimidazopyrazinones, related compounds as modulators of nuclear hormone receptor function.

INVENTOR(S): Salvati, Mark E.; Balog, James Aaron; Shan, Weifang; Giese, Soren

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 228 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000653	A2	20020103	WO 2001-US19663	20010620 <--
WO 2002000653	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413683	AA	20020103	CA 2001-2413683	20010620 <--
EP 1299385	A2	20030409	EP 2001-984054	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011869	A	20030923	BR 2001-11869	20010620
JP 2004515462	T2	20040527	JP 2002-505777	20010620
TR 200202702	T2	20041221	TR 2002-200202702	20010620
NZ 523802	A	20051125	NZ 2001-523802	20010620
NO 2002006167	A	20021220	NO 2002-6167	20021220
US 2005256048	A1	20051117	US 2005-130935	20050517

PRIORITY APPLN. INFO.:

US 2000-214392P	P 20000628
US 2001-284438P	P 20010418
US 2001-284617P	P 20010418
US 2000-233519P	P 20000919
US 2001-284730P	P 20010418
US 2001-885827	A3 20010620
WO 2001-US19663	W 20010620

OTHER SOURCE(S):
GI

CASREACT 136:85827; MARPAT 136:85827



AB Title compds. [I; G = (substituted) aryl, heterocyclyl; E = C:Z2, CR7CR71, SO2, P:OR2, P:OOR2; Z1, Z2 = O, S, NH, NR6; A1, A2 = CR7, N; Y = JJ1J2; J = (CR7R7)n; n = 0-3; J1 = bond, O, S, SO, SO2, NH, NR6, CO, O2C, NR1C:O, CR7R71, C:CR1R8, R2P:O, OPO2, OSO2, C:N, NHNH, NHNR6, NR6NH, N:N, (substituted) cycloalkyl, cycloalkenyl, heterocyclyl, aryl; J2 = (CR7R71)n; n = 0-3; Y is not a bond; W = CR7R71CR7R71, CRS:CR8, CR7R7CO, NR9CR7R7, N:CR8, N:N, NR9R91, (substituted) cycloalkyl, cycloalkenyl, heterocyclyl, aryl; Q = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, arylalkyl, alkynyl, aryl, heterocyclyl, halo, CN, R10CO, R4CO, R5R6NC, HOCR7R71, NO2, R10CH2, R10, NH2, C:OSR1, SO2R1, NR4R5; M = bond, O, CR7R71, NR10; M1 = bond, NR10; ≥1 of M, M1 must = bond; L = bond, (CR7R71)n, NH, NR5, N(CR7R71)n; R1 = H, R2; R2 = (substituted) alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, cycloalkylalkyl, cycloalkenylalkyl, heterocycloalkyl, aryl, arylalkyl; R3 = R1, halo, cyano, etc.; R4 = R1, R1CO, R1NHCO etc.; R5 = R2, R1CO, R1NHCO, etc.; R6 = R2, CN, OH, OR1, R1CO, R1NHCO, etc.; R7, R71 = R1, halo, CN, nitro, amino, alkylthio, etc.; R8, R81 = R1, nitro, halo, CN, amino, alkylthio, etc.; R9, R91 = R1, CN, OH, etc.; R10 = CN, OH, OR1, R1CO, etc.] with provisos, were prepared as **drugs** (no data). Thus, 2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid Et ester in toluene was treated with 3-(trifluoromethylphenyl)isocyanate followed by heating at 70 °C for 3 h to give the urea derivative which was heated at 80° with DBU in PhMe to give (5α,8α,8aα)-8,8a-dihydro-2-[3-(trifluoromethyl)phenyl]-5,8-methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione.


IT 385440-94-8P 385806-72-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of methanoimidazopyridinones, methanoimidazopyrazinones, and related compds. as **modulators** of nuclear hormone **receptor** function)

RN 385440-94-8 HCPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5S,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-72-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, hexahydro-3-thioxo-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 385440-10-8P 385440-11-9P 385440-33-5P
 385440-34-6P 385440-35-7P 385440-36-8P
 385440-37-9P 385440-38-0P 385440-39-1P
 385440-77-7P 385440-78-8P 385806-32-6P
 385806-34-8P 385806-35-9P 385806-36-0P
 385806-37-1P 385806-38-2P 385806-39-3P
 385806-40-6P 385806-41-7P 385806-42-8P
 385806-43-9P 385806-44-0P 385806-45-1P
 385806-46-2P 385806-47-3P 385806-48-4P
 385806-49-5P 385806-50-8P 385806-51-9P
 385806-53-1P 385806-54-2P 385806-55-3P
 385806-56-4P 385806-57-5P 385806-58-6P
 385806-59-7P 385806-60-0P 385806-61-1P
 385806-62-2P 385806-63-3P 385806-64-4P
 385806-65-5P 385806-66-6P 385806-67-7P
 385806-68-8P 385806-69-9P 385806-70-2P
 385806-71-3P 385806-73-5P 385806-74-6P
 385806-75-7P 385806-76-8P 385806-77-9P
 385806-78-0P 385806-79-1P 385806-80-4P
 385806-81-5P 385806-82-6P 385806-83-7P
 385806-84-8P 385806-85-9P 385806-86-0P
 385806-87-1P 385806-88-2P 385806-89-3P
 385806-90-6P 385806-91-7P 385806-92-8P
 385806-93-9P 385806-94-0P 385806-95-1P

385806-96-2P 385806-97-3P 385806-98-4P
 385806-99-5P 385807-00-1P 385807-01-2P
 385807-02-3P 385807-03-4P 385807-04-5P
 385807-05-6P 385807-06-7P 385807-07-8P
 385807-08-9P 385807-09-0P 385807-10-3P
 385807-11-4P 385807-12-5P 385807-13-6P
 385807-14-7P 385807-15-8P 385807-16-9P
 385807-17-0P 385807-18-1P 385807-19-2P
 385807-20-5P 385807-21-6P 385807-22-7P
 385807-23-8P 385807-25-0P 385807-26-1P
 385807-27-2P 385807-28-3P 385807-29-4P
 385807-30-7P 385807-31-8P 385807-32-9P
 385807-33-0P 385807-34-1P 385807-35-2P
 385807-36-3P 385807-37-4P 385807-38-5P
 385807-39-6P 385807-40-9P 385807-41-0P
 385807-42-1P 385807-43-2P 385807-44-3P
 385807-45-4P 385807-46-5P 385807-47-6P
 385807-48-7P 385807-49-8P 385807-50-1P
 385807-51-2P 385807-52-3P 385807-53-4P
 385807-54-5P 385807-55-6P 385807-56-7P
 385807-57-8P 385807-58-9P 385807-59-0P
 385807-60-3P 385807-61-4P 385807-62-5P
 385807-63-6P 385807-64-7P 385807-65-8P
 385807-66-9P 385807-67-0P 385807-68-1P
 385807-69-2P 385807-70-5P 385807-71-6P
 385807-72-7P 385807-73-8P 385807-74-9P
 385807-75-0P 385807-76-1P 385807-77-2P
 385807-78-3P 385807-79-4P 385807-80-7P
 385807-81-8P 385807-82-9P 385807-83-0P
 385807-84-1P 385807-85-2P 385807-86-3P
 385807-87-4P 385807-88-5P 385807-89-6P
 385807-90-9P 385807-91-0P 385807-92-1P
 385807-93-2P 385807-94-3P 385807-95-4P
 385807-96-5P 385807-97-6P 385807-98-7P
 385807-99-8P 385808-00-4P 385808-01-5P
 385808-02-6P 385808-03-7P 385808-04-8P
 385808-05-9P 385808-06-0P 385808-07-1P
 385808-08-2P 385808-09-3P 385808-10-6P
 385808-11-7P 385808-12-8P 385808-13-9P
 385808-14-0P 385808-15-1P 385808-16-2P
 385808-17-3P 385808-18-4P 385808-19-5P
 385808-20-8P 385808-21-9P 385808-22-0P
 385808-23-1P 385808-24-2P 385808-25-3P
 385808-27-5P 385808-28-6P 385808-29-7P
 385808-30-0P 385808-31-1P 385808-32-2P
 385808-33-3P 385808-34-4P 385808-35-5P
 385808-36-6P 385808-37-7P 385808-38-8P
 385808-39-9P 385808-40-2P 385810-12-8P
385810-13-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of methanoimidazopyridinones, methanoimidazopyrazinones, and related compds. as modulators of nuclear hormone receptor function)

RN 385440-10-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-butylbenzoyl)tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 385440-11-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 4-fluorophenyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-33-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-,
1,1-dimethylethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-34-6 HCAPLUS

CN Benzonitrile, 4-[(5S,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-35-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-fluorobenzoyl)tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-36-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)tetrahydro-7-(5-isoxazolylcarbonyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-37-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-, 4-fluorophenyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-38-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)tetrahydro-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-39-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-1-naphthalenyl)-N-(4-fluorophenyl)hexahydro-1,3-dioxo-, (5S,8S,8aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 385440-77-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-78-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 1,1-dimethylethyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-32-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-34-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(1-naphthalenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-35-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, 2,3,8,8a-tetrahydro-3-thioxo-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-36-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-8a-methyl-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 385806-37-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, 2,3,8,8a-tetrahydro-8a-methyl-3-thioxo-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 385806-38-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-39-3 HCAPLUS


CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 385806-40-6 HCAPLUS


CN 5,8-Ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 385806-41-7 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-42-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-43-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(2-naphthalenyl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-44-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(2-naphthalenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 385806-45-1 HCAPLUS

CN Cyanamide, [(5R,8S,8aR)-2-(3,4-dichlorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 385806-46-2 HCAPLUS

CN Cyanamide, [(5R,8S,8aS)-2-(3,4-dichlorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 385806-47-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 385806-48-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(2-naphthalenyl)-3-(phenylimino)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 385806-49-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-50-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-51-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-53-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(1H-indol-3-yl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-54-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(1H-indol-3-yl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-55-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-benzo[b]thien-3-yl-, 8,8a-dihydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-56-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(1,2-benzisoxazol-3-yl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-57-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(1,2-benzisoxazol-3-yl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-58-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, 2,3,8,8a-tetrahydro-2-(1-naphthalenyl)-3-thioxo-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-59-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[3,5-bis(trifluoromethyl)phenyl]-8,8a-dihydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-60-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(2-naphthalenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-61-1 HCAPLUS


CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)-8,8a-dihydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 385806-62-2 HCAPLUS


CN 5,8-Ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 385806-63-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-bromo-1-naphthalenyl)-8,8a-dihydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-64-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-65-5 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]-, (5S,8R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-66-6 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-, (5R,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-67-7 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-, (5S,8R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-68-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-bromo-1-naphthalenyl)tetrahydro-, (5R,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-69-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-bromo-1-naphthalenyl)tetrahydro-, (5S,8R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385806-70-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-71-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-73-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, hexahydro-3-thioxo-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-74-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(1-naphthalenyl)-3-thioxo-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-75-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-8a-methyl-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-76-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-77-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-8a-(2-propenyl)-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-78-0 HCPLUS


CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-8a-(phenylmethyl)-2-[3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 385806-79-1 HCPLUS

CN Cyanamide, (hexahydro-1-oxo-2-phenyl-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene)- (9CI) (CA INDEX NAME)




RN 385806-80-4 HCPLUS

CN Cyanamide, [(5R,8S,8aS)-2-(3-chloro-4-fluorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 385806-81-5 HCPLUS

CN Cyanamide, [(5R,8S,8aR)-2-(3-chloro-4-fluorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 385806-82-6 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chlorophenyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-83-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chlorophenyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 385806-84-8 HCAPLUS

CN Cyanamide, [(5R,8S,8aS)-2-(3-chlorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 385806-85-9 HCAPLUS

CN Cyanamide, [(5R,8S,8aR)-2-(3-chlorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 385806-86-0 HCAPLUS

CN Cyanamide, [(5R,8S,8aS)-2-(3,5-dichlorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 385806-87-1 HCAPLUS

CN Cyanamide, [(5R,8S,8aR)-2-(3,5-dichlorophenyl)hexahydro-1-oxo-5,8-methanoimidazo[1,5-a]pyridin-3(2H)-ylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 385806-88-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chloro-4-fluorophenyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-89-3 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chloro-4-fluorophenyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-90-6 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-91-7 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-92-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chloro-4-fluorophenyl)-8,8a-dihydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-93-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chloro-4-fluorophenyl)-8,8a-dihydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-94-0 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-95-1 HCPLUS

CN Benzonitrile, 4-[(5R,8S,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-96-2 HCPLUS

CN Benzonitrile, 4-[(5R,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-97-3 HCPLUS

CN Benzonitrile, 4-[(5R,8S,8aS)-1,5,8,8a-tetrahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-98-4 HCAPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5R,8S,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385806-99-5 HCAPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5R,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-00-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-01-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-02-3 HCPLUS

CN Benzonitrile, 4-[(5R,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-03-4 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-, (5S,8R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385807-04-5 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-nitro-

Shiao 10_780415

3-(trifluoromethyl)phenyl]-, (5S,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-05-6 HCPLUS

CN Benzonitrile, 4-[(5S,8R,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-06-7 HCPLUS

CN Benzonitrile, 4-[(5S,8R,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385807-07-8 HCPLUS

CN Benzonitrile, 4-[(5R,8S,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-

a]pyridin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-08-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-, (5R,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-09-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3-chlorophenyl)-8,8a-dihydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-10-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]-, (5S,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-11-4 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(4-nitro-1-naphthalenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-12-5 HCPLUS

CN 1-Naphthalene carbonitrile, 4-[(5R,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-13-6 HCPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5R,8S,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-14-7 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(1-naphthalenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-15-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(1-naphthalenyl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-16-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-fluoro-1-naphthalenyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-17-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-fluoro-1-naphthalenyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-18-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-1-naphthalenyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-19-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-1-naphthalenyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-20-5 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-(1-oxidobenzo[b]thien-3-yl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-21-6 HCPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5R,8S,8aS)-1,5,8,8a-tetrahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyridin-2(3H)-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-22-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8,8a-dihydro-2-[4-(1H-tetrazol-5-yl)-1-naphthalenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-23-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-25-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester, (5R,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-26-1 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-,
1,1-dimethylethyl ester, (5R,8R,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-27-2 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[(4-fluorophenyl)sulfonyl]tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-28-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(7-fluoro-3-benzofuranyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-29-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(7-fluoro-3-benzofuranyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-30-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-8a-methyl-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-31-8 HCAPLUS

CN Benzonitrile, 4-[(5S,8S,8aR)-hexahydro-8a-methyl-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-32-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-benzoyl-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-8a-methyl-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-33-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-benzoyltetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-34-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 1,1-dimethylethyl ester,
(5R,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-35-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-36-3 HCPLUS

CN Benzonitrile, 4-[(5R,8R,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-37-4 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-benzoyl-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385807-38-5 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,

2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, phenylmethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-39-6 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(2-methyl-4-nitrophenyl)-, (5S,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-40-9 HCPLUS

CN Benzonitrile, 4-[(5S,8S,8aR)-hexahydro-7-methyl-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385807-41-0 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,

Shiao 10_780415

hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, phenylmethyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-42-1 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(3-methyl-4-nitrophenyl)-, (5S,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-43-2 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-7-methyl-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-44-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-(2-propenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-45-4 HCAPLUS

CN Benzonitrile, 4-[(5S,8S,8aR)-hexahydro-1,3-dioxo-7-(phenylmethyl)-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-46-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-(2-propenyl)-, (5R,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-47-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[{(4-fluorophenyl)sulfonyl}tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-48-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-benzoyltetrahydro-2-(4-nitro-1-naphthalenyl)-, (5R,8R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-49-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-[(phenylmethyl)sulfonyl]-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-50-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-(phenylacetyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-51-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-(1-oxo-3-phenylpropyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-52-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(2-benzofuranyl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-53-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-methoxy-4-(5-oxazolyl)phenyl]-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-54-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-55-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)tetrahydro-7-(2-methyl-1-oxopropyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-56-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-57-8 HCAPLUS

CN Benzonitrile, 4-[(5S,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-58-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(2-methyl-3-benzofuranyl)-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-59-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(2,2-dimethyl-2H-1-benzopyran-4-yl)tetrahydro-, (5R,8S,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385807-60-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-acetyltetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-61-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-7-(2-methyl-1-oxopropyl)-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-62-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[4-fluoro-3-(trifluoromethyl)benzoyl]tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-63-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-chloro-3-nitrobenzoyl)tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-64-7 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-7-(5-isoxazolylcarbonyl)-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-65-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, N-(3-chloro-4-fluorophenyl)hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-66-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-N-[4-(trifluoromethyl)phenyl]-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-67-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, hexahydro-N-(1-methylethyl)-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-68-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, N-(4-fluorophenyl)hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-69-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, N-[(4-fluorophenyl)methyl]hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-70-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 4-nitrophenyl ester,
(5S,8S,8aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-71-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, hexahydro-2-(4-nitro-1-naphthalenyl)-N-[(4-nitrophenyl)methyl]-1,3-dioxo-, (5S,8S,8aR) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 385807-72-7 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, butyl ester, (5S,8S,8aR)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-73-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-(4-nitro-1-naphthalenyl)-,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-74-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[(4-chloro-3-nitrophenyl)sulfonyl]tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-75-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-[(2,2,2-trifluoroethyl)sulfonyl]-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-76-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-acetyl-2-(4-cyano-1-naphthalenyl)tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-77-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)-7-[4-fluoro-3-(trifluoromethyl)benzoyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-78-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-chloro-3-nitrobenzoyl)-2-(4-cyano-1-naphthalenyl)tetrahydro-, (5S,8S,8aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 385807-79-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-butylbenzoyl)-2-(4-cyano-1-naphthalenyl)tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-80-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, N-(3-chloro-4-fluorophenyl)-2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-81-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-N-[4-(trifluoromethyl)phenyl]-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-82-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-1-naphthalenyl)hexahydro-N-(1-methylethyl)-1,3-dioxo-, (5S,8S,8aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 385807-83-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-1-naphthalenyl)-N-[(4-fluorophenyl)methyl]hexahydro-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-84-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-1-naphthalenyl)hexahydro-N-[(4-nitrophenyl)methyl]-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-85-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-, butyl ester, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-86-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[(4-chloro-3-nitrophenyl)sulfonyl]-2-(4-cyano-1-naphthalenyl)tetrahydro-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-87-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)tetrahydro-7-[(2,2,2-trifluoroethyl)sulfonyl]-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-88-5 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-acetyl-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-89-6 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-7-(2-methyl-1-oxopropyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-90-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-[4-cyano-3-(trifluoromethyl)phenyl]-7-[4-fluoro-3-(trifluoromethyl)benzoyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-91-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-chloro-3-nitrobenzoyl)-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-92-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-7-(5-isoxazolylcarbonyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-93-2 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-butylbenzoyl)-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-94-3 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, N-(3-chloro-4-fluorophenyl)-2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385807-95-4 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-[4-cyano-3-

(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-N-[4-(trifluoromethyl)phenyl]-
, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-96-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-N-(1-methylethyl)-1,3-dioxo-,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-97-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-[4-cyano-3-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hexahydro-1,3-dioxo-,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-98-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-[4-cyano-3-(trifluoromethyl)phenyl]-N-[(4-fluorophenyl)methyl]hexahydro-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385807-99-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, 4-nitrophenyl ester, (5S,8S,8aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385808-00-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, 4-fluorophenyl

ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-01-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-,
(4-nitrophenyl)methyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-02-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, butyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-03-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-04-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[(4-chloro-3-nitrophenyl)sulfonyl]-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-05-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-7-[(2,2,2-trifluoroethyl)sulfonyl]-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-06-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-acetyl-2-(4-cyano-3-iodophenyl)tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-07-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-3-iodophenyl)tetrahydro-7-(2-methyl-1-oxopropyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-08-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-3-iodophenyl)-7-[4-fluoro-3-(trifluoromethyl)benzoyl]tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-09-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-chloro-3-nitrobenzoyl)-2-(4-cyano-3-iodophenyl)tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-10-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-3-iodophenyl)tetrahydro-7-(5-isoxazolylcarbonyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-11-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-butylbenzoyl)-2-(4-cyano-3-iodophenyl)tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-12-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, N-(3-chloro-4-fluorophenyl)-2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-13-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-N-[4-(trifluoromethyl)phenyl]-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-14-0 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-3-iodophenyl)hexahydro-N-(1-methylethyl)-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-15-1 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-3-iodophenyl)-N-(4-fluorophenyl)hexahydro-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-16-2 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-3-iodophenyl)-N-[(4-fluorophenyl)methyl]hexahydro-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-17-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, 4-nitrophenyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-18-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, 4-fluorophenyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-19-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, (4-nitrophenyl)methyl ester,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-20-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, butyl ester, (5S,8S,8aR)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-21-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-3-iodophenyl)tetrahydro-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-,
(5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-22-0 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-[(4-chloro-3-nitrophenyl)sulfonyl]-2-(4-cyano-3-iodophenyl)tetrahydro-, (5S,8S,8aR)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-23-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-3-iodophenyl)tetrahydro-7-(methylsulfonyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-24-2 HCAPLUS

CN Benzonitrile, 4-[(5S,8S,8aS)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-25-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 1,1-dimethylethyl ester, (5R,8R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385808-27-5 HCPLUS


CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 385808-26-4

CMF C17 H14 N4 O4


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 385808-28-6 HCAPLUS
CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 1,1-dimethylethyl ester,
(5S,8S,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385808-29-7 HCAPLUS
CN Benzonitrile, 4-[{(5R,8R,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl}-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385808-30-0 HCAPLUS
CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-benzoyl-2-[4-cyano-3-(trifluoromethyl)phenyl]tetrahydro-, (5S,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-31-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(2-methyl-4-nitrophenyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385808-32-2 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-benzoyltetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-33-3 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(2-benzofuranyl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385808-34-4 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4,5,6,7-tetrafluoro-2-methyl-3-benzofuranyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385808-35-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-methoxy-4-(5-oxazolyl)phenyl]-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385808-36-6 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-37-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,
2-(4-cyano-3-iodophenyl)hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester,
(5S,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-38-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(2-methyl-3-benzofuranyl)-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 385808-39-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid,

Shiao 10_780415

2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester,
(5S,8S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385808-40-2 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(2,2-dimethyl-2H-1-benzopyran-4-yl)tetrahydro-, (5R,8S,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 385810-12-8 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-, (5R,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385810-13-9 HCPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-7-(phenylmethyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



116 ANSWER 5 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:10437 HCPLUS

DOCUMENT NUMBER: 136:85823

TITLE: Synthesis of selective androgen receptor modulators and methods for their identification, design and use

INVENTOR(S): Salvati, Mark E.; Gottardis, Marco M.; Krystek, Stanley R., Jr.; Attar, Ricardo M.; Sack, John S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000617	A2	20020103	WO 2001-US19665	20010620 <--
WO 2002000617	A3	20030130		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW




RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2413417	AA	20020103	CA 2001-2413417	20010620 <--
AU 2001088213	A5	20020108	AU 2001-88213	20010620 <--
EP 1299094	A2	20030409	EP 2001-967933	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509072	T2	20040325	JP 2002-505365	20010620
BR 2001011298	A	20050510	BR 2001-11298	20010620
NO 2002006194	A	20030226	NO 2002-6194	20021223
ZA 2003002963	A	20040715	ZA 2003-2963	20030415
US 2005256048	A1	20051117	US 2005-130935	20050517

PRIORITY APPLN. INFO.:

US 2000-214392P	P	20000628
US 2000-233519P	P	20000919
US 2001-284438P	P	20010418
US 2001-284617P	P	20010418
US 2001-284730P	P	20010418
US 2001-885827	A3	20010620
WO 2001-US19665	W	20010620

GI



AB A method for inhibiting the growth of hormone-dependent tumor cells by administering a selective **androgen receptor modulator** which exhibits antagonist activity in said hormone-dependent tumor while exhibiting no activity or agonist activity against other, non-tumor tissues containing the **androgen receptor**. Examples include data for over 100 compds., breast-tumor line and C2C12 muscle cell reporter assays, and crystal

structure coordinates for the **androgen receptor-ligand** binding domain. E.g., 2(S)-trans-4-hydroxy-2-[[[tert-butylidemethylsilyl]oxy]methyl]-1-boc-pyrrolidine (preparation given) was protected as the tosylate (Pyridine, TsCl) and desilylated (THF, H₂O, p-TSA) to give the 2-hydroxymethyl derivative. This was oxidized to the aldehyde (CH₂Cl₂, ClCOCOCl, DMSO, -78°C) and treated with di-Et cyanophosphonate and benzylamine (THF, 2 h) to give after purification nitrile I [X = OTs] as a 1:1 mixture of diastereomers. I was treated with iPr₂NEt in dichloroethane to give a mixture of [2.2.1]-bicyclo isomers II which were separated by chromatog. The endo-cyano isomer II was converted to the carbomethoxy derivative (MeOH, NaOMe, 60°C), debenzylated (EtOH, 10% Pd/C, 1 atm-H₂) and the resulting ester reacted with 4-isocyanato-2-(trifluoromethyl)benzonitrile (PhMe, 4Å MS, 25°C, 10 h; DBU, 81°C, 2 h) to give III. All example compds. exhibited an IC₅₀ of less than 0.8 μM and an EC₅₀ of greater than 5 μM in the MDA MB-453 breast tumor line reporter assay. Also claimed is a computational method of designing an **androgen receptor** ligand that fits spatially into the **androgen receptor** ligand binding domain (structure coordinates given).

IT 385440-33-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug; synthesis of selective **androgen receptor modulators** and methods for their identification, design and use)

RN 385440-33-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-[4-cyano-3-(trifluoromethyl)phenyl]hexahydro-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 385440-09-5P 385440-10-8P 385440-11-9P

385440-34-6P 385440-35-7P 385440-36-8P

385440-37-9P 385440-38-0P 385440-39-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; synthesis of selective **androgen receptor modulators** and methods for their identification, design and use)

RN 385440-09-5 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)-7-(4-fluorobenzoyl)tetrahydro-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-10-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-butylbenzoyl)tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 385440-11-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 4-fluorophenyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-34-6 HCAPLUS

CN Benzonitrile, 4-[(5S,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]-2-(trifluoromethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-35-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 7-(4-fluorobenzoyl)tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-36-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)tetrahydro-7-(5-isoxazolylcarbonyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-37-9 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, 2-(4-cyano-1-naphthalenyl)hexahydro-1,3-dioxo-, 4-fluorophenyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-38-0 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(4-cyano-1-naphthalenyl)tetrahydro-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-39-1 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxamide, 2-(4-cyano-1-naphthalenyl)-N-(4-fluorophenyl)hexahydro-1,3-dioxo-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 385440-77-7P 385440-78-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(intermediate; synthesis of selective androgen receptor modulators and methods for their identification, design and use)

RN 385440-77-7 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitro-1-naphthalenyl)-, (5S,8S,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385440-78-8 HCAPLUS

CN 5,8-Methanoimidazo[1,5-a]pyrazine-7(1H)-carboxylic acid, hexahydro-2-(4-nitro-1-naphthalenyl)-1,3-dioxo-, 1,1-dimethylethyl ester, (5S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 385440-94-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; synthesis of selective **androgen receptor**
modulators and methods for their identification, design and
 use)

RN 385440-94-8 HCPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5S,8S,8aR)-hexahydro-1,3-dioxo-5,8-methanoimidazo[1,5-a]pyrazin-2(3H)-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 6 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:905331 HCPLUS

DOCUMENT NUMBER: 136:241071

TITLE: Increased rigidity of the chiral centre of tocainide
 favours stereoselectivity and use-dependent block of
 skeletal muscle Na⁺ channels enhancing the
 antimyotonic activity in vivo

AUTHOR(S): Talon, Sophie; De Luca, Annamaria; De Bellis, Michela;
 Desaphy, Jean-Francois; Lentini, Giovanni; Scilimati,
 Antonio; Corbo, Filomena; Franchini, Carlo;
 Tortorella, Paolo; Jockusch, Harald; Camerino, Diana
 Conte

CORPORATE SOURCE: Department of Pharmacobiology, Unit of Pharmacology,

Faculty of Pharmacy, University of Bari, Bari,
I-70125, Italy

SOURCE: British Journal of Pharmacology (2001),
134(7), 1523-1531
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1 Searching for the structural requirements improving the potency and the stereoselectivity of Na⁺ channel blockers as antimyotonic agents, new derivs. of tocainide, in which the chiral carbon atom is constrained in a rigid α-proline or pyrrolo-imidazolic cycle, were tested as pure enantiomers. 2 Their ability to block Na⁺ currents, elicited from -100 to -20 mV at 0.3 Hz (tonic block) and 2-10 Hz (use-dependent block) frequencies, was investigated in vitro on single fibers of frog semitendinosus muscle using the vaseline-gap voltage-clamp method. 3 The α-proline derivative, To5, was 5 and 21 fold more potent than tocainide in producing tonic and 10 Hz-use-dependent block, resp. Compared to To5, the presence of one Me group on the aminic (To6) or amidic (To7) nitrogen atom decreased use-dependence by 2- and 6-times, resp. When methylene moieties were present on both nitrogen atoms (To8), both tonic and use-dependent block were reduced. 4 Contrarily to tocainide, all proline derivs. were stereoselective in relation to an increased rigidity. A further increase in the mol. rigidity as in pyrrolo-imidazolic derivs. markedly decreased the drug potency with respect to tocainide.

5 Antimyotonic activity, evaluated as the shortening of the time of righting reflexes of myotonic adr/adr mice upon acute drug in vivo administration was 3 fold more effective for R-To5 than for R-Tocainide. 6 Thus, constraining the chiral center of tocainide in α-proline cycle leads to more potent and stereoselective use-dependent Na⁺ channel blockers with improved therapeutic potential.

IT 403995-20-0 403995-21-1


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(increased rigidity of the chiral center of tocainide favors stereoselectivity and use-dependent block of skeletal muscle Na⁺ channels enhancing the antimyotonic activity in vivo)

RN 403995-20-0 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(2,6-dimethylphenyl)hexahydro-, (7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403995-21-1 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(4-chloro-2-methylphenyl)hexahydro-, (7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:380546 HCAPLUS

DOCUMENT NUMBER: 134:367194

TITLE: Preparation of novel phenylalanine derivatives as $\alpha 4$ -integrin inhibitors

INVENTOR(S): Tanaka, Yasuhiro; Yoshimura, Toshihiko; Izawa, Hiroyuki; Ejima, Chieko; Kojima, Mitsuhiro; Atake, Yuko; Nakanishi, Eiji; Suzuki, Nobuyasu; Makino, Shingo; Suzuki, Manabu; Murata, Masahiro

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036376	A1	20010525	WO 2000-JP8152	20001120 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001014165	A5	20010530	AU 2001-14165	20001120 <--
EP 1233013	A1	20020821	EP 2000-976347	20001120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003149083	A1	20030807	US 2002-150067	20020520
US 6855706	B2	20050215		
US 2005070485	A1	20050331	US 2004-986829 JP 1999-328468 JP 2000-197139 WO 2000-JP8152 US 2002-150067	20041115 A 19991118 A 20000629 W 20001120 A1 20020520
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): GI		MARPAT 134:367194		




AB Phenylalanine derivs. represented by general formula (I) or pharmaceutically acceptable salts thereof [wherein X represents an interat. bond, O, OSO₂, N-(un)substituted NH, NHCO, NHSO₂, NHCONH, or NH(CS)NH, CO; Y and Z represent each CO, SO, or SO₂; A represents a specific substituted Ph group or nitrogen-containing heterocycle such as aromatic-fused pyrimidinedione or pyrimidinone, 2,4- or 2,5-imidazolidinedione, or 5-imidazolone; C represents hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclic alkyl-lower alkyl optionally containing heteroatoms in the ring, aryl-lower alkyl, heteroaryl-lower alkyl; D and E represent each lower alkyl, lower alkenyl, lower alkynyl, cyclic alkyl-lower alkyl optionally containing heteroatoms in the ring, aryl-lower alkyl, heteroaryl-lower alkyl, etc. or D and E may be bonded to each other to form a ring optionally containing 1 or 2 O, N, or S in the ring; F and G represent each hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclic alkyl-lower alkyl optionally containing heteroatoms in the ring, aryl-lower alkyl, heteroaryl-lower alkyl, etc. or F and G may be bonded to each other to form a ring; n is from 0 to 2; K represents OR₇, NR₇R₈, NHNR₇R₈, SR₇, or R₇; R₇ and R₈ represents H, lower alkyl, etc.; and J and J' represent each hydrogen, halogeno, lower alkyl, lower alkoxy, or NO₂] are prepared. These derivs. and analogs thereof show an $\alpha 4$ integrin inhibitory activity and are usable as remedies for various diseases relating to $\alpha 4$ integrin, such as inflammatory diseases related to $\alpha 4$ integrin-dependent adhesion process, arthritis, inflammatory intestinal diseases, systemic lupus erythematosus, multiple sclerosis, Sjoegren syndrome, psoriasis, allergy, diabetes, cardiovascular diseases, arteriosclerosis, restenosis, tumor proliferation, tumor metastasis, or transplant rejection. Thus, O-(2,6-dichlorobenzyl)-L-tyrosine bound to Wang resin was allowed to react with diethylmalonic acid, HOAt, 2-dimethylaminoisopropyl chloride hydrochloride (DIC), and N-methyl-2-pyrrolidinone (NMP) at room temperature for 16 h, washed with DMF five times, and condensed with pyrroline using HOAt, DIC, and NMP, followed by oxidation with OsO₄ in dioxane at room temperature for 16 and resin-cleavage in aqueous CF₃CO₂H to give N-[2-[(cis-2,4-dihydroxypyrrolidin-1-yl)carbonyl]-2-ethylbutanoyl]-O-(2,6-dichlorobenzyl)-L-tyrosine (II). II and N-[2-[(pyrrolidin-1-yl)carbonyl]-2-ethylbutanoyl]-4-(2,6-dichlorobenzoylamino)-L-phenylalanine inhibited the binding of human recombinant VCAM-1 to human B lymphoma cell line expressing integrin $\alpha 4\beta 7$ with IC₅₀ of $\leq 0.02 \mu\text{mol/L}$.

IT 340717-95-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel phenylalanine derivs. as $\alpha 4$ -integrin inhibitors)

RN 340717-95-5 HCPLUS
CN L-Phenylalanine, N-[[1-[(dimethylamino)carbonyl]cyclopropyl]carbonyl]-4-[(7aS)-tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L16 ANSWER 8 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:319894 HCAPLUS
 DOCUMENT NUMBER: 134:326532
 TITLE: Preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion
 INVENTOR(S): Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 195 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030781	A2	20010503	WO 2000-US29273	20001019 <--
WO 2001030781	A3	20011122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2388639	AA	20010503	CA 2000-2388639	20001019 <--
BR 2000014651	A	20020618	BR 2000-14651	20001019
JP 2003512468	T2	20030402	JP 2001-533134	20001019
EP 1307455	A2	20030507	EP 2000-976625	20001019
EP 1307455	B1	20050406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 518369	A	20030926	NZ 2000-518369	20001019
AU 778757	B2	20041216	AU 2001-14370	20001019
AT 292634	E	20050415	AT 2000-976625	20001019
PT 1307455	T	20050630	PT 2000-976625	20001019
CN 1651431	A	20050810	CN 2004-10096397	20001019
ES 2240201	T3	20051016	ES 2000-976625	20001019
US 6897225	B1	20050524	US 2002-111110	20021016

HK 1053473	A1	20050909	HK 2003-105854	20030814
US 2005148602	A1	20050707	US 2005-70335	20050303
PRIORITY APPLN. INFO.:				
			US 1999-160629P	P 19991020
			US 2000-209847P	P 20000607
			WO 2000-US29273	W 20001019
			US 2002-111110	A3 20021016

OTHER SOURCE(S) : MARPAT 134:326532

GI




AB Title compds. (I) [wherein A = :CZ1 or :N; B = CH:CH, S, SO, SO₂, O, or (un)substituted N or CH₂; K = CH₂, CHO, CO, or CF₂, M = a bond, (CH₂)_p, CO, or NH; W = CQ, CR₆C(:Q), or C(:Q)CR₆; X and Y = independently H, halo, NO₂, CN, alkylthio, (halo)alkyl, alkoxy, acyl, or (un)substituted amino or (hetero)aryl; Z and Z₁ = independently H, OH, halo, NO₂, CF₃, acyl, (un)substituted amino, carbamoyl, or alkoxy; P and Q = independently O or S; R = (un)substituted (hetero)aryl; R₆ = H or (un)substituted alkyl; m = 0-3; n = 0-2; p and q = independently 1 or 2; or a pharmaceutically acceptable salt thereof] were prepared as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion. For example, 4-bromobenzyl bromide was added to N-(tert-butoxycarbonyl)proline Me ester in THF, the proline deprotected using TFA, 3,5-dichlorophenyl isocyanate added in the presence of DIEA in THF, and the dichlorophenylcarbamoyl derivative cyclized using NaOEt in EtOH to afford II. In the Jurkat/ICAM-1 adhesion assay, I gave IC₅₀ values from low nM to μ M. I are useful in the treatment of a variety of inflammatory diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, atopic dermatitis, Sjogren's Syndrome, rejection after transplantation, and graft vs. host disease (no data).

IT 336817-46-0P 336818-06-5P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.)

RN 336817-46-0 HCPLUS**CN** 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)-6-[(1,1-dimethylethyl)dimethylsilyloxy]tetrahydro-, (6R,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336818-06-5 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-6-[(1,1-dimethylethyl)dimethylsilyl]oxy]tetrahydro-7a-[(4-(trifluoromethoxy)phenyl)methyl]-, (6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 336817-55-1P 336817-59-5P 336818-04-3P

336818-08-7P 336818-10-1P 336818-30-5P

336818-39-4P 336818-49-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]prolin e derivs.)

RN 336817-55-1 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-6-[(methylsulfonyl)oxy]-, (6R,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-59-5 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-, (7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336818-04-3 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-6-[(1,1-dimethylethyl)dimethylsilyl]oxytetrahydro-, (6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336818-08-7 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-6-[(1,1-dimethylethyl)dimethylsilyl]oxytetrahydro-7a-[4-(trifluoromethoxy)phenyl]methyl-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336818-10-1 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-6-[(1,1-dimethylethyl)dimethylsilyloxy]tetrahydro-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336818-30-5 HCPLUS

CN Benzoyl chloride, 4-[[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336818-39-4 HCAPLUS
CN Glycine, N-[4-[(7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorobenzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 336818-49-6 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxylic acid, 2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, methyl ester, (6R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 336817-49-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (intermediate; preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.)

RN 336817-49-3 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)-6-[(1,1-dimethylethyl)dimethylsilyloxy]tetrahydro-, (6R,7aR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 336812-15-8P 336812-17-0P 336812-19-2P

336812-21-6P 336812-25-0P 336812-27-2P

336812-28-3P 336812-30-7P 336812-31-8P

336812-34-1P 336812-35-2P 336812-52-3P

336812-60-3P 336812-61-4P 336812-65-8P

336812-71-6P 336812-72-7P 336812-74-9P

336812-76-1P 336812-77-2P 336812-79-4P

336812-84-1P 336812-85-2P 336813-07-1P

336813-24-2P 336813-25-3P 336813-27-5P

336813-28-6P 336813-44-6P 336813-45-7P

336813-47-9P 336813-49-1P 336813-51-5P

336813-57-1P 336813-91-3P 336814-37-0P

336814-67-6P 336814-69-8P 336814-71-2P
 336814-83-6P 336815-01-1P 336815-20-4P
 336815-31-7P 336815-71-5P 336815-81-7P
 336815-87-3P 336815-93-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.)

RN 336812-15-8 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-, (6R,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-17-0 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-(acetyloxy)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-19-2 HCPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336812-21-6 HCPLUS

CN [1,1'-Biphenyl]-2-carboxaldehyde, 4'-[[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336812-25-0 HCPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-8a-[[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 336812-27-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-ylmethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 336812-28-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-ylmethyl]- (9CI) (CA INDEX NAME)




RN 336812-30-7 HCPLUS

CN 2-Propenoic acid, 3-[4'-(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl][1,1'-biphenyl]-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 336812-31-8 HCPLUS

CN [1,1'-Biphenyl]-2-propanoic acid, 4'-(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 336812-34-1 HCAPLUS

CN Benzonitrile, 4-[{[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl}- (9CI) (CA INDEX NAME)




RN 336812-35-2 HCAPLUS

CN Benzoic acid, 4-[{[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl}-, methyl ester (9CI) (CA INDEX NAME)



RN 336812-52-3 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(2,6-dichloro-4-pyridinyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 336812-60-3 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-azido-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-61-4 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-amino-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336812-65-8 HCPLUS


CN Benzonitrile, 4-[[2-[3-chloro-5-(1H-pyrrol-1-yl)phenyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 336812-71-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-6-hydroxy-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-72-7 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-6-hydroxy-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-74-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-, (6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-76-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-amino-2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-77-2 HCPLUS

CN Acetamide, N-[{(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl}amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-79-4 HCPLUS

CN Butanoic acid, 4-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-84-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-azido-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (6R,7aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 336812-85-2 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-amino-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (6R,7aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 336813-07-1 HCAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2,2'-[4-[(4-cyanophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-pyridinediylyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 336813-24-2 HCAPLUS

CN Benzonitrile, 4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]hydroxymethyl]- (9CI) (CA INDEX NAME)




RN 336813-25-3 HCAPLUS

CN Benzonitrile, 4-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 336813-27-5 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(4'-nitro[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336813-28-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4'-amino[1,1'-biphenyl]-4-yl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336813-44-6 HCAPLUS

CN Carbamic acid, [2,6-dichloro-4-[7a-[(4-cyanophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 336813-45-7 HCPLUS

CN Benzonitrile, 4-[2-(4-amino-3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-47-9 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichloro-4-methoxyphenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336813-49-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichloro-4-hydroxyphenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336813-51-5 HCAPLUS

CN Butanoic acid, 4-[4-[(7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorophenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 336813-57-1 HCAPLUS

CN Benzonitrile, 4-[(2-(3,5-dichloro-4-methoxyphenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336813-91-3 HCAPLUS

CN Benzoic acid, 4-[(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-37-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(4-(methylthio)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-67-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-69-8 HCAPLUS

CN Benzonitrile, 5-[(2-(2,6-dichloro-4-pyridinyl)tetrahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-7a(5*H*)-yl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 336814-71-2 HCAPLUS

CN 1*H*-Pyrrolo[1,2-c]imidazole-1,3(2*H*)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[(4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-83-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-7a-[(4-ethoxyphenyl)methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-01-1 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxaldehyde, 4'-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl- (9CI) (CA INDEX NAME)




RN 336815-20-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(3'-amino[1,1'-biphenyl]-4-yl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 336815-31-7 HCAPLUS


CN Benzoic acid, 4-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichloro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 336815-71-5 HCPLUS

CN Carbamic acid, [2-[[[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-81-7 HCPLUS

CN Carbamic acid, [1-(aminocarbonyl)-3-[[[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-87-3 HCAPLUS

CN Acetamide, 2-amino-N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-93-1 HCAPLUS

CN Butanediamide, 2-amino-N4-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 336812-14-7P 336812-16-9P 336812-18-1P
 336812-20-5P 336812-22-7P 336812-23-8P
 336812-24-9P 336812-26-1P 336812-29-4P
 336812-32-9P 336812-33-0P 336812-36-3P
 336812-37-4P 336812-38-5P 336812-51-2P
 336812-53-4P 336812-55-6P 336812-56-7P
 336812-57-8P 336812-58-9P 336812-59-0P
 336812-62-5P 336812-63-6P 336812-64-7P
 336812-66-9P 336812-73-8P 336812-75-0P
 336812-78-3P 336812-80-7P 336812-81-8P
 336812-82-9P 336812-88-5P 336812-89-6P
 336812-90-9P 336812-91-0P 336812-92-1P
 336812-93-2P 336812-94-3P 336812-96-5P
 336812-97-6P 336812-98-7P 336812-99-8P
 336813-00-4P 336813-01-5P 336813-02-6P
 336813-03-7P 336813-04-8P 336813-05-9P
 336813-06-0P 336813-08-2P 336813-09-3P
 336813-10-6P 336813-11-7P 336813-26-4P
 336813-29-7P 336813-30-0P 336813-31-1P
 336813-32-2P 336813-33-3P 336813-34-4P
 336813-35-5P 336813-36-6P 336813-37-7P
 336813-38-8P 336813-39-9P 336813-40-2P
 336813-41-3P 336813-42-4P 336813-43-5P
 336813-46-8P 336813-53-7P 336813-55-9P
 336813-59-3P 336813-61-7P 336813-63-9P
 336813-65-1P 336813-67-3P 336813-69-5P
 336813-71-9P 336813-73-1P 336813-75-3P
 336813-77-5P 336813-79-7P 336813-81-1P
 336813-83-3P 336813-85-5P 336813-87-7P
 336813-89-9P 336813-93-5P 336813-95-7P
 336813-97-9P 336813-99-1P 336814-19-8P
 336814-21-2P 336814-23-4P 336814-25-6P
 336814-27-8P 336814-29-0P 336814-31-4P
 336814-33-6P 336814-35-8P 336814-39-2P
 336814-41-6P 336814-43-8P 336814-45-0P
 336814-47-2P 336814-49-4P 336814-51-8P
 336814-53-0P 336814-55-2P 336814-57-4P
 336814-59-6P 336814-61-0P 336814-63-2P
 336814-65-4P 336814-73-4P 336814-75-6P
 336814-77-8P 336814-79-0P 336814-81-4P
 336814-85-8P 336814-87-0P 336814-89-2P
 336814-91-6P 336814-93-8P 336814-95-0P


336814-97-2P 336814-99-4P 336815-03-3P
 336815-05-5P 336815-07-7P 336815-09-9P
 336815-11-3P 336815-13-5P 336815-15-7P
 336815-17-9P 336815-22-6P 336815-25-9P
 336815-27-1P 336815-29-3P 336815-33-9P
 336815-35-1P 336815-37-3P 336815-39-5P
 336815-41-9P 336815-43-1P 336815-45-3P
 336815-47-5P 336815-49-7P 336815-51-1P
 336815-53-3P 336815-55-5P 336815-57-7P
 336815-59-9P 336815-62-4P 336815-65-7P
 336815-67-9P 336815-69-1P 336815-73-7P
 336815-75-9P 336815-77-1P 336815-79-3P
 336815-83-9P 336815-89-5P 336815-91-9P
 336815-95-3P 336815-97-5P 336815-99-7P
 336816-01-4P 336816-03-6P 336816-05-8P
 336816-07-0P 336816-09-2P 336816-11-6P
 336816-13-8P 336816-15-0P 336816-17-2P
 336816-19-4P 336816-23-0P 336816-25-2P
 336816-27-4P 336816-29-6P 336816-31-0P
 336816-33-2P 336816-35-4P 336816-37-6P
 336816-39-8P 336816-41-2P 336816-43-4P
 336816-45-6P 336816-47-8P 336816-49-0P
 336816-51-4P 336816-53-6P 336816-55-8P
 336816-57-0P 336816-63-8P 336816-65-0P
 336816-67-2P 336816-69-4P 336816-71-8P
 336816-73-0P 336816-75-2P 336816-77-4P
 336816-79-6P 336816-81-0P 336816-83-2P
 336816-85-4P 336816-87-6P 336817-04-0P
 336817-06-2P 336817-08-4P 336817-10-8P
 336817-12-0P 336817-14-2P 336817-16-4P
 336817-18-6P 336817-20-0P 336817-22-2P
 336817-24-4P 336817-26-6P 336817-29-9P
 336818-92-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.)

RN 336812-14-7 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 336812-16-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-azido-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-18-1 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-20-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-8a-[[4-(3-pyridinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336812-22-7 HCAPLUS

CN 3-Furancarboxaldehyde, 2-[4-[(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 336812-23-8 HCAPLUS

CN 3-Thiophenecarboxaldehyde, 2-[4-[(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 336812-24-9 HCAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]phenyl]-3-formyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 336812-26-1 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)-8a-[(2'-(dimethylamino)methyl)[1,1'-biphenyl]-4-yl]methyltetrahydro- (9CI) (CA INDEX NAME)




RN 336812-29-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 4'-(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 336812-32-9 HCAPLUS

CN [1,1'-Biphenyl]-2-propanoic acid, 4'-(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl- (9CI) (CA INDEX NAME)




RN 336812-33-0 HCAPLUS

CN [1,1'-Biphenyl]-2-propanamide, 4'-[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 336812-36-3 HCAPLUS

CN Benzamide, 4-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 336812-37-4 HCAPLUS

CN Benzoic acid, 4-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 336812-38-5 HCAPLUS


CN Benzamide, 4-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 336812-51-2 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro-5-phenyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-53-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dinitrophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336812-55-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(4-chloro-3-nitrophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336812-56-7 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]tetrahydro-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 336812-57-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dimethylphenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336812-58-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-[4-(dimethylamino)phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 336812-59-0 HCAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)-8a-[[2'-[2-(dimethylamino)ethoxy]methyl][1,1'-biphenyl]-4-yl]methyl]tetrahydro-(9CI) (CA INDEX NAME)



RN 336812-62-5 HCAPLUS

CN Acetamide, N-[(6S,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-63-6 HCPLUS

CN Methanesulfonamide, N-[(6S,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 336812-64-7 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)-6-(dimethylamino)tetrahydro-, (6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-66-9 HCAPLUS
CN Benzonitrile, 4-[[2-[3-chloro-5-(2-formyl-1H-pyrrol-1-yl)phenyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 336812-73-8 HCAPLUS
CN Benzonitrile, 4-[(6R,7aR)-2-(2,6-dichloro-4-pyridinyl)tetrahydro-6-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-75-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-azido-2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-78-3 HCAPLUS

CN Urea, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-N'-ethyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-80-7 HCAPLUS

CN 4-Pyridinecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-81-8 HCAPLUS

CN Acetamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-
[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-2-
(dimethylamino)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-82-9 HCPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[(4-(trifluoromethoxy)phenyl)methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl- γ -oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-88-5 HCPLUS

CN Acetamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-89-6 HCAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-90-9 HCAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-91-0 HCAPLUS

CN Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-92-1 HCAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336812-93-2 HCAPLUS


CN Benzoic acid, 4-[[[(6*R*,7*a**R*)-7*a*-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336812-94-3 HCAPLUS

CN 1*H*-Pyrrolo[1,2-c]imidazole-1,3,5(2*H*,6*H*)-trione, 7*a*-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)dihydro- (9CI) (CA INDEX NAME)




RN 336812-96-5 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-[2-chloro-6-(dimethylamino)-4-pyridinyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336812-97-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-[2-chloro-6-(methylamino)-4-pyridinyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336812-98-7 HCAPLUS

CN Benzonitrile, 4-[(2-[2,6-bis(4-methoxyphenyl)-4-pyridinyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336812-99-8 HCAPLUS

CN Benzonitrile, 4-[(2-(2,6-diphenyl-4-pyridinyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336813-00-4 HCPLUS

CN Benzonitrile, 4-[[2-[2,6-bis[4-(trifluoromethoxy)phenyl]-4-pyridinyl]tetrahydro-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-01-5 HCPLUS

CN Benzonitrile, 4-[[2-[2-chloro-6-(4-methoxyphenyl)-4-pyridinyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-02-6 HCAPLUS

CN Benzonitrile, 4-[[2-[2-chloro-6-[4-(trifluoromethoxy)phenyl]-4-pyridinyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl] - (9CI) (CA INDEX NAME)




RN 336813-03-7 HCAPLUS

CN Benzonitrile, 4-[[2-(2-chloro-6-phenyl-4-pyridinyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl] - (9CI) (CA INDEX NAME)




RN 336813-04-8 HCAPLUS

CN Benzonitrile, 4-[[2-[2-chloro-6-[4-(trifluoromethyl)phenyl]-4-pyridinyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-(9CI) (CA INDEX NAME)




RN 336813-05-9 HCAPLUS

CN Benzonitrile, 4-[6-chloro-4-[7a-[(4-cyanophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2-pyridinyl]-(9CI) (CA INDEX NAME)




RN 336813-06-0 HCAPLUS

CN Benzonitrile, 4-[[2-[2-chloro-6-(3,5-dimethyl-4-isoxazolyl)-4-pyridinyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-(9CI) (CA INDEX NAME)




RN 336813-08-2 HCAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[6-chloro-4-[(4-cyanophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2-pyridinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 336813-09-3 HCAPLUS

CN Benzonitrile, 4-[[2-(6-chloro[2,3'-bipyridin]-4-yl)tetrahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-10-6 HCAPLUS

CN Benzonitrile, 4-[[2-(2,6-di-1*H*-pyrrol-2-yl-4-pyridinyl)tetrahydro-1,3-dioxo-1*H*-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-11-7 HCAPLUS

CN Benzonitrile, 4-[[2-[2-chloro-6-(1H-pyrrol-2-yl)-4-pyridinyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-26-4 HCAPLUS

CN Benzonitrile, 4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]difluoromethyl]- (9CI) (CA INDEX NAME)




RN 336813-29-7 HCAPLUS

CN Acetamide, N-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 336813-30-0 HCAPLUS


CN Methanesulfonamide, N-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 336813-31-1 HCAPLUS
CN Butanoic acid, 4-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-4-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 336813-32-2 HCAPLUS
CN Acetamide, N-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 336813-33-3 HCAPLUS

CN Methanesulfonamide, N-[4' - [2 - (3,5 - dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-ylmethyl] [1,1'-biphenyl]-3-yl] -N-(methylsulfonyl) - (9CI) (CA INDEX NAME)




RN 336813-34-4 HCAPLUS

CN Methanesulfonamide, N-[4' - [2 - (3,5 - dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-ylmethyl] [1,1'-biphenyl]-3-yl] - (9CI) (CA INDEX NAME)




RN 336813-35-5 HCAPLUS

CN Carbamic acid, [4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 336813-36-6 HCAPLUS

CN Benzamide, N-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 336813-37-7 HCPLUS

CN Imidodicarbonic diamide, 2-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]-N,N'-dimethyl- (9CI) (CA INDEX NAME)




RN 336813-38-8 HCPLUS

CN Thiourea, N-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 336813-39-9 HCAPLUS

CN Urea, N-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 336813-40-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[3'-(2-oxo-1-pyrrolidinyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-41-3 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(4-(1H-tetrazol-5-yl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336813-42-4 HCPLUS

CN Benzenecarboximidamide, 4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336813-43-5 HCAPLUS

CN Benzonitrile, 4-[2-(2,6-dichloro-4-pyridinyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl- (9CI) (CA INDEX NAME)




RN 336813-46-8 HCAPLUS

CN Acetamide, N-[2,6-dichloro-4-[7a-[(4-cyanophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 336813-53-7 HCAPLUS

CN Butanoic acid, 4-[4-[(7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 336813-55-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-[3,5-dichloro-4-(phenylmethoxy)phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336813-59-3 HCAPLUS

CN Hexanoic acid, 6-[4-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorophenoxy]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 336813-61-7 HCAPLUS

CN Hexanoic acid, 6-[4-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorophenoxy]- (9CI) (CA INDEX NAME)



RN 336813-63-9 HCAPLUS


CN Benzoic acid, 4-[[2-(3,5-dichloro-4-hydroxyphenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-ylmethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336813-65-1 HCAPLUS

CN L-Asparagine, N2-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-ylmethyl]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336813-67-3 HCPLUS

CN L-Alanine, N-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336813-69-5 HCPLUS

CN L-Phenylalanine, N-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336813-71-9 HCAPLUS

CN L-Aspartic acid, N-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336813-73-1 HCAPLUS

CN L-Alanine, N-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336813-75-3 HCAPLUS



CN L-Phenylalanine, N-[4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336813-77-5 HCAPLUS

CN Benzamide, 4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 336813-79-7 HCAPLUS

CN Benzamide, 4-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336813-81-1 HCAPLUS


CN Benzamide, 4-[(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 336813-83-3 HCAPLUS

CN Benzamide, 4-[(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 336813-85-5 HCAPLUS

CN Benzamide, 4-[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 336813-87-7 HCAPLUS

CN Benzamide, 4-[(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl]-N-(4-methyl-3-pyridinyl)-(9CI) (CA INDEX NAME)




RN 336813-89-9 HCAPLUS

CN Benzoic acid, 4-[(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 336813-93-5 HCAPLUS

CN Benzamide, 4-[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 336813-95-7 HCAPLUS

CN Benzamide, 4-[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 336813-97-9 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)-8a-[(4-(2-(2-hydroxyimino)-2-oxethyl)phenyl)methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336813-99-1 HCAPLUS

CN Benzonitrile, 4-[(2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-19-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromo-3-methylphenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-21-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(3-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-23-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(2-bromophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-25-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-27-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-
7a-[4-(trifluoromethyl)phenyl]methyl- (9CI) (CA INDEX NAME)




RN 336814-29-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)-7a-[2-
fluoro-4-(trifluoromethyl)phenyl]methyltetrahydro- (9CI) (CA INDEX NAME)




RN 336814-31-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)-7a-[3-
fluoro-4-(trifluoromethyl)phenyl]methyltetrahydro- (9CI) (CA INDEX NAME)




RN 336814-33-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-35-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)-7a-[(4-ethylphenyl)methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-39-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 336814-41-6 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-aminophenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 336814-43-8 HCAPLUS

CN Urea, N-(3,5-dichlorophenyl)-N'-(4-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]phenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 336814-45-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-(trifluoromethoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 336814-47-2 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-7a-[[4-(difluoromethoxy)phenyl]methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-49-4 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-7a-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-51-8 HCAPLUS
CN Benzonitrile, 5-[[2-(2,6-dichloro-4-pyridinyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 336814-53-0 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-(5-benzofuranyl methyl)-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-55-2 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-(1,3-benzodioxol-5-ylmethyl)-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-57-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-(methylsulfinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336814-59-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336814-61-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 336814-63-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[(2-methyl-4-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-65-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 336814-73-4 HCAPLUS

CN Benzonitrile, 5-[[2-(2,6-dichloro-4-pyridinyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 336814-75-6 HCAPLUS

Shiao 10_780415

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-[2-(4-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 336814-77-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-[2-(2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 336814-79-0 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-[2-(4-piperidinyl)ethoxy]phenyl]methyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 336814-81-4 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-7a-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-85-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[(4-propoxypyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-87-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-(1-methylethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336814-89-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-(2-methylpropoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336814-91-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)-7a-[(4-ethoxy-3-fluorophenyl)methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-93-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-([1,1'-biphenyl]-4-ylmethyl)-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-95-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)-7a-[[4-(3,5-dimethyl-4-isoxazolyl)phenyl]methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336814-97-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(2'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336814-99-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 336815-03-3 HCPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 4'-[[2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 336815-05-5 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(3'-acetyl[1,1'-biphenyl]-4-yl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-07-7 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxaldehyde, 4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl] - (9CI) (CA INDEX NAME)




RN 336815-09-9 HCAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl] - (9CI) (CA INDEX NAME)




RN 336815-11-3 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4'-acetyl[1,1'-biphenyl]-4-yl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-13-5 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-(3-thienyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336815-15-7 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-benzo[b]thien-2-ylphenyl)methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-17-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[2-(2,6-dichloro-4-pyridinyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl- (9CI) (CA INDEX NAME)




RN 336815-22-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-(2-thienyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 336815-25-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[3'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 336815-27-1 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[(3'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 336815-29-3 HCAPLUS


CN 2-Propenoic acid, 3-[4'-(2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl)methyl][1,1'-biphenyl]-3-yl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 336815-33-9 HCAPLUS

CN Benzoic acid, 4-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichloro- (9CI) (CA INDEX NAME)



RN 336815-35-1 HCAPLUS


CN Glycine, N-[4-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorobenzoyl]- (9CI) (CA INDEX NAME)



RN 336815-37-3 HCAPLUS

CN L-Alanine, N-[4-[(7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorobenzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-39-5 HCAPLUS


CN L-Asparagine, N2-[4-[(7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichlorobenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336815-41-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3-chlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-43-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]tetrahydro-2-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 336815-45-3 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[3,5-bis(trifluoromethyl)phenyl]-7a-[(4-bromophenyl)methyl]tetrahydro- (9CI)
(CA INDEX NAME)




RN 336815-47-5 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]tetrahydro-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 336815-49-7 HCAPLUS

CN Benzonitrile, 3-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]- (9CI) (CA INDEX NAME)




RN 336815-51-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3,5-dimethoxyphenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-53-3 HCAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]- (9CI) (CA INDEX NAME)




RN 336815-55-5 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3-acetylphenyl)-7a-[(4-bromophenyl)methyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-57-7 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7a-[(4-bromophenyl)methyl]-2-(3-fluorophenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 336815-59-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 336815-62-4 HCAPLUS


CN Benzonitrile, 4-[2-(2-amino-3,5-dichlorophenyl)tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-7a(5H)-yl]methyl- (9CI) (CA INDEX NAME)



RN 336815-65-7 HCAPLUS

CN 3-Isoxazolecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-67-9 HCAPLUS

CN 4-Isoxazolecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-69-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-73-7 HCAPLUS

CN Butanediamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-75-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-77-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-79-3 HCPLUS

CN 3-Thiophenecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-83-9 HCPLUS

CN Carbamic acid, [(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] -, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-89-5 HCPLUS

CN Acetamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-91-9 HCPLUS

CN Methanesulfonamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-2-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-95-3 HCPLUS

CN Butanediamide, 2-(acetylamino)-N4-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-97-5 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-N,N-dimethyl-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336815-99-7 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-N-methyl-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-01-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, N-cyclopropyl-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-03-6 HCPLUS

CN Morpholine, 4-[(6R,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-05-8 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-N-[2-(4-morpholinyl)ethyl]-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-07-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-N-(phenylmethyl)-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-09-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-N-(2-thienylmethyl)-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-11-6 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-13-8 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-15-0 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-7a-(phenylmethyl)-, (6R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336816-17-2 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336816-19-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-7a-[4-(trifluoromethoxy)phenylmethyl]-, (6R,7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-23-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-25-2 HCAPLUS

CN 3-Furancarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-27-4 HCPLUS

CN 2-Furancarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-29-6 HCPLUS

CN 3-Pyridineacetamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-31-0 HCAPLUS

CN Carbamic acid, [(6*S*,7*a*R)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7*a*-[[4-(trifluoromethoxy)phenyl]methyl]-1*H*-pyrrolo[1,2-c]imidazol-6-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-33-2 HCAPLUS

CN Carbamic acid, [(6*S*,7*a*R)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7*a*-[[4-(trifluoromethoxy)phenyl]methyl]-1*H*-pyrrolo[1,2-c]imidazol-6-yl]-, phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-35-4 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-37-6 HCAPLUS

CN Urea, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-N'-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-39-8 HCPLUS

CN Thiourea, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-N'-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-41-2 HCPLUS

CN Butanediamide, N1-acetyl-2-[[[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-43-4 HCAPLUS

CN L-Asparagine, N2-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-45-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-amino-2-(2,6-dichloro-4-pyridinyl)tetrahydro-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-47-8 HCPLUS

CN Cyclopropanecarboxamide, N-[(6R,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-49-0 HCPLUS

CN Acetamide, N-[(6R,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-51-4 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(6R,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-53-6 HCAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6R,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-55-8 HCAPLUS

CN Pentanamide, N-[(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-57-0 HCAPLUS

CN Urea, [(6S,7aR)-2-(2,6-dichloro-4-pyridinyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-63-8 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-azido-2-(3,5-dichlorophenyl)tetrahydro-7a-[4-(trifluoromethoxy)phenyl]methyl-, (6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-65-0 HCPLUS

CN Acetamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-67-2 HCPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-69-4 HCPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-71-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-73-0 HCAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-75-2 HCPLUS

CN Butanediamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-77-4 HCPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-γ-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-79-6 HCPLUS

CN Carbamic acid, [(6*S*,7*aR*)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7*a*-[[4-(trifluoromethoxy)phenyl]methyl]-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-81-0 HCPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6*S*,7*aR*)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7*a*-[[4-(trifluoromethoxy)phenyl]methyl]-1*H*-pyrrolo[1,2-*c*]imidazol-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-83-2 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-amino-2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-85-4 HCPLUS

CN Acetamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336816-87-6 HCAPLUS


CN Butanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-(dimethylamino)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336817-04-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-[(trifluoromethyl)sulfinyl]phenyl]methyl]-(9CI) (CA INDEX NAME)



RN 336817-06-2 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 336817-08-4 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-10-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(3,5-dichlorophenyl)hexahydro-N,N-dimethyl-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-12-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(3,5-dichlorophenyl)hexahydro-N-methyl-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-14-2 HCPLUS

CN Morpholine, 4-[[[(6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-16-4 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(3,5-dichlorophenyl)hexahydro-N-4-morpholinyl-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6R,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-18-6 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-20-0 HCAPLUS

CN Morpholine, 4-[[[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336817-22-2 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-6-carboxamide, 2-(3,5-dichlorophenyl)hexahydro-N-methyl-1,3-dioxo-7a-[4-(trifluoromethoxy)phenyl]methyl-, (6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336817-24-4 HCPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)-8a-[[2'-(dimethylamino)methyl][1,1'-biphenyl]-4-yl]methyltetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 336817-26-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[2-(3,5-dichlorophenyl)hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-8a(1H)-yl]methyl-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 336817-29-9 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)-8a-[2'-(2-(dimethylamino)ethoxy)methyl][1,1'-biphenyl]-4-yl)methyltetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 336818-92-9 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-7a-[4-(trifluoromethoxy)phenyl]methyl-, (6R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 336818-67-8 336818-85-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of α1β2 mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.)


RN 336818-67-8 HCPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 8a-[[2'-(chloromethyl)[1,1'-biphenyl]-4-yl]methyl]-2-(3,5-dichlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 336818-85-0 HCPLUS

CN Benzoyl chloride, 4-[7a-[(4-bromophenyl)methyl]tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]-2,6-dichloro- (9CI) (CA INDEX NAME)



L16 ANSWER 9 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:78243 HCPLUS

DOCUMENT NUMBER: 134:131537

TITLE: Novel N-aryl cycloalkyl fused imidazolediones useful
in the treatment of inflammatory disease

INVENTOR(S): Kelly, Terence Alfred; Wu, Jiang-Ping; Kuzmich, Daniel

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007052	A1	20010201	WO 2000-US17752	20000628 <--

W: CA, JP, MX

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

US 6365615

B1 20020402

US 2000-605675

20000628 <--

PRIORITY APPLN. INFO.:



US 1999-144894P

P 19990721

OTHER SOURCE(S):

MARPAT 134:131537

GI



AB Novel N-aryl cycloalkyl fused imidazoles I [Y and Z independently = O or S; R1 = H, (un)substituted unbranched or branched alkyl or cycloalkyl, alkoxy or acyloxy; R2 = (un)substituted aryl; R3 = H, OH, alkoxy, acyloxy, or (un)substituted unbranched or branched alkyl or cycloalkyl; R4 = Cl or CF₃; X = N or CR₅ where R₅ = H, halo, Me, or CF₃; R6 = H, halo, Me, CN, NO₂ or CF₃ with condition that when X = N or CH, R6 = Cl or CF₃; A = (CHR₈)_m where m = 0 or 1; W = (CHR₉)_n where n = 0 or 1 and m + n = 1 or 2; R₇, R₈ and R₉ independently = H, oxo, R₁₀, OR₁₀, NHR₁₀, COR₁₀, CONHR₁₀, CO₂R₁₀, SO₂R₁₀ or SR₁₀ wherein R₁₀ = H, (un)substituted branched or unbranched alkyl or cycloalkyl, alkylcarboxylic acid, alkylphosphonic acid, alkylamidino, etc.] which are useful for treating or preventing inflammatory and immune cell-mediated diseases are disclosed as well as methods for their preparation. Thus, II was prepared in four steps via a cyclocondensation reaction of an intermediate N-(3,5-dichlorophenylamido)-3-phenylpyrrolidin-2-yl carboxylic acid. The title compds. possessed K_d values < 10 μM for inhibition of LFA-1 binding to ICAM-1.

Pharmaceutical compns. of I suitable for prevention or treatment of inflammatory and immune cell-mediated conditions are disclosed.

IT 321983-02-2P 321983-03-3P 321983-04-4P

321983-05-5P 321983-22-6P 321983-23-7P


321983-24-8P 321983-25-9P 321983-26-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and biol. activity of N-aryl cycloalkyl fused imidazoles as antiinflammatory agents)

RN 321983-02-2 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7-phenyl-, (7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-03-3 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-methyl-7-phenyl-, (7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-04-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7-(4-bromophenyl)-2-(3,5-dichlorophenyl)tetrahydro-, (7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-05-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-8a-methyl-8-phenyl-, (8R,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-22-6 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7-(4-bromophenyl)-2-(3,5-dichlorophenyl)tetrahydro-7a-methyl-, (7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-23-7 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7a-methyl-7-[4-(3-pyridinyl)phenyl]-, (7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-24-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7-(4-bromophenyl)-2-(3,5-dichlorophenyl)tetrahydro-6-hydroxy-, (6R,7S,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-25-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7-(4-bromophenyl)-2-(3,5-dichlorophenyl)tetrahydro-7a-(2-propenyl)-, (7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-26-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7-(4-bromophenyl)-2-(3,5-dichlorophenyl)tetrahydro-5-hydroxy-7a-methyl-, (5R,7S,7aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 321983-10-2P 321983-12-4P 321983-20-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and biol. activity of N-aryl cycloalkyl fused imidazolediones as antiinflammatory agents)

RN 321983-10-2 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-7-phenyl-, (7R,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-12-4 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 7-(4-bromophenyl)-2-(3,5-dichlorophenyl)tetrahydro-, (7R,7aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 321983-20-4 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-8-phenyl-, (8R,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:50634 HCAPLUS

DOCUMENT NUMBER: 134:100879

TITLE: Preparation of 2-(2-aryl-2-morpholinyl)ethanols as drug intermediates

INVENTOR(S): Aulombard, Alain; Bernon, Francoise; Bonnefoy, Sabrina; Burgos, Alain; Cabos, Claude; Lucas, Eric

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001004105	A1	20010118	WO 2000-FR1966	20000707 <-
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2796069	A1	20010112	FR 1999-9061	19990709 <-
FR 2796069	B3	20010824		
CA 2378002	AA	20010118	CA 2000-2378002	20000707 <-
BR 2000012324	A	20020319	BR 2000-12324	20000707 <-
EP 1200417	A1	20020502	EP 2000-949673	20000707 <-
EP 1200417	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003504362	T2	20030204	JP 2001-509715	20000707

AT 252566	E 20031115	AT 2000-949673	20000707
ES 2208381	T3 20040616	ES 2000-949673	20000707
CN 1534015	A 20041006	CN 2004-10032296	20000707
HR 2002000021	A1 20030831	HR 2002-21	20020109
HR 20020021	B1 20041031		
US 7038044	B1 20060502	US 2002-30600	20020401

PRIORITY APPLN. INFO.: FR 1999-9061 A 19990709
 WO 2000-FR1966 W 20000707

OTHER SOURCE(S): CASREACT 134:100879; MARPAT 134:100879
 GI




AB Enantiomeric RZCH₂CH₂OH (R = 3,4-dihalophenyl; Z = 2-morpholinylidene) were prepared. Thus, 3,4-F₂C₆H₃COCH₂Cl (preparation given) was condensed with C₆H₄:CHMgBr and the product aminated by PhCH₂NH₂ to give, after (+)-PhCH(OH)CO₂H treatment, (R)-(+) -PhCH₂NHCH₂C(OH)(CH₂)C₆H₃F₂-3,4 (+)-mandelic acid salt which was treated with oxirane to give aminobutanol (R)-(+)-I. The latter was cyclized and the product converted in 2 steps to title compound (R)-(+)-II.

IT 71350-58-8P 320337-77-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of 2-(2-aryl-2-morpholinyl)ethanols as drug intermediates)


RN 71350-58-8 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-3-carboxylic acid, hexahydro-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 320337-77-7 HCPLUS

CN Methanone, (3,4-difluorophenyl)(hexahydro-2-phenyl-1H-pyrrolo[1,2-c]imidazol-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:12273 HCAPLUS

DOCUMENT NUMBER: 134:86271

TITLE: Preparation of pyrimidine derivatives as Src-family protein tyrosine kinase inhibitor compounds

INVENTOR(S): Armstrong, Helen M.; Beresis, Richard; Goulet, Joung L.; Holmes, Mark A.; Hong, Xingfang; Mills, Sander G.; Parsons, William H.; Sinclair, Peter J.; Steiner, Mark G.; Wong, Frederick; Zaller, Dennis M.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 470 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000213	A1	20010104	WO 2000-US17443	20000626 <-
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2383546	AA	20010104	CA 2000-2383546	20000626 <-
EP 1206265	A1	20020522	EP 2000-941701	20000626
EP 1206265	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6498165	B1	20021224	US 2000-604305	20000626
JP 2003523942	T2	20030812	JP 2001-505922	20000626
AT 253915	E	20031115	AT 2000-941701	20000626
PRIORITY APPLN. INFO.:			US 1999-141639P	P 19990630
			WO 2000-US17443	W 20000626

OTHER SOURCE(S): MARPAT 134:86271
GI



AB What are claimed are pyrimidine compds. (shown as I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compns. including the same and their use as inhibitors of tyrosine kinase enzymes and consequently their use in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogenesis, atherosclerosis, graft rejection, rheumatoid arthritis and psoriasis. In I, R1, R2 = independently H, halo, OH, SH, CN, NO₂, alkyl, alkoxy, acyloxy, alkoxycarbonyloxy, carbamoyloxy, alkylthio, sulfinyl, sulfonyl, acyl, alkoxycarbonyl, carbamoyl, amino, acylamino, ureido, sulfamoyl, sulfonylamino, or R1 and R2 can join together to form a fused methylenedioxy ring or a fused 6-membered aromatic ring; terms such as 'alkyl' here and below are further defined in the claims. R3, R5 = independently H, C₁-C₆-alkyl unsubstituted or substituted with 1-3 substituents, aryl, or R3 and R5 taken together can represent :O; R3 or R5 can represent a 2 or 3 C methylene bridge forming a ring of 5-8 atoms fused to the A ring. R4 = H, C₁-C₆-alkyl, C₁-C₆-alkoxyl. X₁, X₂, X₃, X₄ in -X₁:X₂-X₃:X₄- are substituted or unsubstituted CH or N where 0-2 of X₁, X₂, X₃, X₄ are N. X₅, X₆ = independently N, C, optionally substituted CH. A ring = Ph, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, benzothienyl, benzofuranyl, indolyl, imidazolyl, benzimidazolyl, thiadiazolyl. R₇, R₈, R₉, R₁₀ = independently H, halo, OH, SH, CN, NO₂, N₃, N₂+BF₄⁻, alkyl, alkoxy, alkylthio, sulfinyl, sulfonyl, C₁-C₆-alkyl, C₁-C₆-perfluoroalkyl, acyl, alkoxycarbonyl, carbamoyl, acyloxy, alkoxycarbonyloxy, carbamoyloxy, amino, acylamino, ureido, sulfamoyl, sulfonylamino, two of R₇, R₈, R₉, and R₁₀ when on adjacent carbons join together to form a methylenedioxy bridge. N = 0-2. More than 500 example preps. are given, but no preparative method is claimed and no data relating to the usefulness of the compds. are given.

IT 140208-17-9, Gene Lyn protein kinase

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; pyrimidine derivs. as)

RN 140208-17-9 HCPLUS

CN Kinase (phosphorylating), gene lyn protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 317826-43-0P, 2-[(S)-(3-Trifluoromethylphenyl)ethylamino]-4-[5-(3-

diazabicyclo[3.3.0]oct-3-yl)benzimidazol-1-yl]pyrimidine
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation of pyrimidine derivs. as Src-family protein tyrosine kinase
 inhibitor compds.)

RN 317826-43-0 HCAPLUS

CN 2-Pyrimidinamine, 4-[5-(tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]-N-[(1S)-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 317826-08-7P, 2-[(S)-1-Phenylethylamino]-4-[5-(1,3-diazabicyclo[3.3.0]oct-3-yl)benzimidazol-1-yl]pyrimidine
 317826-09-8P, 2-[(S)-1-Phenylethylamino]-4-[6-(1,3-diazabicyclo[3.3.0]oct-3-yl)benzimidazol-1-yl]pyrimidine
 317826-11-2P, 2-[(S)-1-Phenylethylamino]-4-[5-((S)-1,3-diazabicyclo[3.3.0]octan-2-on-3-yl)benzimidazol-1-yl]pyrimidine
 317826-12-3P, 2-[(S)-1-Phenylethylamino]-4-[5-(1,3-diazabicyclo[4.3.0]nonan-2-on-3-yl)benzimidazol-1-yl]pyrimidine
 317826-13-4P, 2-[(S)-1-Phenylethylamino]-4-[6-(1,3-diazabicyclo[3.3.0]octan-2-on-3-yl)benzimidazol-1-yl]pyrimidine
 317826-14-5P, 2-[(S)-1-Phenylethylamino]-4-[5-(1,3-diazabicyclo[3.3.0]octan-2-on-3-yl)-6-methylbenzimidazol-1-yl]pyrimidine
 317826-40-7P, 2-[(S)-1-(3-Nitrophenyl)ethylamino]-4-[5-(1,3-diazabicyclo[3.3.0]octan-2-on-3-yl)benzimidazol-1-yl]pyrimidine
 317826-41-8P, 2-[(S)-1-(3-Trifluoromethylphenyl)ethylamino]-4-[5-(1,3-diazabicyclo[3.3.0]octan-2-on-3-yl)benzimidazol-1-yl]pyrimidine
 317826-42-9P, 2-[(S)-1-(3-Nitrophenyl)ethylamino]-4-[5-(1,3-diazabicyclo[3.3.0]oct-3-yl)benzimidazol-1-yl]pyrimidine
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidine derivs. as Src-family protein tyrosine kinase inhibitor compds.)

RN 317826-08-7 HCAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[5-(tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-09-8 HCAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-11-2 HCAPLUS

CN 3H-Pyrrolo[1,2-c]imidazol-3-one, hexahydro-2-[1-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-1H-benzimidazol-5-yl]-, (7aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-12-3 HCAPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, hexahydro-2-[1-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-1H-benzimidazol-5-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-13-4 HCAPLUS

CN 3H-Pyrrolo[1,2-c]imidazol-3-one, hexahydro-2-[1-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-1H-benzimidazol-6-yl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-14-5 HCAPLUS

CN 3H-Pyrrolo[1,2-c]imidazol-3-one, hexahydro-2-[6-methyl-1-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-1H-benzimidazol-5-yl]-, (7aS)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 317826-40-7 HCAPLUS

CN 3H-Pyrrolo[1,2-c]imidazol-3-one, hexahydro-2-[1-[2-[(1S)-1-(3-nitrophenyl)ethyl]amino]-4-pyrimidinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-41-8 HCAPLUS

CN 3H-Pyrrolo[1,2-c]imidazol-3-one, hexahydro-2-[1-[2-[[[(1S)-1-[3-(trifluoromethyl)phenyl]ethyl]amino]-4-pyrimidinyl]-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317826-42-9 HCAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-(3-nitrophenyl)ethyl]-4-[5-(tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:12267 HCAPLUS

DOCUMENT NUMBER: 134:71602

TITLE: Preparation and effect of benzimidazolylpyrimidine derivatives as SRC kinase inhibitors

INVENTOR(S): Goulet, Joung L.; Holmes, Mark A.; Hunt, Julianne A.; Mills, Sander G.; Parsons, William H.; Sinclair, Peter J.; Zaller, Dennis M.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 173 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000207	A1	20010104	WO 2000-US17510	20000626 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2376957	AA	20010104	CA 2000-2376957	20000626 <--
US 6329380	B1	20011211	US 2000-603688	20000626 <--
EP 1206260	A1	20020522	EP 2000-953637	20000626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503351	T2	20030128	JP 2001-505916	20000626
PRIORITY APPLN. INFO.:			US 1999-141630P	P 19990630
			WO 2000-US17510	W 20000626

OTHER SOURCE(S): MARPAT 134:71602

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title Pyrimidine compds. [I; R1, R2 independently = H, Br, Cl, I, F, OH, SH, CN, NO₂, NH₂; R1R2 ; fused methylenedioxy ring, fused 6-membered aromatic ring; R3, R5 independently = H, alkyl, aryl; R3R5 = O; R4 = H, alkyl, alkoxy; X₁, X₂, X₃, X₄ independently = CH, CBr, COH, CSH, CNO₂, N; R7 = H, NH₂, alkyl, aryl, alkylamino, arylamino; Y = O, N, CH; Z = CO, SO₂, bond; m, n independently = 0, 1, 2, 3, 4], or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compns. including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogenesis, atherosclerosis, graft rejection, rheumatoid arthritis and psoriasis. Thus, the title compound II was prepared and tested.


IT 315717-50-1P 315717-53-4P 315717-68-1P

315717-69-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and effect of benzimidazolypyrimidine derivs. as SRC kinase inhibitors)


RN 315717-50-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-phenyl-3-[1-[[4-[5-(tetrahydro-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]-2-pyrimidinyl]amino]ethyl] - (9CI) (CA INDEX NAME)




RN 315717-53-4 HCAPLUS

CN 1-Piperidinecarboxamide, N-1-naphthalenyl-3-[1-[[4-[5-(tetrahydro-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]-2-pyrimidinyl]amino]ethyl] - (9CI) (CA INDEX NAME)




RN 315717-68-1 HCPLUS

CN 1-Piperidinecarboxamide, N-phenyl-3-[1-[[4-[5-(tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]-2-pyrimidinyl]amino]ethyl]-(9CI) (CA INDEX NAME)



RN 315717-69-2 HCPLUS

CN 1-Piperidinecarboxamide, N-1-naphthalenyl-3-[1-[[4-[5-(tetrahydro-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1H-benzimidazol-1-yl]-2-pyrimidinyl]amino]ethyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:861490 HCPLUS

DOCUMENT NUMBER: 134:25357

TITLE: Phenyl urea IL-8 receptor antagonists for therapeutic use

INVENTOR(S): Palovich, Michael R.; Widdowson, Katherine L.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072845	A1	20001207	WO 2000-US14661	20000526 <--
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375683	AA	20001207	CA 2000-2375683	20000526 <--



RN 311320-07-7 HCPLUS

CN Benzonitrile, 4-[[2-(2-bromophenyl)hexahydro-1-oxoimidazo[1,5-a]pyridin-3(2H)-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)



IT 311320-02-2 311320-03-3 311320-04-4

311320-05-5 311320-06-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phenylurea IL-8 receptor antagonists for therapeutic use)

RN 311320-02-2 HCPLUS

CN Benzonitrile, 4-[[[(7aR)-2-(2-bromophenyl)hexahydro-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

BR 2000010843	A 20020219	BR 2000-10843	20000526 <--
EP 1180028	A1 20020220	EP 2000-936369	20000526 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200103448	T2 20020621	TR 2001-200103448	20000526
JP 2003500447	T2 20030107	JP 2000-620957	20000526
AU 766082	B2 20031009	AU 2000-51691	20000526
NZ 514729	A 20031128	NZ 2000-514729	20000526
US 6566387	B1 20030520	US 2001-9212	20011108
ZA 2001009628	A 20021122	ZA 2001-9628	20011122
NO 2001005775	A 20011127	NO 2001-5775	20011127 <--
PRIORITY APPLN. INFO.: .		US 1999-136717P	P 19990528
		WO 2000-US14661	W 20000526

OTHER SOURCE(S) : MARPAT 134:25357

AB The invention discloses the use of Ph ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). Preparation of compds. of the invention is described.

IT 311319-99-0P 311320-01-1P 311320-07-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylurea IL-8 receptor antagonists for therapeutic use)

RN 311319-99-0 HCPLUS

CN Benzonitrile, 4-[[(7aS)-2-(2-bromophenyl)hexahydro-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 311320-01-1 HCPLUS

CN Benzonitrile, 4-[[(6R,7aS)-2-(2-bromophenyl)hexahydro-6-hydroxy-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 311320-03-3 HCPLUS

CN Benzonitrile, 4-[[^{7aS}]-2-(2,3-dichlorophenyl)hexahydro-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 311320-04-4 HCPLUS

CN Benzonitrile, 4-[[^{7aR}]-2-(2,3-dichlorophenyl)hexahydro-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 311320-05-5 HCPLUS

CN Benzonitrile, 4-[[2-(2,3-dichlorophenyl)hexahydro-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 311320-06-6 HCPLUS


CN Benzonitrile, 4-[[2-(2-bromophenyl)hexahydro-1-oxo-3H-pyrrolo[1,2-c]imidazol-3-ylidene]amino]-3-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 14 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:810729 HCPLUS
 DOCUMENT NUMBER: 134:110100
 TITLE: Immunomodulator structure-activity
 relationships: contribution of molecular modeling
 Panouse, J. J.; Giorgi, H.; Daspet, J.-P.; Seilles,
 E.; Robert, J.-F.
 CORPORATE SOURCE: Equipe de Chimie therapeutique et Laboratoire de
 Biophysique medicale et pharmaceutique, Faculte de
 Medecine et de Pharmacie, Besancon, F 25000, Fr.
 SOURCE: Annales Pharmaceutiques Francaises (2000),
 58(5), 291-302
 CODEN: APFRAD; ISSN: 0003-4509
 PUBLISHER: Masson Editeur
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 AB Mol. modeling used to compare 64 immunostimulant compds. with pyrrole quinolein or purine nuclei has pointed out that a common spatial structure is found in most of the active compds. An addnl. study of immunostimulants (levamisole, muramyldipeptide) or immunosuppressive mols. (rapamycin) was performed. A common **pharmacophore** was found on every studied compound. It was composed of three neighboring electroattractive atoms and a further fourth atom. The favorable conformation of rapamycin for immunosuppressive action, which is not the more stable conformation, could explain the loss of its activity, or those of related macrolides, when some minor chemical modifications are tested. These findings validate the proposed concept and provide a view of the mechanism of action of most of the **immunomodulator** compds. for preparing novel compds.
 IT 60725-59-9D, derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mol. modeling and structure-activity relationships for
 immunomodulators)
 RN 60725-59-9 HCPLUS
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-chlorophenyl)tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L16 ANSWER 15 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:166588 HCPLUS
 DOCUMENT NUMBER: 130:196952
 TITLE: Preparation of N-alkanoylphenylalanine derivatives as vascular cell adhesion molecule-1 (VCAM-1) binding inhibitors
 INVENTOR(S): Chen, Li; Guthrie, Robert William; Huang, Tai-Nang;
 Hull, Kenneth G.; Sidduri, Achyutharao; Tilley,
 Jefferson Wright
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: EnglishFAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910312	A1	19990304	WO 1998-EP5135	19980813 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2301377	AA	19990304	CA 1998-2301377	19980813 <--
AU 9892620	A1	19990316	AU 1998-92620	19980813 <--
AU 739511	B2	20011011		
EP 1005445	A1	20000607	EP 1998-945235	19980813 <--
EP 1005445	B1	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000482	T2	20000621	TR 2000-200000482	19980813 <--
BR 9811730	A	20000905	BR 1998-11730	19980813 <--
JP 2001514162	T2	20010911	JP 2000-507643	19980813 <--
JP 3555876	B2	20040818		
NZ 502813	A	20021025	NZ 1998-502813	19980813
RU 2220950	C2	20040110	RU 2000-106434	19980813
EP 1403247	A1	20040331	EP 2003-27533	19980813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AT 267801	E	20040615	AT 1998-945235	19980813
PT 1005445	T	20040930	PT 1998-945235	19980813
ES 2221197	T3	20041216	ES 1998-945235	19980813
ZA 9807604	A	19990518	ZA 1998-7604	19980821 <--
US 6229011	B1	20010508	US 1998-137798	19980821 <--
TW 490458	B	20020611	TW 1998-87113768	19980821
HR 2000000080	A1	20001231	HR 2000-80	20000211 <--
NO 2000000841	A	20000221	NO 2000-841	20000221 <--
PRIORITY APPLN. INFO.:			US 1997-56718P	P 19970822
			US 1998-94592P	P 19980729
			EP 1998-945235	A3 19980813
			WO 1998-EP5135	W 19980813

OTHER SOURCE(S) : MARPAT 130:196952

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [one of X, X1 = H, halo, lower alkyl and the other = (un)substituted group X6, X7, X10; R1 = H, lower alkyl; n = 0, 1; Het = 5-6 membered heteroarom. ring containing 1-3 heteroatoms N, O, S, or 9-10 membered bicyclic heteroarom. ring containing 1-4 heteroatoms N, O, S; R18 = lower alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl; R19 = (un)substituted lower alkyl, aryl, heteroaryl; R20 = lower alkyl, lower

alkanoyl; R19R20 = (CH₂)₄; Y = group Y₁, (un)substituted 5-6 membered monocyclic heteroarom. group containing 1-3 heteroatoms N, O, S, 9-10 membered bicyclic heteroarom. group containing 1-4 heteroatoms N, O, S; R22, R23 = H, lower alkyl, lower alkoxy, lower alkoxyaryl, lower alkylamino, aryl, arylalkyl, NO₂, CN, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkanoyl, halo, perfluoroalkyl; both R22 and R23 ≠ H; R24 = H, OH, lower alkyl, lower alkoxy, lower alkylsulfonyl, amino, aryl, NO₂, CN, halo, (un)substituted 1-amino-5-tetrazolyl, sulfonamido, carboxamido; R22R24 = fused benzene ring; Z = H, lower alkyl; R31 = H, (un)substituted lower alkyl] and pharmaceutically acceptable salts and esters thereof, are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing integrin VLA-4. Such compds. are useful for treating diseases whose symptoms and /or damage are related to the binding of VCAM-1 to cells expressing VLA-4. Thus, amidation of 4-amino-N-tert-butoxycarbonyl-L-phenylalanine Me ester with 2,6-dichlorobenzoyl chloride, followed by acidic deprotection, amidation with 2-chloro-6-methylbenzoic acid, and saponification gave desired title derivative II. II inhibited VLA-4 binding to immobilized VCAM-1 with IC₅₀ = 0.33 nM in solid-phase dual antibody assay.

IT 220847-15-4P 220847-16-5P 220847-25-6P

220849-17-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-alkanoylphenylalanine derivs. as vascular cell adhesion mol.-1 (VCAM-1) binding inhibitors)

RN 220847-15-4 HCPLUS

CN L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-[(8aS)-hexahydro-3-(4-hydroxyphenyl)-1-oxoimidazo[1,5-a]pyridin-2(3H)-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220847-16-5 HCPLUS

CN L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-[(8aS)-hexahydro-3-(2-naphthalenyl)-1-oxoimidazo[1,5-a]pyridin-2(3H)-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220847-25-6 HCPLUS

CN L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-[(8aS)-hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220849-17-2 HCPLUS

CN L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-[(8aR)-hexahydro-3-(4-hydroxyphenyl)-1-oxoimidazo[1,5-a]pyridin-2(3H)-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220848-57-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation of N-alkanoylphenylalanine derivs. as vascular cell adhesion mol.-1 (VCAM-1) binding inhibitors)

RN 220848-57-7 HCPLUS

CN L-Phenylalanine, N-(2-chloro-6-methylbenzoyl)-4-[(8aS)-hexahydro-3-(4-hydroxyphenyl)-1-oxoimidazo[1,5-a]pyridin-2(3H)-yl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 16 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:753972 HCPLUS

DOCUMENT NUMBER: 128:123431

TITLE: Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide

AUTHOR(S): De Luca, Annamaria; Natuzzi, Fedele; Falcone, Giulia; Duranti, Andrea; Lentini, Giovanni; Franchini, Carlo; Tortorella, Vincenzo; Conte Camerino, D.

CORPORATE SOURCE: Facolta di Farmacia, Dipartimento Farmacobiologico, Unita di Farmacologia, Via Orabona 4, Bari, I-70125, Italy

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1997), 356(6), 777-787

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To search for potent use-dependent blockers of skeletal muscle sodium channels as potential antimyotonic agents, the actions of newly synthesized chiral analogs of mexiletine and tocainide were tested in vitro on sodium currents of single fibers of frog semitendinosus muscle by vaseline-gap voltage clamp method. The effect of each drug on the maximal peak Na^+ transient ($I_{\text{Na max}}$) was evaluated as both tonic and use-dependent block by using infrequent depolarizing stimulation and trains of pulses at 2-10 Hz frequency, resp. The mexiletine analog 3-(2,6-dimethylphenoxy)-2-methylpropanamine (Me2), having an increased distance between the Ph and the amino groups, was less potent than mexiletine in producing a tonic block but produced a remarkable use-dependent block. In fact, the half-maximal concentration (IC_{50}) for tonic block of S(-)-Me2 was 108 μM vs. 54.5 μM of R(-)-mexiletine, but the

IC₅₀ was 6.2 times lowered by the 10 Hz stimulation with respect to the 2.4-fold decrease observed with mexiletine. The R(-)-mexiletine and the S(-)-Me2 were about twofold more potent than the corresponding enantiomers in producing a tonic block, but the stereoselectivity attenuated during use-dependent blockade. The more lipophilic 2-(4-chloro-2-methylphenoxy)-1-phenylethylamine (Me1), presently available as raceme, produced a potent and irreversible tonic block of the sodium currents with an IC₅₀ of 29 μM, but had a less pronounced use-dependent inhibition, with a 1.9-fold decrease of the IC₅₀ at 10 Hz. The R(-) isomer of 2',6'-valinoxylidide (To1), a tocainide derivative with an increased hindrance on the chiral carbon atom, was twofold (IC₅₀ = 209 μM) and tenfold (IC₅₀ = 27.4 μM) more potent than R(-)-tocainide in tonic and use-dependent block, resp. Tocainide was almost devoid of stereoselectivity, whereas the eudismic ratio of To1 [IC₅₀ S(+)-To1/IC₅₀ R(-)-To1] was 1.7. As for mexiletine and Me2, the stereoselectivity of To1 was the weaker the higher the frequency of stimulation. The cyclic pyrroloimidazolonic tocainide analog To2 produced a small tonic block at 500 μM, and 1 min stimulation at 10 Hz was needed to show up a 50% block of INa maximum. All the compds. produced a left-shift of the steady-state inactivation curve correlated pos. with the extent of use-dependent inhibition, with the exception of the cyclic To2 that acted as an open-channel blocker. The highly use-dependent blockers Me2 and To1 might be promising drugs to solve high frequency discharges of action potentials typical of myotonic muscles. Concomitantly the high potency of Me1 and the open-channel block exerted by To2 can represent important features to get selective blockers for skeletal muscle sodium channels.


IT 201986-87-0 201986-88-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivs. of mexiletine and tocainide)

RN 201986-87-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(4-chlorophenyl)hexahydro-, monohydrobromide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

RN 201986-88-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(4-chlorophenyl)hexahydro-, monohydrobromide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:608903 HCPLUS
 DOCUMENT NUMBER: 125:316198
 TITLE: New 7-hydroxy-1,3-diazabicyclo[3.3.0]octane derivatives: evaluation of their in vitro immunomodulating effects
 AUTHOR(S): Issartel, V.; Spehner, V.; Bahaji, H.; Seilles, E.; Couquelet, J.
 CORPORATE SOURCE: Faculte de Pharmacie, Groupe de Recherche en Pharmacochimie, Clermont-Ferrand, 63001, Fr.
 SOURCE: European Journal of Medicinal Chemistry (1996), 31(9), 717-723
 CODEN: EJMCA5; ISSN: 0223-5234
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In order to improve the water solubility of some previously reported immunoactive dioxothiadiazabicyclo[3.3.0]octanes, we synthesized a series of new diazabicyclo[3.3.0]octanols from the trans-4-hydroxy-L-proline Me ester in two steps. Acylation of the ester with an isocyanate or an isothiocyanate under the appropriate conditions afforded N-acylated derivs. exclusively. Then through a cyclization process in the presence of sodium methylate, bicyclic derivs. were obtained, most of them as a mixture of two diastereomers which were separated by column chromatog. A mitogenic stimulation assay using the T-cell mitogen phytohemagglutinin was performed with human peripheral blood leukocytes in the presence of the different synthesized compds. and with levamisole as reference. Several compds. showed marked stimulant effects on the proliferation of lymphocytes as compared to levamisole, but no correlation could be established between mol. configuration and stimulation or inhibition effects on proliferation.
 IT 81703-65-3P 183290-18-8P 183290-19-9P
 183290-20-2P 183290-22-4P 183506-52-7P
 183506-53-8P 183506-54-9P 183506-55-0P
 183506-56-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (diazabicyclo[3.3.0]octanols preparation and structure-related immunomodulating effect)

RN 81703-65-3 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-6-hydroxy-2-phenyl-3-thioxo-
(9CI) (CA INDEX NAME)



RN 183290-18-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-6-hydroxy-2-phenyl-,
(6R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 183290-19-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3-chlorophenyl)tetrahydro-6-
hydroxy-, (6R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 183290-20-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-cyclohexyltetrahydro-6-hydroxy-,
(6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 183290-22-4 HCAPLUS
 CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-cyclohexylhexahydro-6-hydroxy-3-thioxo- (9CI) (CA INDEX NAME)




RN 183506-52-7 HCAPLUS
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-chlorophenyl)tetrahydro-6-hydroxy-, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 183506-53-8 HCAPLUS
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-6-hydroxy-2-phenyl-, (6R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 183506-54-9 HCAPLUS
 CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-chlorophenyl)tetrahydro-6-

Shiao 10_780415

hydroxy-, (6R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 183506-55-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3-chlorophenyl)tetrahydro-6-hydroxy-, (6R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 183506-56-1 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-cyclohexyltetrahydro-6-hydroxy-, (6R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L16 ANSWER 18 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:46111 HCAPLUS

DOCUMENT NUMBER: 120:46111


TITLE: Nanomolar-affinity, non-peptide oxytocin receptor antagonists

AUTHOR(S): Evans, Ben E.; Lundell, George F.; Gilbert, Kevin F.; Bock, Mark G.; Rittle, Kenneth E.; Carroll, Leigh Anne; Williams, Peter D.; Pawluczyk, Joseph M.; Leighton, James L.; et al.

CORPORATE SOURCE: Dep. Med. Chem. New Lead Pharmacol., Merck Res. Lab.,

SOURCE: West Point, PA, 19486, USA
 Journal of Medicinal Chemistry (1993),
 36(25), 3993-4005
 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Non-peptide antagonists of the peptide hormone oxytocin (OT) with nanomolar OT **receptor** affinities are described. These compds. incorporate novel amido- and amidoalkylcamphor variations to the lead structure L-366,509 (I, R = OH, R1 = CH₂CO₂H) to achieve **receptor** affinity enhancements of 2-3 orders of magnitude over that compound. The new OT antagonist L-367,773 (I, R = H R1 = 4-imidazolylacetylarnino) is shown to be an orally bioavailable agent with good duration *in vivo* and to inhibit OT-stimulated uterine contractions effectively in several *in vitro* and *in vivo* models.

IT 151952-79-3P 151952-91-9P 152140-38-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as oxytocin antagonist)

RN 151952-79-3 HCPLUS


CN Spiro[1H-indene-1,4'-piperidine], 2,3-dihydro-1'-[[[7,7-dimethyl-2-(tetrahydro-6-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)bicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 151952-91-9 HCPLUS

CN Spiro[1H-indene-1,4'-piperidine], 1'-[[[7,7-dimethyl-2-(tetrahydro-5-imino-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)bicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]-2,3-dihydro-, [1S-[1 α ,2 α (R*)],4 β]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152140-38-0 HCPLUS




CN Spiro[1H-indene-1,4'-piperidine], 1'-[[[7,7-dimethyl-2-(tetrahydro-5-imino-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)bicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]-2,3-dihydro-, [1S-[1 α ,2 α (S*),4 β]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 19 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:539210 HCAPLUS
 DOCUMENT NUMBER: 119:139210
 TITLE: Preparation of isoxazolyl-4,5,6,7-tetrahydroisoindoline-1,3-dione derivatives as herbicides
 INVENTOR(S): Sano, Hiromi; Mizukai, Muneharu; Shindo, Masahiro;
 Honma, Toyokuni
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04352784	A2	19921207	JP 1991-154700	19910626 <--
PRIORITY APPLN. INFO.:			JP 1990-171443	A1 19900629
OTHER SOURCE(S): GI	MARPAT	119:139210		



AB The title compds. [I; R1 = (halo)alkyl, (halo- or alkyl-substituted)aryl; R2 = H, halo, (halo)alkyl, (halo- alkyl-substituted) aryl; R3 = Q, Q1, etc.; R4 = H, alkyl, alkenyl, alkynyl; R5 = H, halo, alkyl, alkenyl, alkynyl, OH, SH, halo, alkoxy, alkoxy carbonyl, (CO2H- or acyl-substituted) alkoxy, etc.; R6 - R9 = H, halo, alkyl; W = O, S; Z = O, S, CHR8], also useful as growth regulators, are prepared Thus, 620 mg 3-ethoxycarbonylthiomorpholine and a catalytic amount of Et3N were added to a solution of 590 mg 5-tert-butyl-3-isocyanatoisoxazole in PhMe and the mixture was stirred at room temperature for 1 h and at 60° for 1.5 h to give a thiadiazabicyclonanonanedione I (R1 = CMe3, R2 = H, R3 = 3-Q2). I (R1 =


CMe₃, R₂ = Cl, R₃ = 3-Q3) at 0.5kg/ha preemergence controlled 96-100% 7 weeds such as Echinochloa crus-galli, Sorghum halepense , and Abutilon avicinnae. A total of 105 I were prepared

IT 148014-00-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)

RN 148014-00-0 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[5-(1,1-dimethylethyl)-3-isoxazolyl]tetrahydro- (9CI) (CA INDEX NAME)



L16 ANSWER 20 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:115937 HCAPLUS

DOCUMENT NUMBER: 118:115937

TITLE: Detection of liquid injection using an atmospheric pressure ionization radiofrequency plasma source

AUTHOR(S): Zhao, Jianguo; Lubman, David M.

CORPORATE SOURCE: Dep. Chem., Univ. Michigan, Ann Arbor, MI, 48109, USA

SOURCE: Analytical Chemistry (1993), 65(7), 866-76

CODEN: ANCHAM; ISSN: 0003-2700

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An atmospheric pressure rf plasma source which operates in a variety of different

buffer gases has been developed as an ionization method for organic samples introduced by liquid injection into atmospheric pressure ionization mass spectrometry (API/MS). The rf source can operate in He at <1 W of load power at 165 kHz. It can also be sustained in Ar, N₂, air, and CO₂ at a load power of <15 W. In most cases studied, the protonated mol., MH⁺, is observed with little or no fragmentation even under the relatively high current conditions of the discharge. However, using increasingly higher acceleration voltages between the skimmers in the differentially pumped region between atmospheric pressure and high vacuum, one can induce fragmentation

via collision-induced dissociation. This can be assisted in these expts. via the use of a heavy buffer gas. The detection limits achieved for rf/API plasma detection are typically in the low femtomole region for small organic mols. including neurotransmitters, PTH-amino acids, steroids, drugs, pesticides, and explosives. The detection can be performed with quantitation over at least 4 orders of magnitude.


IT 29635-99-2, PTH-proline

RL: ANT (Analyte); ANST (Analytical study)
(detection of, by atmospheric pressure ionization mass spectrometry using radiofrequency plasma source)

RN 29635-99-2 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-phenyl-3-thioxo-, (7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 21 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:214522 HCAPLUS
 DOCUMENT NUMBER: 116:214522
 TITLE: Preparation of (heterocyclphenylthio)]cycloalkanecarboxylic acid derivatives as herbicides and plant growth regulators
 INVENTOR(S): Pissiotas, Georg; Moser, Hans; Brunner, Hans Georg; Steiner, Eginhard
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 223 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 468924	A2	19920129	EP 1991-810577	19910716 <--
EP 468924	A3	19920429		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2047489	AA	19920124	CA 1991-2047489	19910719 <--
US 5180418	A	19930119	US 1991-732988	19910719 <--
AU 9181261	A1	19920130	AU 1991-81261	19910722 <--
AU 638854	B2	19930708		
ZA 9105720	A	19920325	ZA 1991-5720	19910722 <--
BR 9103125	A	19920428	BR 1991-3125	19910722 <--
JP 04234360	A2	19920824	JP 1991-206542	19910723 <--
PRIORITY APPLN. INFO.:			CH 1990-2439	A 19900723
OTHER SOURCE(S):	MARPAT 116:214522			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; W = Q1-Q3, etc.; A = COR3, cyano; R1 = H, F; R2 = halo, cyano; R3 = Cl, amino, XR5, pyrrolidino, morpholino, etc.; R4, R14 = H, F, Cl, Br, alkyl, CF3; R5 = H, (cyclo)alkyl, alkoxyalkyl, haloalkyl, alkylthioalkyl, cyanoalkyl, alkenyl, (substituted) PhCH2, etc.; X, Z = O, S; n = 0-4], were prepared Thus, Me 1-(5-amino-2-chloro-4-fluorophenylthio)cyclobutanecarboxylate (preparation given) and 3,4,5,6-tetrahydrophtalic anhydride were refluxed 5 h in AcOH to give title compound II. II at 250 g/ha postemergent gave 100% control of Abutilon, Sida spinosa, etc.


IT 140909-12-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except

adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide and plant growth regulator)

RN 140909-12-2 HCAPLUS

CN Cyclobutanecarboxylic acid, 1-[(2-chloro-4-fluoro-5-(1,5,6,7,8,8a-hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)phenyl)thio]-, methyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 22 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:450305 HCAPLUS

DOCUMENT NUMBER: 115:50305

TITLE: Preparation of tripeptides having thyrotropin-releasing hormone activities

INVENTOR(S): Vincent, Michel; Remond, Georges; Portevin, Bernard; Herve, Yolande; Lepagnol, Jean; Biton, Catherine

PATENT ASSIGNEE(S): ADIR et Cie., Fr.

SOURCE: Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 406119	A1	19910102	EP 1990-401877	19900629 <--
EP 406119	B1	19940119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2649110	A1	19910104	FR 1989-8672	19890629 <--
FR 2649110	B1	19941021		
ZA 9004495	A	19910327	ZA 1990-4495	19900611 <--
US 5098888	A	19920324	US 1990-536193	19900611 <--
CA 2019633	AA	19901229	CA 1990-2019633	19900622 <--
AU 9057911	A1	19910103	AU 1990-57911	19900628 <--
AU 627898	B2	19920903		
JP 03048695	A2	19910301	JP 1990-168632	19900628 <--
AT 100464	E	19940215	AT 1990-401877	19900629 <--
ES 2062443	T3	19941216	ES 1990-401877	19900629 <--
PRIORITY APPLN. INFO.:			FR 1989-8672	A 19890629
			US 1989-384429	B2 19890724
			EP 1990-401877	A 19900629

OTHER SOURCE(S): MARPAT 115:50305

GI




AB The title compds. [I; A = part of a 2-oxo heterocycle, e.g., 2-oxo-5-pyrrolidine, 2-oxo-6-piperidine, 2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidine, 2-oxo-4-thiazolidine, etc.; B = part of a 2-azabicyclo[2.2.1]heptane ring, a 1,4-dialkyl-2-azabicyclo[2.2.2]octane ring; R = H, alkyl, (substituted) 4-imidazolylmethyl, etc.] and their **pharmaceutically** acceptable salts were prepared via treating amides II with BOC-NH-CHRCO₂H [BOC = tert-butoxycarbonyl], deprotection, condensation of the product with the appropriate (N-protected) or/and ester-activated cyclic amino acid and optional deprotection.
 2-Azabicyclo[2.2.1]heptane-3-carboxamide III [R₂ = H] (preparation given) was condensed with (S)-BOC-His(N_γ-Me)-OH to give III [R₂ = (S)-BOC-His(N_γ-Me)], which was deprotected and then condensed with Z-(S)-PyroGlu-OH [Z = benzyloxycarbonyl] to give, after deprotection, III [R₂ = H-(S)-PyroGlu-(S)-His(N_γ-Me)]. This at 10 mg/kg i.p. inhibited 66% the decrease of cholinergic neurotransmission (manifested by the decrease of synaptosomal uptake of choline) in pentobarbital-narcotized rats compared with 35% inhibition by TSH releasing hormone (TRH) at the same dose.

IT **134795-23-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of TRH analogs)

RN 134795-23-6 HCPLUS

CN 5,8-Ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chlorophenyl)-8,8a-dihydro-5,8-dimethyl- (9CI) (CA INDEX NAME)



L16 ANSWER 23 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:611972 HCPLUS

DOCUMENT NUMBER: 113:211972

TITLE: Preparation of herbicidally active N-phenyl azoles

INVENTOR(S): Pissiotas, Georg; Moser, Hans; Brunner, Hans Georg

PATENT ASSIGNEE(S) : Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 49 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 370955	A1	19900530	EP 1989-810875	19891116 <--
EP 370955	B1	19941012		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5049181	A	19910917	US 1989-440007	19891121 <--
CA 2003666	AA	19900525	CA 1989-2003666	19891123 <--
AU 8945542	A1	19900628	AU 1989-45542	19891124 <--
AU 621166	B2	19920305		
ZA 8908986	A	19900829	ZA 1989-8986	19891124 <--
JP 02184676	A2	19900719	JP 1989-306341	19891125 <--
BR 8905952	A	19900619	BR 1989-5952	19891127 <--
PRIORITY APPLN. INFO. :			CH 1988-4384	A 19881125
OTHER SOURCE(S) :	MARPAT 113:211972			
GI				



AB The title compds. [I; R = SOMR₃, di(C₁₋₄ alkyl)amino, (un)substituted, optionally benzo-fused 5- or 6-membered heterocycle bound via C or N atom; R₁ = H, halo; R₂ = halo; R₃ = C₁₋₁₀ alkyl; C₆H₄R₄p, CH₂C₆H₄R₄p; R₄ = C₁₋₄ alkyl, C₁₋₄ alkoxy, halo; A = C₁₋₄ alkylene; W = heterocyclic moiety Q, Q₁, Q₂; X = H, halo, C₁₋₄ alkyl; Y = C₁₋₄ alkyl; XY = (un)substituted (CH₂)_q chain; Z = halo, Me, C₁₋₆ alkoxy, C₁₋₆ alkylthio; m = 0-2; n = 0, 1; p = 0-3; q = 3, 4] and their salts, were prepared as herbicides and plant growth regulators. A solution of 3.5 g 3-chloro-2-(4-chloro-2-fluoro-5-chlorocarbonylphenyl)-4,5,6,7-tetrahydro-2H-indazole in 50 mL PhMe was added dropwise to 1.4 g Me₂CHSCH₂CHMeOH and 1.5 mL Et₃N in 50 mL PhMe and the mixture was stirred 5 h at room temperature to give 3.2 g I [R = SCHMe₂, R₁ = F, R₂ = Cl, A = CHMeCH₂, W = Q, XY = (CH₂)₄, Z = Cl] (II). The analogous II (R = SEt) at 250 g/ha gave 100% control of Sinapis, Setaria, and Stellaria preemergence, and of approx. 11 weeds, e.g., Abutilon, postemergence.


IT 130432-52-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide and plant growth **regulator**)

RN 130432-52-9 HCAPLUS

CN Benzoic acid, 2-chloro-4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 2-(dimethylamino)-1-methylethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 24 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:459178 HCAPLUS

DOCUMENT NUMBER: 113:59178

TITLE: Preparation of (dioxoheterobicycyl)alkoxybenzenes as herbicides and plant growth **regulators**

INVENTOR(S): Fischer, Reiner; Lindel, Hans; Schallner, Otto; Marhold, Albrecht; Ooms, Pieter; Santel, Hans Joachim; Schmidt, Robert R.; Luerssen, Klaus; Strang, Harry

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 94 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3827221	A1	19900215	DE 1988-3827221	19880811 <-
EP 363585	A1	19900418	EP 1989-114065	19890729 <-
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 02101066	A2	19900412	JP 1989-207032	19890811 <-
PRIORITY APPLN. INFO.:			DE 1988-3827221	A 19880811
OTHER SOURCE(S):	CASREACT 113:59178; MARPAT 113:59178			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = H, halo; R2 = alkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, COR4, SO2R5; R4 = alkoxyalkylamino, alkoxyalkyl, (halo-substituted) alkyl, alkoxy, alkoxyalkoxyl; R5 = (halo)alkyl, (substituted) aryl; R6,R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl; R6R7 = alkylene; R8 = H, alkyl, alkenyl, alkynyl, alkoxyalkyl, cycloalkyl; R9 = Q1-Q5; X1, X2 = O, S], useful as herbicides and plant growth **regulators** (no data), were prepared. Thus, 2-(2-fluoro-5-hydroxy-4-methylphenyl)hexahydroimidazo[1,5-a]pyridine-1,3-


dione, (preparation given) K₂CO₃, and propargyl bromide were stirred .apprx.6 h in MeCN at 70° to give 72% II. I are said to have superior herbicidal activity/selectivity and are useful as defoliants/desiccants on cotton.

IT 128185-95-5P 128185-96-6P 128185-99-9P
 128186-00-5P 128186-01-6P 128186-02-7P
 128186-03-8P 128186-04-9P 128186-05-0P
 128186-06-1P 128186-07-2P 128186-09-4P
 128186-10-7P 128186-11-8P 128186-15-2P
 128186-16-3P 128186-17-4P 128186-18-5P
 128186-19-6P 128186-20-9P 128186-21-0P
 128186-22-1P 128186-23-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide and plant growth regulator)


RN 128185-95-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-(2-propynloxy)phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128185-96-6 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[5-(2-ethoxypropoxy)-2-fluoro-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128185-99-9 HCAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-methyl-3-(2-propynloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 128186-00-5 HCAPLUS
 CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-methyl-3-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 128186-01-6 HCAPLUS
 CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-methyl-3-(2-propenyl)phenyl]- (9CI) (CA INDEX NAME)




RN 128186-02-7 HCAPLUS
 CN Propanoic acid, 2-[5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 128186-03-8 HCAPLUS
 CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-(2-

propenyl oxy)phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-04-9 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-(1-methylethoxy)phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-05-0 HCAPLUS

CN Propanenitrile, 2-[4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 128186-06-1 HCAPLUS

CN Propanoic acid, 2-[4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 128186-07-2 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-09-4 HCAPLUS

CN Carbonic acid, 2-ethoxyethyl 4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-2-methylphenyl ester (9CI) (CA INDEX NAME)




RN 128186-10-7 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[5-(2-ethoxyethoxy)-2-fluoro-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-11-8 HCAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[5-(difluoromethoxy)-2-fluoro-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-15-2 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[5-(3-ethoxy-2-methylpropoxy)-2-fluoro-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 128186-16-3 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-5-(3-methoxybutoxy)-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-17-4 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-5-(3-methoxy-2-methylpropoxy)-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-18-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-5-[3-methoxy-2-(methoxymethyl)-2-methylpropoxy]-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-19-6 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-[2-methyl-3-(methylthio)propoxy]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-20-9 HCAPLUS

CN Carbamic acid, [1-methyl-2-(1-methylethoxy)ethyl]-, 4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-2-methylphenyl ester (9CI) (CA INDEX NAME)




RN 128186-21-0 HCAPLUS


CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[5-(2-ethoxy-1-methylethoxy)-2-fluoro-4-methylphenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-22-1 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-(1-methyl-2-oxopropoxy)phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 128186-23-2 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[2-fluoro-4-methyl-5-[(tetrahydro-2-furanyl)methoxy]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



IT 128186-25-4P 128186-26-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for herbicide and plant growth regulator)
RN 128186-25-4 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(2-fluoro-5-hydroxy-4-methylphenyl)tetrahydro- (9CI) (CA INDEX NAME)





RN 128186-26-5 HCAPLUS
 CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(2-fluoro-5-hydroxy-4-methylphenyl)-
 2,3,6,7,8,8a-hexahydro-3-thioxo- (9CI) (CA INDEX NAME)



L16 ANSWER 25 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:406337 HCAPLUS
 DOCUMENT NUMBER: 113:6337
 TITLE: (Annelated) azolylthiobenzoates as herbicides, plant
 growth regulators, defoliants, and
 desiccants
 INVENTOR(S): Pissiotas, Georg; Moser, Hans; Brunner, Hans Georg
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Ger. Offen., 47 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3919320	A1	19891221	DE 1989-3919320	19890613 <--
US 4946492	A	19900807	US 1989-361188	19890605 <--
EP 347382	A2	19891220	EP 1989-810432	19890607 <--
EP 347382	A3	19900314		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8936433	A1	19891221	AU 1989-36433	19890615 <--
AU 616978	B2	19911114		
BR 8902898	A	19900201	BR 1989-2898	19890615 <--
ZA 8904554	A	19900228	ZA 1989-4554	19890615 <--
JP 02040367	A2	19900209	JP 1989-154369	19890616 <--
US 5039329	A	19910813	US 1990-528662	19900524 <--
PRIORITY APPLN. INFO.:				
		CH 1988-2322	A 19880616	
		CH 1988-3719	A 19881006	
		US 1989-361188	A3 19890605	
OTHER SOURCE(S):	MARPAT 113:6337			
GI				




AB The title compds. [I; R1 = H, halo; R2 = halo; A = (substituted) alkylene; R3 = alkyl, hydroxyalkyl; Q = OH, halo, SCN, CN, alkenyl, haloalkenyl, cyanoalkenyl, alkynyl, amino, silyl, carboxyalkenyl, PhCO, PhCH2CO, etc.; AQ = CH(COMe)CO2R3; W = heterocycles Q1-Q3; X = H, halo; Y = alkyl; XY = atoms to complete a (Me-substituted) 5-6 membered ring; Z = halo, Me, alkoxy, alkylthio; n = 0, 1], were prepared Thus, HSCHMeCO2Me and Et3N in PhMe at 10° were treated with heterocyclbenzoyl chloride II (R4 = Cl) in PhMe and the mixture was stirred 12 h to give II (R4 = SCHMeCO2Me) (III). III at 4 kg/ha postemergent gave complete control of Solanum lycopersicum. Several I were useful as desiccants/defoliants on cotton and as plant growth **regulators/yield enhancers** on soybeans.

IT 127452-69-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, with thiolactate)

RN 127452-69-1 HCAPLUS

CN Benzoyl chloride, 2-chloro-4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)- (9CI) (CA INDEX NAME)




IT 127452-43-1P 127452-45-3P 127452-46-4P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide, plant growth **regulator**, desiccant, and defoliant)


RN 127452-43-1 HCAPLUS

CN Propanoic acid, 2-[[2-chloro-4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)benzoyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 127452-45-3 HCAPLUS

CN Acetic acid, [[2-chloro-4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)benzoyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 127452-46-4 HCAPLUS

CN Propanoic acid, 2-[[2-chloro-4-fluoro-5-(hexahydro-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)benzoyl]thio]- (9CI) (CA INDEX NAME)



L16 ANSWER 26 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:406153 HCAPLUS

DOCUMENT NUMBER: 113:6153

TITLE: Preparation of N-(alkoxyhalophenyl)phthalimides and analogs as herbicides and plant growth



regulators

INVENTOR(S) : Schallner, Otto; Fischer, Reiner; Marhold, Albrecht;
 Reubke, Karl Julius; Santel, Hans Joachim; Schmidt,
 Robert R.; Luerssen, Klaus; Strang, Harry
 PATENT ASSIGNEE(S) : Bayer A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 51 pp.
 CODEN: GWXXBX

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3819439	A1	19891214	DE 1988-3819439	19880608 <--
US 5039334	A	19910813	US 1989-354328	19890519 <--
EP 349748	A1	19900110	EP 1989-109458	19890525 <--
EP 349748	B1	19921119		
	R: BE, CH, DE, FR, GB, IT, LI, NL			
JP 02042057	A2	19900213	JP 1989-141280	19890605 <--
US 5118849	A	19920602	US 1991-688003	19910416 <--
PRIORITY APPLN. INFO.:			DE 1988-3819439	A 19880608
			US 1989-354328	A3 19890519
OTHER SOURCE(S) :	CASREACT 113:6153; MARPAT 113:6153			
GI				




AB The title compds. [I; R = H, halo; R1 = alk(en)yl, cycloalk(en)yl, cycloalk(en)ylalkyl optionally interrupted by ≥ 1 O; R2 = Q; R3 = H, R4 = H, OH, Cl; R3R4 = O, S; R5 = O, S; X = Q1, Q2, Q3, etc.; R6, R7 = H, halo, (halo)alkyl] were prepared as herbicides and plant growth regulators (no data), e.g., by condensation reaction of alkoxyhaloanilines with phthalic anhydride. A mixture of 4-chloro-2-fluoro-5-[2-(2-ethoxyethoxy)ethoxy]aniline (preparation given) and 3,4,5,6-tetrahydrophthalic anhydride in AcOH was stirred 5 h at 80° to give 50.7% title compound II.

IT **127537-08-0P**
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as herbicide and plant growth regulator)

RN 127537-08-0 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-chloro-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-fluorophenyl]tetrahydro- (9CI) (CA INDEX NAME)



L16 ANSWER 27 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:77226 HCAPLUS

DOCUMENT NUMBER: 112:77226

TITLE: 5-Lipoxygenase-inhibiting 4-(4-phenyl-1-piperazinyl)phenols and their preparation and pharmaceutical compositions

INVENTOR(S): Van Wauwe, Jean Pierre Frans; Heeres, Jan; Backx, Leo Jacobus Jozef

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: Eur. Pat. Appl., 40 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 331232	A2	19890906	EP 1989-200424	19890221 <--
EP 331232	A3	19910424		
EP 331232	B1	19940518		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1331757	A1	19940830	CA 1989-587830	19890110 <--
US 4931444	A	19900605	US 1989-297010	19890112 <--
JP 02003678	A2	19900109	JP 1989-38486	19890220 <--
JP 07005564	B4	19950125		
AT 105711	E	19940615	AT 1989-200424	19890221 <--
ES 2056190	T3	19941001	ES 1989-200424	19890221 <--
AU 8930739	A1	19890831	AU 1989-30739	19890224 <--
AU 615519	B2	19911003		
DK 8900918	A	19890830	DK 1989-918	19890227 <--
FI 8900931	A	19890830	FI 1989-931	19890227 <--
FI 97383	B	19960830		
FI 97383	C	19961210		
NO 8900813	A	19890830	NO 1989-813	19890227 <--

NO 174049	B	19931129		
NO 174049	C	19940309		
IL 89426	A1	19930610	IL 1989-89426	19890227 <--
CN 1036569	A	19891025	CN 1989-100931	19890228 <--
CN 1021223	B	19930616		
HU 52080	A2	19900628	HU 1989-927	19890228 <--
ZA 8901547	A	19901031	ZA 1989-1547	19890228 <--
RU 2107064	C1	19980320	RU 1989-4613548	19890228 <--
KR 133074	B1	19980417	KR 1989-2435	19890228 <--
HU 68931	A2	19950828	HU 1993-3071	19931028 <--
PRIORITY APPLN. INFO.:			US 1988-161825	A 19880229
			EP 1989-200424	A 19890221
			HU 1989-927	A 19890228

OTHER SOURCE(S) : MARPAT 112:77226

GI




AB Over 220 title compds. I [R1, R2 = H, halo, C1-6 alkyl; R3, R4 = H, halo, NH₂, NO₂, CF₃; Y = H, NO₂, NH₂, mono- or dialkylamino, alkylcarbonylamino, C1-6 alkyl, alkylcarbonyl, OH, halo, mono- or dialkylaminosulfonyl, various (un)substituted 5- or 6-membered N-containing heterocycles with optional O or S atoms] and/or their acid addition salts and stereoisomers were prepared as selective inhibitors of 5-lipoxygenase. Thus, 4-[4-(4-methoxyphenyl)-1-piperazinyl]benzenamine was condensed with (MeO)₂CHCH₂NCS to give the thiourea (36%), followed by cyclization in HCO₂H to give a dihydromethoxythiazolamine (52%), alkylation with EtBr and NaOH in DMF (44.4%) and demethylation/elimination using 48% HBr (81.5%) to give I [R1-R4 = H, Y = ethyl(2-thiazolyl)amino]. Various I gave up to 100% inhibition of 5-lipoxygenase in vitro at 2.5 mM and up to 94% inhibition of dextran-induced mouse-ear edema at 10 mg/kg orally. Capsules, tablets, oral and injectable solns., and other forms containing I were prepared

IT 125236-30-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of lipoxygenase-inhibiting (phenylpiperazinyl)phenols)

RN 125236-30-8 HCPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)




IT 125235-12-3P 125235-13-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as lipoxygenase inhibitor)


RN 125235-12-3 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 125235-13-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-7a-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 28 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:611086 HCAPLUS

DOCUMENT NUMBER: 109:211086

TITLE: Bicyclic imides, procedure for their preparation, and
their use as herbicides and plant growth
regulators.INVENTOR(S): Liebl, Rainer; Frey, Michael; Mildenberger, Hilmar;
Bauer, Klaus; Bieringer, Hermann

PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 16 pp.

CODEN: GWXXBX


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3643748	A1	19880630	DE 1986-3643748	19861220 <--
EP 272594	A1	19880629	EP 1987-118639	19871216 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
BR 8706928	A	19880726	BR 1987-6928	19871218 <--
ZA 8709504	A	19880727	ZA 1987-9504	19871218 <--
HU 45852	A2	19880928	HU 1987-5873	19871218 <--
DD 264844	A5	19890215	DD 1987-310751	19871218 <--
JP 63166880	A2	19880711	JP 1987-320169	19871219 <--
AU 8782875	A1	19880623	AU 1987-82875	19871221 <--
PRIORITY APPLN. INFO.:			DE 1986-3643748	A 19861220
OTHER SOURCE(S):	MARPAT 109:211086			
GI				




AB Bicyclic imides I [Ar = (un)substituted Ph, naphthyl, pyridyl, quinolyl, or isoquinolyl; R1 = H, alkyl, (un)substituted Ph; R2,R3 = H, (un)substituted alkyl, Ph, PhCH2, CO2H, Q1, alkoxy, (un)substituted alkoxy carbonyl, CONH2, CONHNH2, CH:NNH2; M = CR2R3; S, S(O), S(O)2, O, (un)substituted NH; Q = CR2R3, S, O; T = CR2R3, S, S(O), S(O)2, O; X = O, S; Y = O, S, NH; when Y = O, R1,R2,R3 = H; Q, T = CH2, M ≠ CH2, S, S(O), S(O)2], useful as herbicides (no data), were prepared by 3 methods. 4,2,5-ClF(MeO)C6H2NCO in PhMe was dropped into Et 6-methyl-2-piperidinecarboxylate in PhMe and the mixture stirred 3 h at 100° to give 99% diazabicyclononane II. Three formulations were given.

IT 117373-52-1P 117373-53-2P 117373-54-3P
 117373-55-4P 117373-56-5P 117373-58-7P
 117373-60-1P 117373-61-2P 117373-63-4P
 117373-64-5P 117373-65-6P 117373-72-5P
 117373-73-6P 117373-74-7P 117373-82-7P
 117373-84-9P 117373-86-1P 117373-87-2P
 117373-88-3P 117373-89-4P 117373-90-7P
 117373-91-8P 117373-92-9P 117373-93-0P
 117373-94-1P 117373-95-2P 117373-96-3P
 117373-97-4P 117373-98-5P 117373-99-6P
 117374-00-2P 117374-01-3P 117374-02-4P
 117374-03-5P 117374-04-6P 117374-05-7P
 117374-06-8P 117374-07-9P 117374-08-0P
 117374-09-1P 117374-10-4P 117374-11-5P
 117374-12-6P 117374-13-7P 117374-14-8P
 117374-15-9P 117374-52-4P 117374-53-5P
 117410-64-7P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide and plant growth regulator)


RN 117373-52-1 HCAPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1-imino- (9CI) (CA INDEX NAME)




RN 117373-53-2 HCAPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-bromo-2-fluoro-5-methoxyphenyl)hexahydro-1-imino- (9CI) (CA INDEX NAME)




RN 117373-54-3 HCAPLUS

CN Benzoic acid, 2-chloro-5-(hexahydro-1-imino-3-oxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 2-ethoxy-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)




RN 117373-55-4 HCAPLUS


CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-[3,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]hexahydro-1-imino- (9CI) (CA INDEX NAME)




RN 117373-56-5 HCAPLUS
 CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1-imino-7-methyl- (9CI) (CA INDEX NAME)




RN 117373-58-7 HCAPLUS
 CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-[4-chloro-2-fluoro-5-(2-propynyloxy)phenyl]hexahydro-1-imino- (9CI) (CA INDEX NAME)



RN 117373-60-1 HCAPLUS
 CN Benzoic acid, 2-bromo-5-(hexahydro-1-imino-3-oxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 117373-61-2 HCAPLUS
 CN Benzoic acid, 5-(hexahydro-1-imino-3-oxoimidazo[1,5-a]pyridin-2(3H)-yl)-2-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 117373-63-4 HCPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1-imino-6,8-dimethyl- (9CI) (CA INDEX NAME)




RN 117373-64-5 HCPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1-imino-5,8a-dimethyl- (9CI) (CA INDEX NAME)




RN 117373-65-6 HCPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1-imino-5,7,8a-trimethyl- (9CI) (CA INDEX NAME)




RN 117373-72-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-3(2H)-thione, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-1-imino-7-methyl- (9CI) (CA INDEX NAME)




RN 117373-73-6 HCAPLUS

CN Imidazo[1,5-a]pyridine-3(2H)-thione, 2-[4-chloro-2-fluoro-5-(2-propynyloxy)phenyl]hexahydro-1-imino- (9CI) (CA INDEX NAME)




RN 117373-74-7 HCAPLUS

CN Imidazo[1,5-a]pyridine-3(2H)-thione, 2-[4-chloro-2-fluoro-5-(1-methylethoxy)phenyl]hexahydro-1-imino-6,8-dimethyl- (9CI) (CA INDEX NAME)




RN 117373-82-7 HCAPLUS

CN Imidazo[1,5-a]pyridin-3(2H)-one, 2-(4-chlorophenyl)hexahydro-1-imino- (9CI) (CA INDEX NAME)




RN 117373-84-9 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-chloro-2-fluoro-5-(2-propynyloxy)phenyl]-5-(1,3-dioxolan-2-yl)tetrahydro- (9CI) (CA INDEX NAME)




RN 117373-86-1 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1-oxo-3-thioxo-, 2,2,2-trifluoroethyl ester (9CI) (CA INDEX NAME)




RN 117373-87-2 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chlorophenyl)-5-(1,3-dioxolan-2-yl)tetrahydro- (9CI) (CA INDEX NAME)




RN 117373-88-3 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 117373-89-4 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-2-fluoro-5-methoxyphenyl)tetrahydro-5-(3,3,3-trifluoro-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 117373-90-7 HCAPLUS

CN Pyrrolidine, 1-[2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxoimidazo[1,5-a]pyridin-5-yl]carbonyl- (9CI) (CA INDEX NAME)




RN 117373-91-8 HCAPLUS

CN Imidazo[1,5-a]pyridine-7-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 117373-92-9 HCAPLUS

CN Imidazo[1,5-a]pyridine-8-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 117373-93-0 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 117373-94-1 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 117373-95-2 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, 2-ethoxy-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)




RN 117373-96-3 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-2-fluoro-5-methoxyphenyl)tetrahydro-5-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 117373-97-4 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-2-fluoro-5-methoxyphenyl)-6-ethyltetrahydro- (9CI) (CA INDEX NAME)




RN 117373-98-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-6-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 117373-99-6 HCAPLUS

CN Imidazo[1,5-a]pyridine-5,7-dicarboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1,3-dioxo-, diethyl ester (9CI) (CA INDEX NAME)




RN 117374-00-2 HCAPLUS

CN Benzoic acid, 2,4-difluoro-5-(hexahydro-5-methyl-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 117374-01-3 HCAPLUS

CN Benzoic acid, 2-bromo-5-(hexahydro-5-methyl-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 117374-02-4 HCAPLUS

CN Imidazo[1,5-a]pyridine-6-carboxylic acid, 2-[4-chloro-3-[(2-ethoxy-1-methyl-2-oxoethoxy)carbonyl]phenyl]octahydro-1,3-dioxo-, methoxymethyl ester (9CI) (CA INDEX NAME)




RN 117374-03-5 HCAPLUS

CN Imidazo[1,5-a]pyridine-8-carboxylic acid, 2-[4-chloro-3-[(1-methylethoxy)carbonyl]phenyl]octahydro-1,3-dioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 117374-04-6 HCAPLUS


CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-[4-chloro-5-(ethoxycarbonyl)-2-fluorophenyl]octahydro-1,3-dioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 117374-05-7 HCAPLUS
 CN Benzoic acid, 2-ethoxy-5-(hexahydro-5-methyl-1,3-dioxoimidazo[1,5-a]pyridin-2(3H)-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 117374-06-8 HCAPLUS
 CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-[3-(ethoxycarbonyl)-4-(2,2,2-trifluoroethoxy)phenyl]octahydro-1,3-dioxo-, 2,2,2-trifluoroethyl ester (9CI) (CA INDEX NAME)




RN 117374-07-9 HCAPLUS
 CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[(2-fluoro-5-methoxy-4-(trifluoromethoxy)phenyl)tetrahydro-5-methyl- (9CI) (CA INDEX NAME)




RN 117374-08-0 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-5-methyl-3-thioxo- (9CI) (CA INDEX NAME)




RN 117374-09-1 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)-6-ethylhexahydro-3-thioxo- (9CI) (CA INDEX NAME)



RN 117374-10-4 HCAPLUS
CN Imidazo[1,5-a]pyridine-8-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1-oxo-3-thioxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 117374-11-5 HCAPLUS
CN Imidazo[1,5-a]pyridine-7-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1-oxo-3-thioxo-, methyl ester (9CI) (CA INDEX NAME)




RN 117374-12-6 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1-oxo-3-thioxo-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 117374-13-7 HCAPLUS

CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-(4-chloro-2-fluoro-5-methoxyphenyl)octahydro-1-oxo-3-thioxo-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 117374-14-8 HCAPLUS


CN Benzoic acid, 2-bromo-5-(hexahydro-5-methyl-1-oxo-3-thioxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 117374-15-9 HCAPLUS
 CN Benzoic acid, 2-chloro-5-(6-ethylhexahydro-1-oxo-3-thioxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 2-ethoxy-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 117374-52-4 HCAPLUS
 CN Imidazo[1,5-a]pyridine-5-carboxylic acid, 2-[4-chloro-3-(ethoxycarbonyl)phenyl]octahydro-1,3-dioxo-, 3-ethoxy-3-oxopropyl ester (9CI) (CA INDEX NAME)




RN 117374-53-5 HCAPLUS
 CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-2-fluoro-5-methoxyphenyl)tetrahydro-5-methyl- (9CI) (CA INDEX NAME)



RN 117410-64-7 HCPLUS

CN Benzoic acid, 2-(ethylthio)-5-(hexahydro-1-imino-3-oxoimidazo[1,5-a]pyridin-2(3H)-yl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)




L16 ANSWER 29 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:6018 HCPLUS
 DOCUMENT NUMBER: 108:6018
 TITLE: Preparation of 1-phenyl-2-imidazolidinones and -2-imidazolidinethiones as herbicides
 INVENTOR(S): Liebl, Rainer; Handte, Reinhard; Mildenberger, Hilmar;
 Bauer, Klaus; Bieringer, Hermann
 PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 11 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3604042	A1	19870813	DE 1986-3604042	19860208 <-
EP 234323	A1	19870902	EP 1987-101242	19870129 <-
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8700619	A	19870809	DK 1987-619	19870206 <-
AU 8768592	A1	19870813	AU 1987-68592	19870206 <-
JP 62192363	A2	19870822	JP 1987-24949	19870206 <-
ZA 8700869	A	19870930	ZA 1987-869	19870206 <-
HU 43317	A2	19871028	HU 1987-480	19870206 <-
BR 8700551	A	19871208	BR 1987-551	19870206 <-
US 4749403	A	19880607	US 1987-11780	19870206 <-
DD 259993	A5	19880914	DD 1987-299756	19870206 <-
CN 87100616	A	19870819	CN 1987-100616	19870207 <-
PRIORITY APPLN. INFO.:			DE 1986-3604042	A 19860208
OTHER SOURCE(S):	CASREACT	108:6018		

GI




AB The title compds. [I; R1 = H, halo; R2, R3 = H, halo, (halo)alkyl, cycloalkyloxy, (halo)alkenyloxy, (halo)alkynyloxy, alkoxy carbonyl, NO₂, cyano, (un)substituted alkoxy, PhO, PhOCH₂, PhCH₂O; R4 = alkenyl, alkynyl, cycloalkyl, cycloalkenyl, R7NHC(:X), (un)substituted alkyl, PhCH₂; R5 = alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl; R6 = H; R5R6 = C₄-5 alkylene; R7 = alkyl, (un)substituted Ph, PhCH₂; X = O, S] were prepared as herbicides and plant growth regulators. 1-Methyl-3-[3-methyl-4-(1,1,2,2-tetrafluoroethoxy)phenyl]-2,4-imidazolidinedione in Me₂CHOH was treated with NaBH₄ at 40°, followed by stirring 30 min at 40° to give 96% I (R1 = R4 = R6 = H, R3 = R5 = Me, R2 = F₂CHCF₂O) (II). In both pre- and postemergence tests, 2.5 kg II/ha gave 80-100% control of, e.g., *Sinapis alba*.

IT 85113-27-5 111658-59-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(selective borohydride reduction of)


RN 85113-27-5 HCPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-2-fluoro-5-methoxyphenyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 111658-59-4 HCPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-chloro-2-fluoro-5-methoxyphenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




L16 ANSWER 30 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:403032 HCPLUS

DOCUMENT NUMBER: 105:3032

TITLE: Pharmaceutical analysis using thermospray liquid chromatography/mass spectrometry and mass spectrometry/mass spectrometry
 AUTHOR(S): Unger, Steve E.; Warrack, Bethanne M.
 CORPORATE SOURCE: Mass Spectromet. Cent., Squibb Inst. Med. Res., Princeton, NJ, 08540, USA
 SOURCE: Spectroscopy (Duluth, MN, United States) (1986), 1(3), 33-8
 CODEN: SPECET; ISSN: 0887-6703
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The anal. of phenylthiohydantoin-amino acids and dipeptides using thermospray liquid chromatog./mass spectrometry and mass spectrometry/mass spectrometry (MS/MS) yields a sensitive and specific method for the rapid sequencing of small peptides. Beta-lactam antibiotics produce informative pos. and neg. thermospray mass spectra, and extensive fragmentation is evident in the MS/MS spectra of cephalosporins and penicillins. Monobactams yield numerous degradation products in their thermospray spectra. Thermospray mass spectra of steroids exhibit both mol. weight and some limited structural information at nanogram levels. MS/MS spectra of steroid sulfoxides resemble electron ionization mass spectra because of the extensive fragmentation of the steroid nucleus.
 IT 29635-99-2
 RL: PROC (Process)
 (identification of, by HPLC and mass spectroscopy)
 RN 29635-99-2 HCPLUS
 CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-phenyl-3-thioxo-, (7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 31 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1982:544792 HCPLUS
 DOCUMENT NUMBER: 97:144792
 TITLE: Substituted azabicyclooctanecarboxylic acids and pharmaceutical compositions containing them
 INVENTOR(S): Vincent, Michel; Remond, Georges; Laubie, Michel
 PATENT ASSIGNEE(S): Science Union et Cie., Societe Francaise de Recherche Medicale, Fr.
 SOURCE: Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 51020	A1	19820505	EP 1981-401642	19811020 <--
EP 51020	B1	19840808		

R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

FR 2492381	A1	19820423	FR 1980-22438	19801021 <--
FR 2492381	B1	19830812		
ES 506222	A1	19830101	ES 1981-506222	19811013 <--
DK 8104601	A	19820422	DK 1981-4601	19811019 <--
DK 162444	B	19911028		
DK 162444	C	19920323		
IL 64075	A1	19841231	IL 1981-64075	19811019 <--
FI 8103279	A	19820422	FI 1981-3279	19811020 <--
FI 73678	B	19870731		
FI 73678	C	19871109		
NO 8103541	A	19820422	NO 1981-3541	19811020 <--
NO 155098	B	19861103		
AU 8176624	A1	19820429	AU 1981-76624	19811020 <--
AU 540609	B2	19841129		
ZA 8107251	A	19820929	ZA 1981-7251	19811020 <--
US 4397857	A	19830809	US 1981-313184	19811020 <--
DD 201891	A5	19830817	DD 1981-234232	19811020 <--
AT 8892	E	19840815	AT 1981-401642	19811020 <--
SU 1138022	A3	19850130	SU 1981-3346599	19811020 <--
CA 1183140	A1	19850226	CA 1981-388374	19811020 <--
JP 57098281	A2	19820618	JP 1981-168516	19811021 <--
JP 61012911	B4	19860410		
HU 27675	O	19831028	HU 1981-3066	19811021 <--
HU 185058	B	19841128		
JP 61126025	A2	19860613	JP 1985-252137	19851112 <--
JP 61046453	B4	19861014		

PRIORITY APPLN. INFO.: FR 1980-22438 A 19801021
EP 1981-401642 A 19811020

OTHER SOURCE(S) : CASREACT 97:144792; MARPAT 97:144792
GI




AB The antihypertensive (no data) title compds. I [R = alkyl; R1 = H, CHR3COR2 [R2 = HO, alkoxy; R3 = H alkyl, cycloalkyl, phenylalkyl, (CH₂)_mSCHR4R5, (R4 = H, alkyl, cycloalkyl; R5 = H cycloalkyl, alkoxy, m = 1, 2)]; n = 0, 1; X = CH:CH, CH₂CH₂; Z = S, NH] were prepared. Thus, the imidazopyridine II was hydrolyzed and its resulting carboxyazabicyclooctane treated with AcSCH₂CHMeCOCl followed by hydrolysis to give III.

IT 83029-36-1 83113-68-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)


RN 83029-36-1 HCAPLUS

CN 5,8-Ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-phenyl-(9CI) (CA INDEX NAME)



RN 83113-68-2 HCAPLUS

CN 5,8-Ethanoimidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chlorophenyl)-8,8a-dihydro- (9CI) (CA INDEX NAME)



L16 ANSWER 32 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1978:22905 HCAPLUS

DOCUMENT NUMBER: 88:22905

TITLE: Hydantoin and thiohydantoin derivatives

INVENTOR(S): Wakabayashi, Osamu; Matsutani, Kuni; Ota, Hiroki;
Naohara, Tetsuo; Watanabe, Hisao

PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52083686	A2	19770712	JP 1976-224	19760101 <-
JP 59033593	B4	19840816		

PRIORITY APPLN. INFO.:

JP 1976-224 A 19760101

GI For diagram(s), see printed CA Issue.


AB Fifty-seven title derivs. I [Z = O, S; R = R₁R₂C₆H₃ (R₁, R₂ = H, alkyl, alkoxy, halo, CF₃, NO₂, 4-ClC₆H₄CH₂O), α-naphthyl; n = 3, 4] were prepared by reaction of II with RNCO or RNCS followed by dehydrative cyclization of the resulting III in the presence of acids if needed. Thus, 2.3 g 4-ClC₆H₄NCO in PhCl was added to an aqueous mixture of 1.94 g pipecolic acid and 0.6 g NaOH, the whole let react 4 h, washed with Et₂O, acidified with HCl, and the reaction mixture containing a solid refluxed 1 h to give 81.1% I (Z = O, R = 4-ClC₆H₄, n = 4). I are useful as agricultural herbicides and fungicides; data were given against Echinochloa crus-galli, Rotana indica, Galinsoga parviflora, Digitaria adscendens, barnyard grass (millet), garden radish, Botrytis cinerea, Pellicularia sasaki, and Chochliobolus miyabeanus.

IT 60725-79-3P 60725-80-6P 60726-08-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and fungicidal activity of)


RN 60725-79-3 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-
 (9CI) (CA INDEX NAME)




RN 60725-80-6 HCPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-
 (9CI) (CA INDEX NAME)



RN 60726-08-1 HCPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3,5-dichlorophenyl)hexahydro-3-thioxo-
 (9CI) (CA INDEX NAME)



IT 59648-13-4P 60408-93-7P 60725-54-4P

60725-55-5P 60725-56-6P 60725-57-7P

60725-58-8P 60725-59-9P 60725-60-2P

60725-61-3P 60725-65-7P 60725-66-8P

60725-67-9P 60725-68-0P 60725-69-1P

60725-70-4P 60725-71-5P 60725-72-6P

60725-73-7P 60725-74-8P 60725-76-0P

60725-77-1P 60725-81-7P 60725-82-8P

60725-83-9P 60725-84-0P 60725-85-1P

60725-86-2P 60725-87-3P 60725-88-4P

60725-89-5P 60725-90-8P 60725-91-9P

60725-92-0P 60725-94-2P 60725-95-3P


60725-96-4P 60725-97-5P 60725-98-6P
 60725-99-7P 60726-00-3P 60726-01-4P
 60726-02-5P 60726-03-6P 60726-04-7P
 60726-05-8P 60726-06-9P 64985-10-0P
 64985-11-1P 64985-12-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and herbicidal activity of)


RN 59648-13-4 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chlorophenyl)tetrahydro-
 (9CI) (CA INDEX NAME)




RN 60408-93-7 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-fluorophenyl)tetrahydro-
 (9CI) (CA INDEX NAME)




RN 60725-54-4 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[3-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 60725-55-5 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 60725-56-6 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 60725-57-7 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-ethoxyphenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-58-8 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-fluorophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-59-9 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-chlorophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-60-2 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(4-bromophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-61-3 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,4-dichlorophenyl)tetrahydro-(9CI) (CA INDEX NAME)




RN 60725-65-7 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(3-methylphenyl)-(9CI) (CA INDEX NAME)




RN 60725-66-8 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 60725-67-9 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(3-nitrophenyl)-(9CI) (CA INDEX NAME)




RN 60725-68-0 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 60725-69-1 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 60725-70-4 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-ethoxyphenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-71-5 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-bromophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-72-6 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-iodophenyl)-
(9CI) (CA INDEX NAME)




RN 60725-73-7 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 60725-74-8 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,4-dichlorophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 60725-76-0 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-chloro-3-methylphenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 60725-77-1 HCAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(4-bromo-3-methylphenyl)tetrahydro- (9CI) (CA INDEX NAME)




RN 60725-81-7 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-thioxo-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 60725-82-8 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(4-methylphenyl)-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-83-9 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(4-methoxyphenyl)-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-84-0 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(4-chlorophenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-85-1 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(4-bromophenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-86-2 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(4-nitrophenyl)-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-87-3 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(3,4-dichlorophenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-88-4 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-[4-[(4-chlorophenyl)methoxy]phenyl]hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-89-5 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(2-methylphenyl)-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-90-8 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(3-methylphenyl)-3-thioxo- (9CI) (CA INDEX NAME)



RN 60725-91-9 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3-fluorophenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-92-0 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3-bromophenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60725-94-2 HCAPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-butylphenyl)hexahydro-3-thioxo-(9CI) (CA INDEX NAME)




RN 60725-95-3 HCAPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(4-methoxyphenyl)-3-thioxo-(9CI) (CA INDEX NAME)




RN 60725-96-4 HCAPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-ethoxyphenyl)hexahydro-3-thioxo-(9CI) (CA INDEX NAME)




RN 60725-97-5 HCAPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-fluorophenyl)hexahydro-3-thioxo-(9CI) (CA INDEX NAME)




RN 60725-98-6 HCAPLUS


CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-bromophenyl)hexahydro-3-thioxo-(9CI) (CA INDEX NAME)




RN 60725-99-7 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(4-iodophenyl)-3-thioxo-
(9CI) (CA INDEX NAME)




RN 60726-00-3 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(4-nitrophenyl)-3-thioxo-
(9CI) (CA INDEX NAME)




RN 60726-01-4 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3,4-dichlorophenyl)hexahydro-3-thioxo-
(9CI) (CA INDEX NAME)




RN 60726-02-5 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3,4-dimethylphenyl)hexahydro-3-thioxo-
(9CI) (CA INDEX NAME)




RN 60726-03-6 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-chloro-3-methylphenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60726-04-7 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(4-bromo-3-methylphenyl)hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60726-05-8 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-[4-[(4-chlorophenyl)methoxy]phenyl]hexahydro-3-thioxo- (9CI) (CA INDEX NAME)




RN 60726-06-9 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(1-naphthalenyl)-3-thioxo- (9CI) (CA INDEX NAME)




RN 64985-10-0 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3-fluorophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




RN 64985-11-1 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3-chlorophenyl)tetrahydro-
(9CI) (CA INDEX NAME)



RN 64985-12-2 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3-bromophenyl)tetrahydro-
(9CI) (CA INDEX NAME)




IT 60726-07-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and herbicidal and fungicidal activities of)
RN 60726-07-0 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(3,5-dichlorophenyl)hexahydro-3-thioxo-
(9CI) (CA INDEX NAME)




IT 60725-75-9P 60725-78-2P 60725-93-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 60725-75-9 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-(3,4-dimethylphenyl)tetrahydro-
(9CI) (CA INDEX NAME)

RN 60725-78-2 HCAPLUS

CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[(4-
chlorophenyl)methoxy]phenyl]tetrahydro- (9CI) (CA INDEX NAME)

RN 60725-93-1 HCAPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-3-thioxo-2-[3-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L16 ANSWER 33 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1971:449087 HCAPLUS


DOCUMENT NUMBER: 75:49087

TITLE: Pyrrololidino[1,2-c]imidazolidinone derivatives

INVENTOR(S): Oshiro, Susumu; Nakura, Takeo; Okamoto, Takashi;


PATENT ASSIGNEE(S) : Okumura, Kentaro
 Tanabe Seiyaku Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 4 pp.
 CODEN: JAXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GI	JP 46016990	B4	19710511	JP	19680319 <--
AB	For diagram(s), see printed CA Issue. I, useful as anti-inflammatory, analgesic, and antispasmodic drugs , are manufactured by reaction of II with R2CHO. II (R2 = Ph) (11.5 g) in 50 ml MeOH is stirred 3 hr with 7.4 g 37% HCHO to give 11.7 g I (R1 = Ph, R2 = H), m. 63-5°, hydrochloride m. 203° (decomposition). Similarly prepared are I (R1, R2, m.p., and that of the hydrochloride given): 3-ClC6H4, H, 107-8°, 184°; 4-MeOC6H4, H 113-15°, 175-6°; Ph, Me, 90°, 151°; Ph, PhCH2, 135-7°, 179°; Ph, 2-furyl, 173-5°, 163-5; 2-methyl-6-pyridyl, H, -(oil), 163-5°; Pr, H, -(oil), 157-9°; Bu, H, -(oil), 145-7°; PhCH2, H, -(oil), 169-71°; 2-ClC6H4, H, -(oil), 198-9°; 4-ClC6H4, H, 95-6°, 141-3°; 2-MeOC6H4, H, -(oil), 193-5°; 3-NO2C6H4, H, 141-3°, 196°; 4-NO2C6H4, H, 198-200°, 174-6°; 4-H2NSO2C6H4, H, 300°,-; 3-H2NC6H4, H, -, 275°; 4-AcC6H4, H, 174-6°, 300°; Ph, Et, -(oil), 166-8°; Ph, Ph, 138-9°, 190-1°; Ph, iso-Pr, 130°, 152-4°; Ph, 2-HOC6H4, 89-91°, 188-90°; Ph, 3-MeOC6H4, 117-19°, 226-8°; Ph, 3-HOC6H4, 117-19°.-.				
IT	32901-46-5P	32901-47-6P	32901-48-7P		
	32901-49-8P	32901-50-1P	32901-51-2P		
	32901-52-3P	32901-53-4P	32901-54-5P		
	32901-55-6P	32901-56-7P	32901-63-6P		
	32901-64-7P	32901-65-8P	32901-66-9P		
	32901-67-0P	32901-68-1P	32901-69-2P		
	32901-70-5P	32901-71-6P	32901-72-7P		
	32901-73-8P	32901-74-9P	32901-75-0P		
	32901-76-1P	32901-77-2P	32901-78-3P		
	32901-79-4P	32901-80-7P	32901-81-8P		
	32901-82-9P	32901-83-0P	32901-84-1P		
	32902-37-7P	32902-38-8P	33024-25-8P		
	33035-94-8P	33035-95-9P	34062-99-2P		
RL	SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	32901-46-5 HCPLUS				
CN	1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(m-chlorophenyl)hexahydro-, monohydrochloride (8CI) (CA INDEX NAME)				




● HCl


RN 32901-47-6 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(m-chlorophenyl)hexahydro- (8CI) (CA INDEX NAME)



RN 32901-48-7 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(p-methoxyphenyl)- (8CI) (CA INDEX NAME)




RN 32901-49-8 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(p-methoxyphenyl)-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 32901-50-1 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-methyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 32901-51-2 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-methyl-2-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 32901-52-3 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 3-benzylhexahydro-2-phenyl- (8CI) (CA INDEX NAME)



RN 32901-53-4 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 3-benzylhexahydro-2-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 32901-54-5 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 3-(2-furyl)hexahydro-2-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 32901-55-6 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(6-methyl-2-pyridyl)- (8CI) (CA INDEX NAME)



RN 32901-56-7 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(6-methyl-2-pyridyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 32901-63-6 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(o-chlorophenyl)hexahydro- (8CI) (CA INDEX NAME)



RN 32901-64-7 HCAPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(o-chlorophenyl)hexahydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 32901-65-8 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(p-chlorophenyl)hexahydro- (8CI) (CA INDEX NAME)




RN 32901-66-9 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(o-methoxyphenyl)- (8CI) (CA INDEX NAME)




RN 32901-67-0 HCAPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(o-methoxyphenyl)-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 32901-68-1 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(m-nitrophenyl)- (8CI) (CA INDEX NAME)




RN 32901-69-2 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(m-nitrophenyl)-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl


RN 32901-70-5 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(p-nitrophenyl)- (8CI) (CA INDEX NAME)



RN 32901-71-6 HCAPLUS
CN Benzenesulfonamide, p-(tetrahydro-1-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)- (8CI) (CA INDEX NAME)




RN 32901-72-7 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(m-aminophenyl)hexahydro-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 32901-73-8 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(4-acetylphenyl)hexahydro- (9CI) (CA INDEX NAME)




RN 32901-74-9 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(p-acetylphenyl)hexahydro-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 32901-75-0 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 3-ethylhexahydro-2-phenyl- (8CI) (CA INDEX NAME)




RN 32901-76-1 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 3-ethylhexahydro-2-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 32901-77-2 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2,3-diphenyl- (8CI) (CA INDEX NAME)




RN 32901-78-3 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2,3-diphenyl-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 32901-79-4 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-isopropyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 32901-80-7 HCPLUS


CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-isopropyl-2-phenyl-,
monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 32901-81-8 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-(o-hydroxyphenyl)-3-phenyl-
(8CI) (CA INDEX NAME)




RN 32901-82-9 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-(m-methoxyphenyl)-2-phenyl-
(8CI) (CA INDEX NAME)




RN 32901-83-0 HCPLUS

CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-(m-methoxyphenyl)-2-phenyl-,
monohydrochloride (8CI) (CA INDEX NAME)




● HCl


RN 32901-84-1 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-(m-hydroxyphenyl)-2-phenyl- (8CI) (CA INDEX NAME)



RN 32902-37-7 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-phenyl- (8CI) (CA INDEX NAME)




RN 32902-38-8 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 33024-25-8 HCPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-3-(o-hydroxyphenyl)-3-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 33035-94-8 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 3-(2-furyl)hexahydro-2-phenyl- (8CI) (CA INDEX NAME)




RN 33035-95-9 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, hexahydro-2-(p-nitrophenyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 34062-99-2 HCAPLUS
CN 1H-Pyrrolo[1,2-c]imidazol-1-one, 2-(p-chlorophenyl)hexahydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L16 ANSWER 34 OF 35 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1970:3429 HCPLUS

DOCUMENT NUMBER: 72:3429

TITLE: Preparation of some substituted imidazolidine-2,4-diones

AUTHOR(S): Sam, Joseph; McLaurin, E. B.; Shafik, R. M.

CORPORATE SOURCE: Dep. of Pharm. Chem., Univ. of Mississippi, University, MS, USA

SOURCE: Journal of Pharmaceutical Sciences (1969), 58(10), 1282-4

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB Heating 2-benzoxazolinone (I) or 5-chloro-2-benzoxazolinone with amino acid esters resulted in the formation of 3-(2-hydroxyphenyl)-2,4-imidazolidinediones, e.g. II. Results of preliminary pharmacol. tests are reported.

IT 24638-06-0P 24638-07-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 24638-06-0 HCPLUS

CN 1,2-Piperidinedicarboximide, N-(o-hydroxyphenyl)- (8CI) (CA INDEX NAME)



RN 24638-07-1 HCPLUS

CN 1,2-Piperidinedicarboximide, N-(5-chloro-2-hydroxyphenyl)- (8CI) (CA INDEX NAME)



L16 ANSWER 35 OF 35 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1968:459272 HCAPLUS
 DOCUMENT NUMBER: 69:59272
 TITLE: Diazahydrindanones and pyridopyrimidinones useful as pharmacological agents
 PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co., A.-G.
 SOURCE: Brit., 9 pp.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1114397	-----	19680522	GB 1967-14879	19670331 <--
FR 1517312	-----		FR	
US 3515725	-----	19700602	US	19670328 <--

PRIORITY APPLN. INFO.: CH 19660406


GI For diagram(s), see printed CA Issue.
 AB The title compds., of the general formulas I and II, where R is a substituted phenyl group, are prepared. The compds. exhibit analgesic, antiphlogistic, inflammation inhibiting, and antiallergic activities when used in salt form. Thus, a solution of 27.7 g. 2-(1-benzylloxycarbonyl-2-piperidyl)acetic acid in 50 ml. dioxane was treated with 16.6 g. m-nitroaniline in 50 ml. dioxane, treated with 24 g. dicyclohexylcarbodiimide in 30 ml. dioxane, kept 18 hrs., worked up, the product, in AcOH, treated, with ice cooling, with 120 ml. 33% HBr, kept 18 hrs., worked up, and the product treated with aqueous NH₃ to give 22.5 g. 2-(2-piperidyl)acetic acid m-nitroanilide, m. 252-3° (as the HCl salt), which was taken up in CH₂Cl₂, washed with water, freed of solvent by distillation, dissolved in 20 ml. MeOH and 100 ml. 38% aqueous HCHO, refluxed 2 hrs., and worked up to give octahydro-2-(m-nitrophenyl)-3H-pyrido[1,2-c]pyrimidin-3-one (I) (R = m-nitrophenyl), m. 237-8° (alc.-ether). Similarly prepared were the following I (R and m.p. of HCl salt given): 4-ethoxyphenyl, 197-9°; 3-chlorophenyl, 190-1°; CH₂Ph, 180-1°; 3,4-dichlorophenyl, 210-20°; 4-nitrophenyl, 228-9°; 2-nitrophenyl, 223-4°; 2-(methoxycarbonyl)phenyl, 193-4°; 2-chlorophenyl, 234-5°; 4-chloro-3-nitrophenyl, 219-20°; 4-chloro-2-nitrophenyl, 209-10°; 2,5-dichlorophenyl, 227-8°; 4-fluorophenyl, and 219-20; 4-(acetamido)phenyl, 231-2°. The following II were prepared (R and m.p. HCl salt given): m-trifluoromethylphenyl, m. 145-6°; 4-methoxyphenyl, 126°; 3,4-dimethoxyphenyl, 215-16°; 4-hydroxyphenyl, 232-3°; 4-fluorophenyl, 202-3°; 4-chlorophenyl, 179-80°; 4-nitrophenyl, 200°; 3-nitrophenyl, 189-90°; 2-(methoxycarbonyl)phenyl, 200° (HBr salt); and

IT CH₂CH₂NET₂, 178° (2HBr salt).
19563-91-8P 19563-92-9P 19563-94-1P
19563-95-2P 19563-97-4P 19612-04-5P
19612-31-8P 19612-33-0P 19612-34-1P
19612-36-3P 19612-37-4P 19612-40-9P
19716-75-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 19563-91-8 HCAPLUS
 CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(p-chlorophenyl)hexahydro- (8CI) (CA INDEX NAME)




RN 19563-92-9 HCAPLUS
 CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(p-chlorophenyl)hexahydro-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 19563-94-1 HCAPLUS
 CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(p-nitrophenyl)- (8CI) (CA INDEX NAME)




RN 19563-95-2 HCAPLUS
 CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(p-nitrophenyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 19563-97-4 HCPLUS


CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(m-nitrophenyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 19612-04-5 HCPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(alpha,alpha,alpha-trifluoro-m-tolyl)- (8CI) (CA INDEX NAME)




RN 19612-31-8 HCPLUS

CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(p-methoxyphenyl)-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 19612-33-0 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3,4-dimethoxyphenyl)hexahydro- (8CI)
(CA INDEX NAME)




RN 19612-34-1 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(3,4-dimethoxyphenyl)hexahydro-,
monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 19612-36-3 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(p-hydroxyphenyl)- (8CI) (CA INDEX NAME)




RN 19612-37-4 HCAPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, hexahydro-2-(p-hydroxyphenyl)-,
monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 19612-40-9 HCPLUS
CN Imidazo[1,5-a]pyridin-1(5H)-one, 2-(p-fluorophenyl)hexahydro-,
monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 19716-75-7 HCPLUS
CN Benzoic acid, o-(hexahydro-1-oxoimidazo[1,5-a]pyridin-2(3H)-yl)-, methyl
ester, monohydrobromide (8CI) (CA INDEX NAME)



● HBr

=>
=> => d stat que l43
L1 STR



REP G1=(1-2) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L3 3704 SEA FILE=REGISTRY SSS FUL L1

L5 STR

C~G3
@10 11O=C~O
12 @13 14O=C~C
15 @16 17C~O
@18 19Ak~C~G5
20 @21 22CH~G5
@23 24C~O~C~O~C
25 26 @27 28 29CH~G7
@30 31C=G8
@32 33

REP G1=(1-2) C

VAR G2=CH/10

VAR G3=AK/CB/13/16/18

VAR G4=CH2/21/23/27

VAR G5=AK/O/S/X/N

VAR G6=CH2/30/32

VAR G7=AK/CY

VAR G8=O/S/N/C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

L6 2769 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L7 420 SEA FILE=HCAPLUS ABB=ON PLU=ON L6

L8 361 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND PD=<MAY 18, 2002

L10 45 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (?MEDIC? OR ?THERP? OR
?DRUG? OR ?PHARM?)

L11 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 AND L10
 L12 101616 SEA FILE=REGISTRY ABB=ON PLU=ON ANDROGEN OR ANDROGENS OR
 RECEPTOR OR RECEPTORS
 L13 1866083 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 OR ?ANDROGEN? OR ?RECEPTOR
 ? OR ?MODULAT? OR REGULAT?
 L14 34 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND L13
 L15 17 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 AND L14
 L16 35 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 OR L15
 L21 204 SEA FILE=HCAPLUS ABB=ON PLU=ON SUN C/AU OR "SUN CHONG"/AU OR
 ("SUN CHONG OING"/AU OR "SUN CHONG QING"/AU)
 L22 73 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HAMANN L"/AU OR "HAMANN
 LAWERENCE G"/AU OR "HAMANN LAWRENCE"/AU OR "HAMANN LAWRENCE
 G"/AU OR "HAMANN LAWRENCE GERARD"/AU OR "HAMANN LAWRENCE
 H"/AU)
 L23 43 SEA FILE=HCAPLUS ABB=ON PLU=ON ("AUGERI DAVID"/AU OR "AUGERI
 DAVID J"/AU OR "AUGERI DAVID JOHN"/AU)
 L24 65 SEA FILE=HCAPLUS ABB=ON PLU=ON BI Y ?/AU OR "BI YINGZHI"/AU
 L25 90 SEA FILE=HCAPLUS ABB=ON PLU=ON "ROBL J A"/AU OR ("ROBL
 JEFF"/AU OR "ROBL JEFF A"/AU OR "ROBL JEFFREY"/AU OR "ROBL
 JEFFREY A"/AU OR "ROBL JEFFREY ADAM"/AU)
 L26 1397 SEA FILE=HCAPLUS ABB=ON PLU=ON "HUANG YAN"/AU OR "HUANG YAN
 TING"/AU OR HUANG Y/AU OR HUANG Y T?/AU
 L27 787 SEA FILE=HCAPLUS ABB=ON PLU=ON ("WANG TAMMY"/AU OR "WANG
 TAMMY C"/AU) OR WANG T/AU OR WANG T C?/AU
 L28 14 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLUBEC A"/AU OR "HOLUBEC
 ALEX"/AU OR "HOLUBEC ALEXANDRA"/AU OR "HOLUBEC ALEXANDRA A"/AU
 OR "HOLUBEC ALEXANDRA ANASTASIA"/AU OR "HOLUBEC ALEXEJ"/AU)
 L29 27 SEA FILE=HCAPLUS ABB=ON PLU=ON ("SIMPKINS L M"/AU OR
 "SIMPINKS LIGAYA"/AU OR "SIMPKINS LIGAYA M"/AU)
 L30 121 SEA FILE=HCAPLUS ABB=ON PLU=ON "SUTTON J"/AU OR ("SUTTON J
 C"/AU OR "SUTTON J CARL"/AU OR "SUTTON J CURTIS"/AU) OR
 "SUTTON JAMES"/AU OR ("SUTTON JAMES C"/AU OR "SUTTON JAMES C
 JR"/AU OR "SUTTON JAMES CLIFFORD JR"/AU)
 L31 2508 SEA FILE=HCAPLUS ABB=ON PLU=ON "LI JAMES"/AU OR "LI JAMES
 J"/AU OR LI J/AU OR LI J J?/AU
 L32 1 SEA FILE=HCAPLUS ABB=ON PLU=ON (L21 AND L22 AND L23 AND L24
 AND L25 AND L26 AND L27 AND L28 AND L29 AND L30 AND L31) NOT
 L16
 L33 15 SEA FILE=HCAPLUS ABB=ON PLU=ON (L21 AND (L22 OR L23 OR L24
 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31)) NOT L16
 L34 22 SEA FILE=HCAPLUS ABB=ON PLU=ON (L22 AND (L23 OR L24 OR L25
 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31)) NOT L16
 L35 10 SEA FILE=HCAPLUS ABB=ON PLU=ON (L23 AND (L24 OR L25 OR L26
 OR L27 OR L28 OR L29 OR L30 OR L31)) NOT L16
 L36 7 SEA FILE=HCAPLUS ABB=ON PLU=ON (L24 AND (L25 OR L26 OR L27
 OR L28 OR L29 OR L30 OR L31)) NOT L16
 L37 27 SEA FILE=HCAPLUS ABB=ON PLU=ON (L25 AND (L26 OR L27 OR L28
 OR L29 OR L30 OR L31)) NOT L16
 L39 10 SEA FILE=HCAPLUS ABB=ON PLU=ON (L27 AND (L28 OR L29 OR L30
 OR L31)) NOT L16
 L40 2 SEA FILE=HCAPLUS ABB=ON PLU=ON (L28 AND (L29 OR L30 OR L31))
 NOT L16
 L41 3 SEA FILE=HCAPLUS ABB=ON PLU=ON (L29 AND (L30 OR L31)) NOT
 L16
 L42 2 SEA FILE=HCAPLUS ABB=ON PLU=ON (L29 AND L31) NOT L16
 L43 52 SEA FILE=HCAPLUS ABB=ON PLU=ON L32 OR L33 OR L34 OR L35 OR
 L36 OR L37 OR L39 OR L40 OR L41 OR L42

=>

=>

=> d ibib abs hitstr 143 1-52

L43 ANSWER 1 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1026854 HCAPLUS
 DOCUMENT NUMBER: 143:306166
 TITLE: Novel bicyclic compounds as modulators of androgen receptor function, their preparation and pharmaceutical compositions
 INVENTOR(S): Li, James J.; Hamann, Lawrence;
 Wang, Haixia
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2005086735	A2	20050922	WO 2005-US7225	20050303		
WO 2005086735	A3	20051222				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						

PRIORITY APPLN. INFO.: US 2004-550155P P 20040304

OTHER SOURCE(S): MARPAT 143:306166

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to bicyclic compds. I, which are modulators of androgen receptors. In compds. I, R1 is selected from H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted arylalkyl, CO₂R₄, CONR₄R₄, and CH₂OR₄; R2 are independently selected from H, halo, (un)substituted alkyl, OR₃, SR₃, halo, NHR₃, NHC(O)R₄, NHCO₂R₄, NHC(O)NR₄R₄, and NHSO₂R₄; R3 is selected from H, (un)substituted alkyl, CHF₂, CF₃, and C(O)R₄; R4 are independently selected from H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, and (un)substituted heteroaryl; R5 are independently selected from H, CF₃, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, and (un)substituted heteroaryl; X is C(O)NR₆ or N(R₆)CO; R₆ is selected from (un)substituted aryl(methyl), (un)substituted heterocyclyl(methyl), and (un)substituted heteroaryl(methyl); and n is 1 or 2; including all prodrug esters, stereoisomers, and pharmaceutically acceptable salts. The

invention also relates to the preparation of I, pharmaceutical compns. containing

at least one compound I and at least one pharmaceutically acceptable diluent or carrier, as well as to the use of the compns. for the treatment of androgen receptor-associated conditions, such as age-related diseases. [2 + 2]-Cycloaddn. of cyclopent-2-enone with 1,1-diethoxyethene followed by hydride reduction, acid hydrolysis and esterification gave bicyclic compound

II,

which underwent condensation with O-(mesitylenesulfonyl)hydroxylamine and Beckmann rearrangement to give regioisomers III (X = CO, Y = NH; X = NH, Y = CO). Ring expansion products III underwent substitution with 2-chloro-4-iodo-3-methylbenzonitrile (preparation in 5 steps from 3-chloro-2-methylaniline given) followed by chiral chromatog. resolution and ester hydrolysis to give two enantiomers of each regioisomeric bicyclic product, e.g., IV. Some of the compds. of the invention act as agonists of androgen receptors, and others as antagonists (no data).

L43 ANSWER 2 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:983773 HCAPLUS

DOCUMENT NUMBER: 143:286280

TITLE: Preparation of pyrrolizines as modulators of androgen receptor function

INVENTOR(S): Li, James J.; Hamann, Lawrence;
Augeri, David; Bi, Yingzhi

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 24 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005197367	A1	20050908	US 2005-70020	20050302
WO 2005089118	A2	20050929	WO 2005-US6925	20050303
WO 2005089118	A3	20060223		
			W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	

PRIORITY APPLN. INFO.: US 2004-550154P P 20040304

OTHER SOURCE(S): MARPAT 143:286280

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors prepared the title compds. I [R1 = H, (un)substituted alkyl, alkenyl, arylalkyl, CO2R4, CONR42, CH2OR4; R2 = H, (un)substituted alkyl, OR3, SR3, halo, NHR3, NHCO2R4, NHCONR42, NHSO2R4; R3 = H,

(un)substituted alkyl, CHF₂, CF₃, COR₄; R₄ = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, aryl, heteroaryl; R₅ = H, OR₃, CF₃, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, aryl, heteroaryl, R₅₂ = double bond with O, S, NR₇ or CR₇₂; W = CR₆₂, SO, SO₂; R₆ = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, heteraryl, aryl where at least one R₆ = H or R₆₂ = double bond with O, S, NR₇ or CR₇₂; R₇ = H, OR₄, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, aryl, heterocycl, heteroaryl] for preventing, inhibiting, or treating the progression or onset of diseases or disorders associated with the androgen receptor. Thus, reacting acetic acid derivative II with proline ester III gave pyrrolidinecarboxylate IV which was cyclized and deprotected to give pyrrolizine V.

L43 ANSWER 3 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:983771 HCPLUS

DOCUMENT NUMBER: 143:286428

TITLE: Preparation of pyrrolo[1,2-c]oxazoles and pyrrolo[1,2-c]imidazoles as modulators of androgen receptor function

INVENTOR(S): Nirschl, Alexandra; Sutton, James C.; Hamann, Lawrence; Wang, Tammy; Zou, Yan; Sun, Chongqing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 38 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005197359	A1	20050908	US 2005-70808	20050302
WO 2005087232	A1	20050922	WO 2005-US7229	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-550042P P 20040304

OTHER SOURCE(S): MARPAT 143:286428

GI



AB The authors prepared the title compds. I [R1 = H, (un)substituted alkyl, (un) substituted alkenyl, (un)substituted arylalkyl, CO₂R₄, CONR₄2, CH₂OR₄; R2 = H, (un)substituted alkyl, OR₃, SR₃, halo, NHR₃, NHCO₄, NHCO₂R₄, NHCONR₄2, NHSO₂R₄; R3 = H, (un)substituted alkyl, CHF₂, CF₃, COR₄; R4 = H, (un)substituted alkyl, (un)substituted alkenyl,, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, (un)substituted heteroaryl; R5 = H, (un)substituted alkyl, (un)substituted alkenyl,, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, (un)substituted heteroaryl where at least one R5 = H, or R52 = double bond to O or S; X = O, S, NR₆, NG; Y = cyano, G; R6 = H, (un)substituted alkyl, (un)substituted alkenyl,, (un)substituted arylalkyl, CO₂R₄, CONR₄2, cyano; G = aryl, heterocyclyl, heteroaryl; Z = (CH₂)_n, n = 1, 2] to be used in the treatment of androgen receptor-associated conditions. Thus, reacting 3-hydroxypyrrrolidine-2-carboxylic acid Me ester with 2-chloro-4-isocyano-3-methylbenzonitrile gave amide II which underwent silylation at the hydroxyl group, reduction of the ester to the alc., cyclization, and deprotection to give pyrrolo[1,2-c]oxazole III.

L43 ANSWER 4 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:904349 HCPLUS

DOCUMENT NUMBER: 143:248278

TITLE: Preparation of sulfonylpyrrolidines as modulators of androgen receptor

INVENTOR(S): Hamann, Lawrence G.; Bi, Yingzhi; Manfredi, Mark C.; Nirschil, Alexandra A.; Sutton, James C.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.

KIND



DATE

APPLICATION NO.

DATE

 US 2005187267 A1 20050825 US 2005-48439 20050201
 PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 143:248278 US 2004-541869P P 20040204
 GI

M



AB Title compds. I or II [R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, SR6, etc.; R3 and R4 independently = H, (un)substituted alkynyl, cycloalkyl, etc.; R5 = H, (un)substituted aryl, arylalkyl, etc.; R6 = H, CHF2, CF3, etc.; X = (CH2)n; G = (un)substituted aryl, heterocycle or heteroaryl; Z = O or NR7; R7 = H, (un)substituted alkyl, alkenyl, etc.; n and m independently = 1-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of androgen receptor. Thus, e.g., III was prepared by hydrolysis of (2S,3R)-1-(3-chloro-4-cyano-2-methyl-phenylsulfamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid Me ester (preparation given) followed by cyclization. The activity of I was evaluated in transactivation assays of a transfected reporter construct and using the endogenous androgen receptor of the host cells (no data). I as modulator of androgen receptor should prove useful in the treatment of neoplasm, Alzheimer's disease and obesity. Pharmaceutical compns. comprising I are disclosed.

L43 ANSWER 5 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:902874 HCPLUS
 DOCUMENT NUMBER: 143:248277
 TITLE: Preparation of sulfonylpyrrolidines as modulators of androgen receptor
 INVENTOR(S): Hamann, Lawrence H.; Bi, Yingzhi;
 Manfredi, Mark C.; Nirschl, Alexandra A.; Sutton, James C.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077925	A1	20050825	WO 2005-US2834	20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2004-541869P	P 20040204
OTHER SOURCE(S):		MARPAT 143:248277		
GI				




AB Title compds. I or II [R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, SR6, etc.; R3 and R4 independently = H, (un)substituted alkynyl, cycloalkyl, etc.; R5 = H, (un)substituted aryl, arylalkyl, etc.; R6 = H, CHF2, CF3, etc.; X = (CH2)n; G = (un)substituted aryl, heterocycle or heteroaryl; Z = O or NR7; R7 = H, (un)substituted alkyl, alkenyl, etc.; n and m independently = 1-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of androgen receptor. Thus, e.g., III was prepared by hydrolysis of (2S,3R)-1-(3-chloro-4-cyano-2-methyl-

phenylsulfamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid Me ester (preparation given) followed by cyclization. The activity of I was evaluated in transactivation assays of a transfected reporter construct and using the endogenous androgen receptor of the host cells (no data). I as modulator of androgen receptor should prove useful in the treatment of neoplasm, Alzheimer's disease and obesity. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 6 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:760338 HCAPLUS
 DOCUMENT NUMBER: 143:367574
 TITLE: Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors
 AUTHOR(S): Zhao, Guohua; Taunk, Prakash C.; Magnin, David R.; Simpkins, Ligaya M.; Robl, Jeffrey A.; Wang, Aiying; Robertson, James G.; Marcinkeviciene, Jovita; Sitkoff, Doree F.; Parker, Rex A.; Kirby, Mark S.; Hamann, Lawrence G.
 CORPORATE SOURCE: Department of Discovery Chemistry, Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ, 08543-5400, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(18), 3992-3995
 CODEN: BMCL8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Dipeptidyl peptidase IV (DPP4) is a multifunctional type II transmembrane serine peptidase which regulates various physiol. processes, most notably plasma glucose homeostasis by cleaving peptide hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Inhibition of DPP4 is a potentially valuable therapy for type 2 diabetes. Synthesis and structure-activity relationships of a series of substituted diprolyl nitriles are described, leading to the identification of compound I with a measured DPP4 Ki of 3.6 nM.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 7 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:739746 HCAPLUS
 TITLE: Structure-activity relationships and scaffold modifications in selective androgen receptor

AUTHOR(S) : modulators (SARMs)
Hamann, Lawrence G.; Li, James;
Nirschl, Alexandra; Sutton, James;
Simpkins, Ligaya M.; Manfredi, Mark; Zou, Yan;
Pi, Zulan; Huang, Yanting; Wang, Haixia; Wang,
Tammy; Sun, Chongqing; Bi, Yingzhi;
Augeri, David J.; Johnson, Rebecca; Driscoll,
Joyce; Lupisella, John; Golla, Rajasree; Seethala,
Ramakrishna; Beehler, Blake; Slep, Paul; Egan,
Donald; Welzel, Gustav; An, Yongmi; Krystek, Stanley;
Fura, Aberra; Grover, Gary; Ostrowski, Jacek
Discovery Chemistry, Bristol-Myers Squibb Company,
Princeton, NJ, 08543-5400, USA
CORPORATE SOURCE: Abstracts of Papers, 230th ACS National Meeting,
SOURCE: Washington, DC, United States, Aug. 28-Sept. 1, 2005
(2005), MEDI-235. American Chemical Society:
Washington, D. C.
CODEN: 69HFCL
DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)
LANGUAGE: English
AB The Nuclear Hormone Receptor (NHR) superfamily of intracellular ligand-dependent transcription factors has historically been a rich source of highly druggable targets, and compds. which selectively modulate gene-transcription through activation of these receptors have the potential to provide more favorable clin. profiles than those of the native hormones. In this regard, clin. use of the endogenous agonists of the Androgen Receptor (AR), testosterone and dihydrotestosterone, as well as related steroidal agents have demonstrated excellent anabolic efficacy in limited clin. trials. However, their use has been limited due to drawbacks associated with both the route of administration and concerns due to the side-effects and toxicity of these steroidal agonists. In order to circumvent these liabilities, several groups have been actively engaged in the discovery and development of Selective Androgen Receptor Modulators (SARMs). The most advanced of these compds. has entered clin. trials for treatment of a variety of disorders, including muscle wasting from HIV, cancer chemotherapy, chronic renal failure, male hypogonadism, benign prostatic hyperplasia, functional decline in the aging male, and osteoporosis and sexual dysfunction in both men and women. SARMs as a class hold significant potential for achieving the beneficial anabolic and cognitive enhancing effects of classical pure agonist compds. without the associated side-effects, by virtue of multiple mechanisms mediating gene- and tissue-selective action. Further exploration of structure-activity-relationships (SAR) within our previously described novel series of SARMs have resulted in the discovery of a number of diverse scaffolds conferring potent and tissue selective agonist activity both in vitro and in vivo. Subtle changes in ligand structure were found to induce profound pharmacol. differences when studied in whole-cells and in rodents. SAR from these series and an examination of selectivity mechanisms will be described.

L43 ANSWER 8 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:738000 HCPLUS
TITLE: Structure-based drug design for nuclear hormone receptors
AUTHOR(S) : Krystek, Stanley; Hamann, Lawrence G.;
Salvati, Mark E.; Balog, Aaron; Hunt, Jack; Li,
James; Manfredi, Mark; Martinez, Rogelio; Nayeem,
Akbar; Nirschl, Alexandra; Pickering, Dacia; Schnur,
Dora; Shan, Weifeng; Sun, Chongqing; Wei, Donna; Zhu,
Hong

CORPORATE SOURCE: Computer-Assisted Drug Design, Bristol-Myers Squibb, Princeton, NJ, 08543-5400, USA
 SOURCE: Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), COMP-090. American Chemical Society: Washington, D. C.
 CODEN: 69HFCL
 DOCUMENT TYPE: Conference; Meeting Abstract; (computer optical disk)
 LANGUAGE: English
 AB Structure-based drug design encompasses a number of technologies that provide the drug discovery process with rapid and unique approaches to ligand discovery and optimization. The aim of structure-based design is optimization of ligand potency and selectivity. However, drug design requires optimization of many properties including absorption, metabolic stability, distribution, plasma protein binding, toxicol. and other pharmaceutical properties. In this talk we will highlight aspects of ligand design for members of the nuclear hormone receptor family.




L43 ANSWER 9 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:543673 HCAPLUS
 DOCUMENT NUMBER: 143:221803
 TITLE: Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
 AUTHOR(S): Augeri, David J.; Robl, Jeffrey A.; Betebenner, David A.; Magnin, David R.; Khanna, Ashish; Robertson, James G.; Wang, Aiying; Simpkins, Ligaya M.; Taunk, Prakash; Huang, Qi; Han, Song-Ping; Abboaa-Offei, Benoni; Cap, Michael; Xin, Li; Tao, Li; Tozzo, Effie; Welzel, Gustav E.; Egan, Donald M.; Marcinkeviciene, Jovita; Chang, Shu Y.; Biller, Scott A.; Kirby, Mark S.; Parker, Rex A.; Hamann, Lawrence G.

CORPORATE SOURCE: Department of Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ, 08543-5400, USA
 SOURCE: Journal of Medicinal Chemistry (2005), 48(15), 5025-5037
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Efforts to further elucidate structure-activity relationships (SAR) within the authors previously disclosed series of β -quaternary amino acid linked L-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the investigation of vinyl substitution at the β -position of α -cycloalkyl-substituted glycines. Despite poor systemic exposure, vinyl-substituted compds. showed extended duration of action in acute rat ex vivo plasma DPP-IV inhibition models. Oxygenated putative metabolites were prepared and were shown to exhibit the potency and extended duration of action of their precursors in efficacy models measuring glucose clearance in Zuckerfa/fa rats. Extension of this approach to adamantylglycine-derived inhibitors led to the discovery of highly potent inhibitors, including hydroxyadamantyl compound BMS-477118 (saxagliptin), a highly efficacious, stable, and long-acting DPP-IV inhibitor, which is currently undergoing clin. trials for treatment of type 2 diabetes.

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 10 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:472130 HCPLUS
 DOCUMENT NUMBER: 143:26607
 TITLE: Monocyclic N-aryl hydantoins as modulators of androgen receptor function, their preparation and pharmaceutical compositions
 INVENTOR(S): Bi, Yingzhi; Hamann, Lawrence G.; Manfredi, Mark C.; Simpkins, Ligaya M.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 71 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049580	A1	20050602	WO 2004-US37688	20041110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005153968	A1	20050714	US 2004-984502--	20041109
PRIORITY APPLN. INFO.:			US 2003-519846P	P 20031113
OTHER SOURCE(S):	MARPAT	143:26607		
GI				



AB The invention relates to a group of novel N-aryl hydantoins I, which are

modulators of androgen receptors. In compds. I, R1, R2, and R3 are independently selected from H, (un)substituted (aryl)alkyl and (un)substituted (aryl)alkenyl, where R1 and R2 may be taken together to form an optionally substituted carbon-carbon double bond; X is selected from O, S, NR1, CH2, H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, and (un)substituted heteroaryl; and G is (un)substituted aryl, heterocyclyl, or heteroaryl. The invention also relates to the preparation of I, pharmaceutical compns. containing I as active ingredients along with a pharmaceutically acceptable adjuvant or carrier, as well as to the use of the compns. for the treatment of androgen receptor associated conditions, such as age-related diseases. Boc-protected Me glycine was deprotected and underwent cyclization with 4-cyano-1-naphthaleneisocyanate, prepared by reaction of 4-amino-1-naphthalenecarbonitrile with phosgene, to give hydantoin II. Condensation of II with salicylaldehyde resulted in the formation of III. Some of compds. I are selective agonists of the androgen receptor, while others are partial agonists, antagonists, or partial antagonists (no data).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 11 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:244457 HCAPLUS

DOCUMENT NUMBER: 142:475247

TITLE: Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues

AUTHOR(S): Li, James J.; Wang, Haixia; Qu, Fucheng; Musial, Christa; Tino, Joseph A.; Robl, Jeffrey A.; Slusarchyk, Dorothy; Golla, Rajasree; Seethala, Ramakrishna; Dickinson, Kenneth; Giupponi, Leah; Grover, Gary; Sleph, Paul; Flynn, Neil; Murphy, Brian J.; Gordon, David; Kung, Melissa; Stoffel, Robert

CORPORATE SOURCE: Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(7), 1799-1802


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Several novel series of tetrahydroisoquinoline 1-carboxamides were prepared and shown to be potent growth hormone (GH) secretagogues. Among them, carbamate I displays excellent in vivo activity by increasing plasma GH 10-fold in an anesthetized IV rat model.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 12 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:120884 HCAPLUS

DOCUMENT NUMBER: 142:219555

TITLE: Preparation of adamantylglycinamide inhibitors of dipeptidyl peptidase IV

INVENTOR(S): Hamann, Lawrence G.; Khanna, Ashish; Kirby, Mark S.; Magnin, David R.; Simpkins, Ligaya M.; Sutton, James C.; Robl, Jeffrey

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012249	A2	20050210	WO 2004-US24257	20040728
WO 2005012249	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005038020	A1	20050217	US 2004-899641	20040727
US 6995183	B2	20060207		
US 2005228021	A1	20051013	US 2005-149414	20050609
US 2005239839	A1	20051027	US 2005-149408	20050609
PRIORITY APPLN. INFO.:			US 2003-491832P	P 20030801
			US 2004-899641	A 20040727

OTHER SOURCE(S): MARPAT 142:219555

GI



AB Title compds. [I; m, n = 0-2; m+n ≤ 2; dashed bonds form a cyclopropyl ring when Y = CH; X = H, CN; Y = CH, CH₂, CHF, CF₂, O, S, SO, SO₂; A = (substituted) adamantly], were prepared Thus, (S)-(3-hydroxy-5,7-dimethyladamantan-1-yl)glycine pyrrolidinamide (preparation from 3,5-dimethyladamantane-1-carboxylic acid given) at 3 μmol/kg orally in rats gave a 39% reduction in serum glucose after 4 h.

L43 ANSWER 13 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:71579 HCAPLUS

DOCUMENT NUMBER: 142:404556

TITLE: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial

AUTHOR(S): Yusuf, S.; Mehta, S. R.; Diaz, R.; Paolasso, E.; Pais, P.; Reddy, S.; Liu, L.; Kazmi, K.; Ahmed, R. J.; Cronin, L.; Xavier, D.; Zhu, J.; Tai, J.; Xie, C.; Gupta, R.; Haridas, K. K.; Jaison, T. M.; Joshi, P. P.; Kerkar, P. G.; Maity, A. K.; Manchanda, S. C.; Naik, S.; Pais, P.; Prabhakaran, D.; Reddy, S.; Singh, B.; Thanikachalam, S.; Xavier, D.; Bai, X. J.; Chen, T.; Cui, J. J.; Cui, T. X.; Fu, S. Y.; Ge, H.; Li, Q. L.; Li, S. M.; Li, W.; Li, Y. Q.; Liu, L.; Liu, Y. H.; Lu, Z. R.; Ma, S. P.; Qiao, D.; Song, Y. C.; Sun, N. L.; Wang, L. H.; Wang, S. W.; Wang, W.; Wang, Y.; Wu, N.; Wu, Y. S.; Xu, C. B.; Xu, S. C.; Xu, Z. M.; Yang, G. J.; Yang, H. S.; Zhang, C. Z.; Zhang, S. T.; Zhang, W. J.; Zhou, J. C.; Zhu, J.; Almahmeed, W.; Avezum, A.; Castro, P.; Corbalan, R.; Diaz, R.; Flors, R. Pitarch; Lombana, B. M.; Marano, L.; McGuire, D.; Orlandini, A.; Paolasso, E.; Perez, J. E. Isea; Piegas, L. Soares; Van De Werf, F.; White, H.; Zubaid, M.; Faruqi, A. M.; Kazmi, K.; Rasool, I.; Soomro, K.; Tai, J.; ul Banna, H.; Yusuf, S.; Mehta, S. R.; Ahmed, R. J.; Cronin, L.; Pavlov, S.; Xie, C.; Pogue, J.; Zhao, F.; Tsuluca, I.; Molec, M.; Holadyk-Gris, I.; Ahmed, K.; Pais, P.; Xavier, D.; Freed, D.; Lidwin, S.; Chenniappan, M.; Isaac, B.; Iyengar, S. S.; Jaison, T. M.; Joshi, P.; Kalantri, S. P.; Kaushik, S. K.; Kerkar, P. G.; Mahorkar, U. K.; Narendra, J.; Paul, S. K.; Santhosh, M. J.; Sastry, B. K. S.; Singh, B.; Siwach, S. B.; Varghese, K.; Liu, L.; Zhu, J.; Yang, H.; Yang, Y.; Zhang, X.; Tan, H.; Tang, J.; Li, X.; Yan, L.; Zhang, Y.; Li, J.; Bai, M. Y.; Jiang, Y. Q.; Lang, Y.; Shi, X. Y.; Song, Y. C.; Tian, Z. R.; Wang, K.; Yan, D. H.; Yu, S. Y.; Pascual, A.; Ozcoidi, H.; Cuesta, C.; Wojdyla, D.; Font, G. M.; Genisans, M. I.; Kazmi, K.; Tai, J.; Chandna, I.; Rafiq, M.; Dadani, N.; Fatima, S. S.; Rehman, S.; Adil, S.; Bhojomal, K.; Hameed, A.; Khan, S. A.; Sleight, P.; Baigent, C.; Hirsh, J.; Taylor, W.; Tognoni, G.; Bacher, P.; Bender, N.; Legler, U.; Magin, U.; Raschke, U.; Brito, M. A.; Alves De Lima, A.; Ahuad Guerrero, R. A.; Nordaby, R.; Barcudi, R. J.; Bono, J.; Ledesma, R. E.; Ramos, H. R.; Caccavo, A.; Macin, S. M.; Ferreyra Cantante, S. N.; Caime, G. D.; Cartasegna, L. R.; Perrino, O. A.; Gambarate, A. J.; Marzetti, E.; Garrido, M.; Balado, R. J.;

Martinez, C. B.; Fernandez, A. A.; Ferro Queirel, E.; Balbi, J. O.; Amuchastegui, G.; Covelli, G.; Gentile, A.; Girino, C. E.; Lopez, J.; Monti, R.; Orlandini, A. D.; Pellizon, O.; Ramos, J. L.; Zapata, G.; Cuneo, C. A.; Sanchez, J. A.; Albisu, J. P.; Berli, M. A.; Hominal, M. A.; Peleteiro Marino, R. A.; Mezzina, V.; Avila, E. M.; Baselga, P.; Castellanos, C. R.; Luciardi, H. L.; Lobo Marquez, L. L.; Muntaner, J.; Van De Werf, F.; Good God, E. M.; Reis, G.; Mello Soares, D. M.; Bodanese, L. C.; Manenti, E.; Prestes, L.; De Castro Amino, J. G.; Uchoa Azevedo, R.; Carvalho, A. C. C.; Ramos, R. F.; Alcaino, M.; Castro Galvez, P.; Corbalan Herreros, R.; Yang, An; Liu, H.; Wang, R.; Liu, Z. C.; Tian, X.; Wang, G.; Zhang, Y.; Nan, Z.; Zhang, J.; Zai, C.; Chen, W.; Gao, M.; Hu, D.; Jia, S.; Li, D. X.; Li, Q.; Li, W.; Liu, S. L.; Sun, Y.; Wang, B.; Xie, G. F.; Xu, Z.; Yang, X.; Zhao, M.; Zhao, X.; Fang, Z.; Liu, S. Y.; Ma, Z.; Jiang, Y.; Li, S. M.; Zhen, Z.; Huo, F.; Yang, H. G.; Liu, H.; Miao, Y.; Yang, C. M.; Chi, X.; Liu, Z. X.; Zhou, S.; Sun, Y.; Zhou, F. S.; Guo, R.; Jing, K.; Xu, Z.; Ren, S.; Zhao, J.; Bai, H.; Bai, H.; Cheng, C.; Cheng, J.; Hao, X.; Li, H.; Li, W. G.; Wang, S.; Zhang, W.; Li, L.; Sun, Y.; Fu, S.; Shao, J.; Tan, X.; Chen, S.; Fu, J.; Zheng, Q.; Ren, Huai; Ma, J.; Chen, H.; Ma, H.; Gong, L.; Zhang, Z.; Li, F.; Yang, B.; Zhou, L. S.; Wang, Z.; Sun, X.; Tao, G.; Wang, Q.; Li, J.; Guo, X.; Wang, X.; Zai, K.; Cui, Q.; Fan, S.; Li, H.; Liu, W.; Meng, Q.; Qi, G.; Qin, Y.; Wang, G.; Wang, N.; Xu, G.; Yin, X.; Zhang, Q.; Zhang, S.; Zhang, Y.; Zhang, Z.; Li, W. K.; Zhang, H.; Xu, X.; Ma, R.; Guan, F.; Yang, T.; Zhqo, R.; Huang, J.; Li, A.; Zhou, J.; You, X.; Hao, L.; Zhangfang, F.; Ma, X.; Shen, C.; Li, Q.; Hou, Z.; Zho, N. F.; Huang, G.; Guo, P.; Lou, J.; Wang, Q. P.; Wang, Z.; Jiang, X.; Li, Z.; Tian, D.; Wang, S.; Wu, Z. D.; Yang, M. G.; Li, Z. C.; Yang, S. G.; Tu, Y.; He, C.; Cao, Y.; Han, Y.; Yang, J. H.; Dong, S.; Li, D. F.; Zhang, Q. F.; Fan, Z.; An, D. Q.; Liu, J.; Yang, G.; Xu, X. C.; Xia, Y.; Xu, H.; Wang, T.; Li, D.; Wei, J.; Yang, P.; Liu, C. Y.; Shang, S.; Zhang, Y. G.; Hernandez Leyva, E.; Cano Lopez, N.; Gonzalez Medina, A. R.; Kanakakis, J. E.; Nanas, J. N.; Papazoglou, D.; Srinivas, J.; Srinivasulu, B.; Dani, S.; Prajapati, J.; Deepak, G.; Shallam, J. F.; Nesaraj, K. J.; Kumar, A.; Sharma, R. K.; Balasubramaniyan, S.; Chidambaram, N.; Umrani, R.; Chandra, S.; Dwivedi, S.; Isaac, B.; Kishore, R.; Kumar, B. J.; Kumble, Y.; Mehrotra, S.; Nayak, P. R.; Ramesh, S. S.; Santhosh, M. J.; Shetty, P. K.; Varghese, K.; Trivedi, S. K.; Beniwal, R.; Kalla, A.; Panwar, R. B.; Alexander, K. G.; Bindu, A. V.; Barkavi, D.; Kalanidhi, A.; Pradeep, T.; Rajesh, J.; Ramesh, M.; Shanmugasundaram, S.; Thanikachalam, S.; Haridas, K. K.; Kumar, P.; Sidhu, G.; Singh, R.; Pradeep, K. N.; Kumar, A.; Mittal, A.; Bijapure, J. B.; Rao, M. S.; Mohanarjun, N. G.; Rao, M. B.; Babu, B. R.; Dinesh, N.; Jain, R. K.; Jiwani, P. A.; Naik, S. R.; Padmanabhan, T. N. C.; Raju, B. S.; Rajaram, R.; Rao, A. S. V. N.; Rao, D.; Rao, V. S. P.; Sastry, B. K. S.; Sinha, S.; Bharani, A.; Verma, G.; Gupta,

R.; Tongia, R. K.; Kalra, S.; Sharma, S.; Mehrotra, R.; Sanghvi, S.; Soni, O. P.; Biswas, A. D.; Maity, A. K.; Paul, S. K.; Boben, J.; Jacob, G.; Joseph, J.; Puri, A.; Puri, V. K.; Singh, H.; Calton, R.; Jaison, T. M.; Aneja, G. K.; Kerkar, P. G.; Nyayadhish, P.; Nathani, P. J.; Rane, S. K.; Fulwani, M.; Jain, A. S.; Joshi, P. P.; Khan, A.; Mahorkar, U. K.; Salkar, R. G.; Somani, A.; Wadhwani, R.; Zawar, S. D.; Shegokar, V. E.; Tungikar, S. L.; Vijan, V.; Singh, B.; Trehan, R.; Garg, A.; Singh, H.; Verma, S.; Borade, S.; Duggal, D.; Hiremath, J.; Katyal, V. K.; Siwach, S. B.; Devendrappa, H. R.; Narendra, J.; Latha, P. B.; Manoj, E. B.; Mohanan, P. P.; Chenniappan, M.; Gandhimadhinathan, P.; Jeremaiyah, K.; Raj, B. S. V.; Udaysankar, R.; Chhaparwal, J. K.; Kaushik, S. K.; Chandy, S. T.; Gupta, S. N.; Raghavan, S.; Ramesh, P.; Reddy, V. S.; Srinivas, P.; Rao, K. D.; Malipeddi, B. R.; Murthy, G. S. R.; Joshi, R.; Kalantri, S. P.; Patil, S.; Tredici, S.; Agnelli, D.; Assanelli, E.; Marano, L.; Marsano, L.; Crivello, R.; Nejrotti, A.; Abdulminem, A.; Saad, H.; Zubaid, M.; Martinez Sanchez, J.; Carrillo Calvillo, J.; White, H.; Hamer, A.; Chandna, I.; Faruqi, A. M.; Rafiq, M.; Rasool, I.; Soomro, K.; Banna, H. U.; Lombana, B. M.; Lopez Ferre, J.; Flors, R. Pitarch; Freedman, R. J.; McGuire, D.; Transk, N., III; Dhabi, Abu; Almahmeed, W.; Almeida, D.; Lujan, P. J. C.; Mata, C.; Isea Perez, J. E.; Becerra, C.; Gonzalez, K.; Torres, F.; Alvarez, M. A.; Carrillo, E.

CORPORATE SOURCE: Department of Medicine, and Population Health Research Institute, Hamilton Health Sciences, McMaster University, Can.

SOURCE: JAMA, the Journal of the American Medical Association (2005), 293(4), 437-446
CODEN: JAMAAP; ISSN: 0098-7484

PUBLISHER: American Medical Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI. The aim of this study was to determine the effect of high-dose GIK infusion on mortality in patients with STEMI. This was a randomized controlled trial conducted in 470 centers worldwide among 20201 patients with STEMI who presented within 12 h of symptom onset. The mean age of patients was 58.6 years, and evidence-based therapies were commonly used. Patients were randomly assigned to receive GIK i.v. infusion for 24 h plus usual care (n=10091) or to receive usual care alone (controls; n=10110). Main outcome measures were mortality, cardiac arrest, cardiogenic shock, and reinfarction at 30 days after randomization. At 30 days, 976 control patients (9.7%) and 1004 GIK infusion patients (10.0%) died (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.95-1.13; P=.45). There were no significant differences in the rates of cardiac arrest 1.5% [151/10107] in control and 1.4% [139/10088] in GIK infusion; HR, 0.93; 95% CI, 0.74-1.17; P=.51, cardiogenic shock (6.3% [640/10107] vs. 6.6% [667/10088]; HR, 1.05; 95% CI, 0.94-1.17; P=.38), or reinfarction (2.4% [246/10107] vs. 2.3% [236/10088]; HR, 0.98; 95% CI, 0.82-1.17; P=.81). The rates of heart failure at 7 days after randomization were

also similar between the groups (16.9% [1711/10107] vs. 17.1% [1721/10088]; HR, 1.01; 95% CI, 0.95-1.08; P=.72). The lack of benefit of GIK infusion on mortality was consistent in prespecified subgroups, including in those with and without diabetes, in those presenting with and without heart failure, in those presenting early and later after symptom onset, and in those receiving and not receiving reperfusion therapy (thrombolysis or primary percutaneous coronary intervention). In this large, international randomized trial, high-dose GIK infusion had a neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute STEMI.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 14 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:71576 HCAPLUS

DOCUMENT NUMBER: 142:403810

TITLE: Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation

AUTHOR(S): Yusuf, S.; Mehta, S. R.; Pais, P.; Reddy, S.; Liu, L.; Ahmed, R. J.; Cronin, L.; Xavier, D.; Zhu, J.; Xie, C.; Gupta, R.; Haridas, K. K.; Jaison, T. M.; Joshi, P. P.; Kerkar, P. G.; Maity, A. K.; Manchanda, S. C.; Naik, S.; Pais, P.; Prabhakaran, D.; Reddy, S.; Singh, B.; Thanikachalam, S.; Xavier, D.; Bai, J.; Chen, T.; Cui, J. J.; Cui, T. X.; Fu, S. Y.; Ge, H.; Li, L.; Li, S. M.; Li, W.; Li, Y. Q.; Liu, L.; Liu, Y. H.; Lu, Z. R.; Ma, S. P.; Qiao, D.; Song, Y. C.; Sun, N. L.; Wang, L. H.; Wang, S. W.; Wang, W.; Wang, Y.; Wu, N.; Wu, Y. S.; Xu, C. B.; Xu, S. C.; Xu, Z. M.; Yang, G. J.; Yang, H. S.; Zhang, Z.; Zhang, S. T.; Zhang, W. J.; Zhou, J. C.; Zhu, J.; Yusuf, S.; Mehta, S. R.; Ahmed, R. J.; Cronin, L.; Pavlov, S.; Xie, C.; Pogue, J.; Zhao, F.; Tsuluca, I.; Molec, M.; Holadyk-Gris, I.; Ahmed, K.; Pais, P.; Xavier, D.; Freeda, D.; Lidwin, S.; Chenniappan, M.; Isaac, B.; Iyengar, S. S.; Jaison, T. M.; Joshi, P.; Kalantri, S. P.; Kaushik, S. K.; Kerkar, P. G.; Mahorkar, U. K.; Narendra, J.; Paul, S. K.; Santhosh, M. J.; Sastry, B. K. S.; Singh, B.; Siwach, S. B.; Varghese, K.; Liu, L.; Zhu, J.; Yang, H.; Yang, Y.; Zhang, X.; Tan, H.; Tang, J.; Li, X.; Yan, L.; Zhang, Y.; Li, J.; Bai, M. Y.; Jiang, Y. Q.; Lang, S. Y.; Shi, X. Y.; Song, Y. C.; Tian, Z. R.; Wang, K.; Yan, D. H.; Yu, S. Y.; Sleight, P.; Baigent, C.; Hirsh, J.; Taylor, W.; Tognoni, G.; Bacher, P.; Bender, N.; Legler, U.; Magin, U.; Raschke, U.; Yang, An; Liu, H.; Wang, R.; Liu, Z. C.; Tian, X.; Wang, G.; Zhang, Y.; Nan, Z.; Zhang, J.; Zai, C.; Chen, W.; Gao, M.; Hu, D.; Jia, S.; Li, D. X.; Li, Q.; Li, W.; Liu, S. L.; Sun, Y.; Qang, B.; Xie, G. F.; Xu, Z.; Yang, X.; Zhao, M.; Zhao, X.; Fang, Z.; Liu, S. Y.; Ma, Z.; Jiang, Y.; Li, S. M.; Zhen, Z.; Huo, F.; Yang, H. G.; Liu, H.; Miao, Y.; Yang, C. M.; Chi, X.; Liu, Z. X.; Zhou, S.; Sun, Y.; Zhou, F. S.; Guo, R.; Jing, K.; Xu, Z.; Ren, S.; Zhao, J.; Bai, H.; Bai, H.; Cheng, C.; Cheng, J.; Hao, X.; Li, H.; Li, W. G.; Wang, S.; Zhang, W.; Li, L.; Sun, Y.; Fu, S.; Shao, J.; Tan, X.; Chen, S.; Fu, J.; Zheng, Q.; Ma, J.; Chen, H.; Ma, H.;

Gong, L.; Zhang, Z.; Li, F.; Yang, B.; Zhou, L. S.;
Wang, Z.; Sun, X.; Tao, G.; Wang, Q.; Li, J.; Guo, X.;
Wang, X.; Zai, K.; Cui, Q.; Fan, S.; Li, H.; Liu, W.;
Meng, Q.; Qi, G.; Qin, Y.; Wang, G.; Wang, N.; Xu, G.;
Yin, X.; Zhang, Q.; Zhang, S.; Zhang, Y.; Zhang, Z.;
Liu, R.; Wang, F.; Zhang, Y.; Li, W. K.; Zhang, H.;
Xu, X.; Ma, R.; Guan, F.; Yang, T.; Zhqo, R.; Huang,
J.; Li, A.; Zhou, J.; You, X.; Hao, L.; Zhangfang, F.;
Ma, X.; Shen, C.; Li, Q.; Hou, Z.; Zhao, N. F.; Huang,
G.; Guo, P.; Lou, J.; Wang, Q. P.; Wang, Z.; Jiang,
X.; Li, Z.; Tian, D.; Wang, S.; Wu, Z. D.; Yang, M.
G.; Li, Z. C.; Yang, S. G.; Tu, Y.; He, C.; Cao, Y.;
Han, Y.; Yang, J. H.; Dong, S.; Li, D. F.; Zhang, Q.
F.; Fan, Z.; An, D. Q.; Liu, J.; Yang, G.; Xu, X. C.;
Xia, Y.; Xu, H.; Wang, T.; Li, D.; Wei, J.; Yang, P.;
Liu, C. Y.; Shang, S.; Zhang, Y. G.; Srinivas, J.;
Srinivasulu, B.; Dani, S.; Prajapati, J.; Deepak, G.;
Shallam, J. F.; Nesaraj, K. J.; Kumar, A.; Sharma, R.
K.; Salasubramaniyan, S.; Chidambaram, N.; Rani, R.;
Chandra, S.; Dwivedi, S.; Isaac, B.; Kishore, R.;
Kumar, B. J.; Kumble, Y.; Mehrotra, S.; Nayak, P. R.;
Ramesh, S. S.; Santhosh, M. J.; Shetty, P. K.;
Varghese, K.; Trivedi, S. K.; Beniwal, R.; Kalla, A.;
Panwar, R. B.; Alexander, K. G.; Bindu, A. V.;
Nambiar, A.; Barkavi, D.; Kalanidhi, A.; Pradeep, T.;
Rajesh, J.; Ramesh, M.; Shanmugasundaram, S.;
Thanikachalam, S.; Haridas, K. K.; Kumar, P.; Sidhu,
G.; Singh, R.; Pradeep, K. N.; Kumar, A.; Mittal, A.;
Bijapure, J. B.; Rao, M. S.; Mohanarjun, N. G.; Rao,
M. B.; Babu, B. R.; Dinesh, N.; Jain, R. K.; Jiwani,
P. A.; Naik, S. R.; Padmanabhan, T. N. C.; Raju, B.
S.; Rajaram, R.; Rao, A. S. V. N.; Rao, D.; Rao, V. S.
P.; Sastry, B. K. S.; Sinha, S.; Bharani, A.; Verma,
G.; Gupta, R.; Tongia, R. K.; Kalra, S.; Sharma, S.;
Mehrotra, R.; Sanghvi, S.; Soni, O. P.; Biswas, A. D.;
Maity, A. K.; Paul, S. K.; Boben, J.; Jacob, G.;
Joseph, J.; Puri, A.; Puri, V. K.; Singh, H.; Calton,
R.; Jaison, T. M.; Aneja, G. K.; Kerkar, P. G.;
Nyayadhish, P.; Nathani, P. J.; Rane, S. K.; Fulwani,
M.; Jain, A. S.; Joshi, P. P.; Khan, A.; Mahorkar, U.
K.; Salkar, R. G.; Soman, A.; Wadhwani, R.; Zawar, S.
D.; Shegokar, V. E.; Tungikar, S. L.; Vijan, V.;
Singh, B.; Trehan, R.; Garg, A.; Singh, H.; Verma, S.;
Borade, S.; Duggal, D.; Hiremeth, J.; Katyal, V. K.;
Siwach, S. B.; Devendrappa, H. R.; Narendra, J.;
Latha, P. B.; Manoj, E. B.; Mohanan, P. P.;
Chenniappan, M.; Gandhimadhinathan, P.; Jeremiaiah,
K.; Raj, B. S. V.; Udaysankar, R.; Chhaparwal, J. K.;
Kaushik, S. K.; Chandy, S. T.; George, O.; John, B.;
Ramesh, P.; Reddy, V. S.; Srinivas, P.; Rao, K. D.;
Malipeddi, B. R.; Murthy, G. S. R.; Joshi, R.;
Kalantri, P.; Patil, S.

CORPORATE SOURCE:
Population Health Research Institute, Hamilton Health
Sciences, McMaster University, Hamilton, ON, L8L 2X2,
Can.

SOURCE:
JAMA, the Journal of the American Medical Association
(2005), 293(4), 427-436

PUBLISHER:
CODEN: JAMAAP; ISSN: 0098-7484
DOCUMENT TYPE:
American Medical Association
Journal

LANGUAGE: English

AB Although reperfusion therapy, aspirin, β -blockers, and angiotensin-converting enzyme inhibitors reduce mortality when used early in patients with acute myocardial infarction (MI), mortality and morbidity remain high. No antithrombotic or newer antiplatelet drug has been shown to reduce mortality in acute MI. The aim of this study was to evaluate the effects of reviparin, a low-mol.-weight heparin, when initiated early and given for 7 days in addition to usual therapy on the primary composite outcome of death, myocardial reinfarction, or strokes at 7 and 30 days. This was a randomized, double-blind, placebo-controlled trial (Clin. Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation [CREATE]) of 15570 patients with ST-segment elevation or new left bundle-branch block, presenting within 12 h of symptom onset at 341 hospitals in India and China from July 2001 through July 2004. Reviparin or placebo was given s.c. twice daily for 7 days. The main outcome measures were death, myocardial reinfarction, or stroke at 7 and 30 days. The primary composite outcome was significantly reduced from 854 (11.0%) of 7790 patients in the placebo group to 745 (9.6%) of 7780 in the reviparin group (hazard ratio [HR], 0.87; 95% CI, 0.79-0.96; P=.005). These benefits persisted at 30 days (1056 [13.6%] vs. 921 [11.8%] patients; HR, 0.87; 95% CI, 0.79-0.95; P=.001) with significant redns. in 30-day mortality (877 [11.3%] vs. 766 [9.8%]; HR, 0.87; 95% CI, 0.79-0.96; P=.005) and reinfarction (199 [2.6%] vs. 154 [2.0%]; HR, 0.77; 95% CI, 0.62-0.95; P=.01), and no significant differences in strokes (64 [0.8%] vs. 80 [1.0%]; P=.19). Reviparin treatment was significantly better when it was initiated very early after symptom onset at 7 days (<2 h: HR, 0.70; 95% CI, 0.52-0.96; P=.03; 30/1000 events prevented; 2 to <4 h: HR, 0.81; 95% CI, 0.67-0.98; P=.03; 21/1000 events prevented; 4 to <8 h: HR, 0.85; 95% CI, 0.73-0.99; P=.05; 16/1000 events prevented; and ≥8 h: HR, 1.06; 95% CI, 0.86-1.30; P=.58; P=.04 for trend). There was an increase in life-threatening bleeding at 7 days with reviparin and placebo (17 [0.2%] vs. 7 [0.1%], resp.; P=.07), but the absolute excess was small (1 more per 1000) vs. redns. in the primary outcome (18 fewer per 1000) or mortality (15 fewer per 1000). In patients with acute ST-segment elevation or new left bundle-branch block MI, reviparin reduces mortality and reinfarction, without a substantive increase in overall stroke rates. There is a small absolute excess of life-threatening bleeding but the benefits outweigh the risks.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 15 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:786346 HCPLUS
 DOCUMENT NUMBER: 143:51650
 TITLE: Dielectric characteristics and their field dependence of (Ba,Ca)TiO₃
 AUTHOR(S): Chen, X. M.; Wang, T.; Li, J.
 CORPORATE SOURCE: Department of Materials Science and Engineering,
 Zhejiang University, Hangzhou, 310027, Peop. Rep. China
 SOURCE: Materials Science & Engineering, B: Solid-State
 Materials for Advanced Technology (2004), B113(2),
 117-120
 CODEN: MSBTEK; ISSN: 0921-5107
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB (Ba_{1-x}Ca_x)TiO₃ ferroelec. ceramics were prepared by a solid state reaction method, and their dielec. properties and the field dependence of dielec. constant were characterized together with the microstructures. The

BaTiO₃-based solid solution with tetragonal structure was obtained for x = 0.1, and a tetragonal to cubic phase transition was observed with increasing x since the CaTiO₃-based solid solution phase with cubic structure appeared for x = 0.3 and became the major phase for x = 0.7. The dielec. constant decreased with increasing x, while the dielec. loss and temperature dependence were significantly suppressed. The obvious field dependence of dielec. constant was obtained for the compns. with x<0.5, and it became weaker with increasing x.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 16 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:759871 HCAPLUS

DOCUMENT NUMBER: 141:277621

TITLE: Preparation of bicyclic compounds as modulators of androgen receptor function

INVENTOR(S): Sun, Chong-Qing; Hamann, Lawrence;
Augeri, David; Bi, Yingzhi;
Robl, Jeffrey; Huang, Yan-Ting;
Wang, Tammy; Holubec, Alexandra;
Simpkins, Ligaya; Sutton, James C.;
Li, James J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 94 pp., Cont.-in-part of U.S. Pat. Appl. 2004 19,063.

CODEN: USXXCO

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004181064	A1	20040916	US 2004-780415	20040217
US 2004019063	A1	20040129	US 2003-438722	20030515
PRIORITY APPLN. INFO.:			US 2002-381616P	P 20020517
			US 2002-406711P	P 20020829
			US 2003-438722	A2 20030515

OTHER SOURCE(S): MARPAT 141:277621
GI



AB Bicyclic compds. of formula I [R1 = H, alkyl, arylalkyl, etc.; R2, R3 = H, alkyl, (substituted) OH, halo, (substituted) NH₂, etc.; R4-R7 = H, alkyl, cycloalkyl, arylalkyl, aryl, etc.; R4R5, R6R7 = O, S, NH, CH₂, etc.; R8, R9 = H, alkyl, (substituted) OH, (substituted) NH₂, etc.; X = (CH₂)_n; n = 1-2] are prepared as modulators of androgen receptor function. Further provided are methods of using such compds. for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for

example sarcopenia. Also provided are pharmaceutical compns. containing such compds. and processes for preparing some of the compds. of the invention. Thus, II was prepared from 4-isocyanato-5,6,7,8-tetrahydronaphthalene-1-carbonitrile and Me (2S,3R)-3-hydroxy-2-pyrrolidinecarboxylate (preps. given).

L43 ANSWER 17 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:671241 HCPLUS
DOCUMENT NUMBER: 141:199856
TITLE: Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries
AUTHOR(S): Wang, T.; Li, H.; Zhao, C.; Chen, C.; Li, J.; Chao, J.; Chao, L.; Xiao, X.; Wang, D. W.
CORPORATE SOURCE: Department of Internal Medicine and Gene Therapy Center, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Peop. Rep. China
SOURCE: Gene Therapy (2004), 11(17), 1342-1350
CODEN: GETHEC; ISSN: 0969-7128
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Gene therapy of hypertension requires long-term expression of a therapeutic gene to achieve stable reduction of blood pressure. Human tissue kallikrein (HK) cleaves kininogen to produce a potent vasoactive peptide kinin, which plays an important role in the regulation of the cardiovascular and renal functions. In the present study, we have delivered human kallikrein cDNA with an rAAV vector to explore the potential therapeutic effects of kallikrein on hypertension and related secondary complications. A single tail vein injection of the rAAV-HK vector into the adult spontaneously hypertensive rats resulted in a significant reduction (12.0 ± 2.55 mmHg, $P < 0.05$, $n = 6$, ANOVA) of the systolic blood pressure from 2 wk after vector injection, when compared with the control rAAV-lacZ vector-injected rats. Weekly blood pressure monitoring showed stable hypertension-reduction effect throughout the course of the 20-wk expts. In addition, total urine microalbumin contents decreased as a result of rAAV-HK treatment. Histol. anal. of various tissues showed remarkable amelioration of cardiovascular hypertrophy, renal injury and collagen depositions in the rAAV-treated group. Finally, persistent expression of the transgene product HK was confirmed by the ELISA and reverse transcription-polymerase chain reaction. We conclude that rAAV-mediated HK delivery rendered a long-term and stable reduction of hypertension and protected against renal injury, cardiac remodeling in the spontaneously hypertensive rat model. Further studies are warranted for the development of a gene therapy strategy for human hypertension.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 18 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:658071 HCPLUS
TITLE: Design, synthesis, and pharmacology of BMS-477118: a long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type II diabetes
AUTHOR(S): Hamann, Lawrence G.; Augeri, David J.; Betebenner, David A.; Robl, Jeff; Magnin, David; Khanna, Ashish; Robertson, James G.; Simpkins, Ligaya M.; Taunk, Prakash; Sitkoff, Doree; Weigelt, Carolyn; Huang, Qi; Han, Song Ping;

Abboaa-Offei, Benoni; Wang, Aiying; Cap, Michael; Xin, Li; Tao, Li; Dorso, Charles R.; Kirby, Mark S.; Parker, Rex A.

CORPORATE SOURCE: Discovery Chemistry, Bristol-Myers Squibb Company, Princeton, NJ, 08543-5400, USA

SOURCE: Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004 (2004), MEDI-207. American Chemical Society: Washington, D. C.

CODEN: 69FTZ8

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Efforts to further elucidate structure-activity relationships within our previously disclosed series of β -quaternary amino acid linked L-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the exploration of vinyl substitution at the β -position of α -cycloalkyl substituted glycines. Despite poor systemic exposure, vinyl-substituted compds. showed extended duration of action in an acute rat ex vivo plasma DPP-IV inhibition model. Putative oxygenated metabolites were prepared and these compds. exhibited the potency and extended duration of action of their precursors in efficacy models measuring glucose clearance in Zuckerfa/fa rats. Extension of this approach to other β -quaternary derived inhibitors led to the discovery of addnl. analogs that are highly efficacious, stable, and long-acting DPP-IV inhibitors. This talk will outline the design, synthesis and pharmacol. of compds. within this series leading to the identification of the clin. candidate BMS-477118.

L43 ANSWER 19 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:515478 HCAPLUS

DOCUMENT NUMBER: 141:54618

TITLE: Preparation of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV

INVENTOR(S): Vu, Truc Chi; Brzozowski, David B.; Fox, Rita; Godfrey, Jollie Duaine, Jr.; Hanson, Ronald L.; Kolotuchin, Sergei V.; Mazzullo, John A., Jr.; Patel, Ramesh N.; Wang, Jianji; Wong, Kwok; Yu, Jurong; Zhu, Jason; Magnin, David R.; Augeri, David J.; Hamann, Lawrence G.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052850	A2	20040624	WO 2003-US38558	20031204
WO 2004052850	A3	20060302		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,			

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2005090539 A1 20050428 US 2003-716012 20031118
 CA 2508619 AA 20040624 CA 2003-2508619 20031204
 EP 1581487 A2 20051005 EP 2003-812799 20031204
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003017139 A 20051129 BR 2003-17139 20031204
 PRIORITY APPLN. INFO.: US 2002-431814P P 20021209
 OTHER SOURCE(S): CASREACT 141:54618; MARPAT 141:54618
 GI



AB The invention provides methods and compds. for the production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV. Also described are methods for the asym. reductive amination of (3-hydroxyadamantan-1-yl)oxoacetic acid. Adamantane derivs. I [R1 is H or OH; R2 is C(O)COR4, C(O)NR5R6, C(X)nCOR4 or C(NR7R8)COR4, where X is halo, n is 1-2, R4 is alkoxy, NH2 or OH, and R5-R8 are H or carbalkoxy; R3 is H, OH or NR9C(O)R10, where R9 is carboxy-substituted alkyl or aryl and R10 is 3-cyano-2-azabicyclo[3.1.0]hex-2-yl] or their pharmaceutically-acceptable salts are claimed. Thus, adamantyl-substituted glycinamide derivative II (Boc = tert-butoxycarbonyl) was prepared via amidation of Boc-protected (S)- α -amino-3-hydroxy-1-adamantaneacetic acid.

L43 ANSWER 20 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:452960 HCPLUS

DOCUMENT NUMBER: 141:28605

TITLE: Open chain prolyl urea-related modulators of androgen receptor function therapeutic use for nuclear hormone receptor-associated conditions

INVENTOR(S): Hamann, Lawrence G.; Augeri, David J.; Manfredi, Mark C.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2004045518	A2	20040603	WO 2003-US36331	20031113
WO 2004045518	A3	20041007		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003302084 A1 20040615 AU 2003-302084 20031113
 US 2005059652 A1 20050317 US 2003-712456 20031113
 EP 1567487 A2 20050831 EP 2003-808410 20031113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-426694P P 20021115
 WO 2003-US36331 W 20031113

OTHER SOURCE(S): MARPAT 141:28605
 GI



AB The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula (I), wherein R₁, R₂ and R₃ are groups consisting of hydrogen (H), alkyl, or substituted alkyl etc; G is a mono- or polycyclic ring system; X is a linking group selected from the group consisting of NR₄ and CHR₄; Y is selected from the group consisting of oxygen (O), NR₄, NOR₄ and sulfur (S); Z is oxygen (-O-) or NR₄. Further provided are methods of using such compds. for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compns. containing such compds.

L43 ANSWER 21 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:392331 HCAPLUS
 DOCUMENT NUMBER: 140:406798
 TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 875,155, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 2004092573	A1	20040513	US 2003-602752	20030624
US 6812345	B2	20041102		
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	B2 20010606
OTHER SOURCE(S):	MARPAT 140:406798			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl, alkanoyl, aroyl, alkoxy carbonyl, etc.; R₉, R₁₀ = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 22 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:300939 HCPLUS

DOCUMENT NUMBER: 141:23891

TITLE: Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α -Aminoacyl-L-cis-4,5-methanoprolinenitrile-Based Inhibitors

AUTHOR(S): Magnin, David R.; Robl, Jeffrey A.; Sulsky, Richard B.; Augeri, David J.; Huang, Yanting; Simpkins, Ligaya M.; Taunk, Prakash C.; Betebenner, David A.; Robertson, James G.; Abboaa-Offei, Benoni E.; Wang, Aiying; Cap, Michael; Xin, Li; Tao, Li; Sitkoff, Doree F.; Malley, Mary F.; Gougoutas, Jack Z.; Khanna, Ashish; Huang, Qi; Han, Song-Ping; Parker, Rex A.; Hamann, Lawrence G.

CORPORATE SOURCE: Departments of Discovery Chemistry, Metabolic Research, Exploratory Pharmaceutics, Computer-Assisted Drug Design, Solid State Chemistry and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(10), 2587-2598

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:23891

AB A series of methanoprolinenitrile-containing dipeptide mimetics were synthesized and evaluated as inhibitors of the N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV). The catalytic action of DPP-IV is the principle means of degradation of glucagon-like peptide-1 (a key mediator of glucose-stimulated insulin

secretion) and DPP-IV inhibition shows clin. benefit as a novel mechanism for treatment of type 2 diabetes. However, many of the reversible inhibitors to date suffer from chemical instability stemming from an amine to nitrile intramol. cyclization. Installation of a cyclopropyl moiety at either the 3,4- or 4,5-position of traditional 2-cyanopyrrolidide proline mimetics led to compds. with potent inhibitory activity against the enzyme. Addnl., cis-4,5-methanoprolinenitriles with β -branching in the N-terminal amino acid provided enhanced chemical stability and high inhibitory potency. This class of inhibitors also exhibited the ability to suppress prandial glucose elevations after an oral glucose challenge in male Zucker rats.

REFERENCE COUNT: 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 23 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:931118 HCAPLUS

DOCUMENT NUMBER: 140:5047

TITLE: Preparation of pyrrolo[1,2-c]imidazoles as bicyclic modulators of androgen receptor function

INVENTOR(S): Sun, Chongqing; Hamann, Lawrence;
Augeri, David; Bi, Yingzhi;
Robl, Jeffrey; Huang, Yan-ting;
Wang, Tammy; Simpkins, Ligaya;
Holubec, Alexandra

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 177 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003096980	A2	20031127	WO 2003-US15375	20030515
WO 2003096980	A3	20041021		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU 2003234609	A1	20031202	AU 2003-234609	20030515
EP 1506178	A2	20050216	EP 2003-728951	20030515
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
JP 2005531555	T2	20051020	JP 2004-504979	20030515
NO 2004004809	A	20050214	NO 2004-4809	20041104
PRIORITY APPLN. INFO.:			US 2002-381616P	P 20020517
			US 2002-406711P	P 20020829
			WO 2003-US15375	W 20030515
OTHER SOURCE(S): GI		MARPAT 140:5047		



AB Title compds. I [R1 = H, (un)substituted-alkyl, -alkenyl, arylalkyl, etc.; R2 and R3 independently = H, halo, (un)substituted alkyl, -alkoxy, etc.; R4 and R5 independently = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, -arylalkyl, etc., wherein at least one of R4 and R5 is H, or R4 and R5 taken together can form a double bond with O, S, substituted N or C; R6 and R7 independently = H, (un)substituted-alkyl, -alkenyl, -heteroaryl, -aryl, etc., wherein at least one of R6 and R7 is H, or R6 and R7 taken together can form a double bond with O, S, substituted N or C; G = aryl, heterocyclo or heteroaryl group, wherein said group is mono- or polycyclic and optionally substituted; W = CR6R7, CR6OR8, CR6NR9R10; R8 = H, F2HC, F3C, COR9, (un)substituted alkyl; R9 and R10 independently = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, etc.; n = 1 or 2] and their pharmaceutically acceptable salts are prepared and disclosed as modulators of androgen receptor functions. Thus, e.g., II was prepared via acetylation of 5,6,7,8-tetrahydronaphthylamine, bromination, cyanation and reduction/oxidation sequence to provide 4-isocyanato-5,6,7,8-tetrahydronaphthalene-1-carbonitrile which was reacted with (2S,3R)-3-hydroxy-2-pyrrolidinecarboxylic acid Me ester trifluoroacetic acid salt. Numerous assays are described for evaluation of I (no data). Also provided are pharmaceutical compns. containing such compds. and processes for preparing some of the compds. of the invention.

L43 ANSWER 24 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:631273 HCPLUS

TITLE: A study of chemical stability of novel, potent inhibitors of DPP-IV

AUTHOR(S): Sitkoff, Doree; Magnin, David; Robl, Jeff; Sulsky, Richard B.; Augeri, David J.; Huang, Yanting; Taunk, Prakash; Betebenner, David A.; Simpkins, Ligaya M.; Robertson, James G.; Khanna, Ashish; Abboia-Offei, Benoni; Wang, Aiying; Cap, Michael; Xing, Li; Tao, Li; Malley, Mary; Gougoutas, Jack Z.; Huang, Qi; Han, Song-Ping; Parker, Rex A.; Hamann, Lawrence G.

CORPORATE SOURCE: Department of Computer Aided Drug Design, Bristol-Myers Squibb Company, Princeton, NJ, 08543-5400, USA

SOURCE: Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), COMP-113. American Chemical Society: Washington, D.C.

CODEN: 69EKY9

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB DPP-IV is a sequence-specific serine protease that catalyzes the cleavage of dipeptides from the N-terminus of proteins with the sequence H-X-Pro-Y or H-X-Ala-Y. Inhibition of the enzyme has shown clin. benefit as a novel mechanism for treatment of type 2 diabetes. Some previously studied

proline-based DPP-IV inhibitors have been shown to be chemically unstable. Here we present two novel methanoproline classes: the cis-4,5-methanoprolinenitrile and the cis-3,4-methanoprolinenitrile dipeptides and show that cis-4,5-methanoprolinenitriles with increased β -branching in the N terminal amino acid provide unique chemical stability and inhibitory potency. The interactions associated with the enhanced chemical stability are probed using computational techniques including quantum chemical calcns.

L43 ANSWER 25 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:236049 HCAPLUS
 DOCUMENT NUMBER: 139:127403
 TITLE: Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents
 AUTHOR(S): Magnin, David R.; Biller, Scott A.; Wetterau, John; Robl, Jeffrey A.; Dickson, John K.; Taunk, Prakash; Harrity, Thomas W.; Lawrence, R. Michael; Sun, C.-Q.; Wang, Tammy; Logan, Janette; Frysztak, Olga; Connolly, Fergal; Jolibois, Kern; Kunschelman, Lori
 CORPORATE SOURCE: Department of Discovery Chemistry and Department of Metabolic Disease, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1337-1340
 CODEN: BMCL8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:127403
 AB A series of newly synthesized phosphonate esters were evaluated for their effects on microsomal triglyceride transfer protein activity (MTP). The most potent compds. were evaluated for their ability to inhibit lipoprotein secretion in HepG2 cells and to affect VLDL secretion in rats. These inhibitors were also found to lower serum cholesterol levels in a hamster model upon oral dosing.
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 26 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:184156 HCAPLUS
 TITLE: Synthesis of novel potent DPP-IV inhibitors with enhanced chemical stability: Interplay between the alkyl fragment of the N-terminal amino acid moiety and the cyclopropyl group of α -aminoacyl-(L)-(cis)-4,5-methanoprolinenitrile-based inhibitors
 AUTHOR(S): Magnin, David; Robl, Jeff; Sulsky, Richard B.; Augieri, David J.; Huang, Yanting; Taunk, Prakash; Betebenner, David A.; Simpkins, Ligaya M.; Robertson, James G.; Khanna, Ashish; Abbo-Offei, Benoni; Wang, Aiying; Cap, Michael; Li, Xing; Li, Tao; Sitkoff, Doree; Malley, Mary; Gougoutas, Jack; Qi, Huang; Han, Song-Ping; Parker, Rex A.; Hamann, Lawrence G.
 CORPORATE SOURCE: Discovery Chemistry, Bristol-Myers Squibb Company, Princeton, NJ, 08543-5400, USA
 SOURCE: Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003 (2003), MEDI-189. American Chemical Society: Washington, D.C.

CODEN: 69DSA4

DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English

AB A series of methanoprolinenitrile-containing dipeptides were synthesized and assayed as inhibitors of dipeptidyl peptidase IV (DPP-IV). DPP-IV is a sequence-specific non-classical serine protease which catalyzes the cleavage of dipeptides from the N-terminus of H-X-Pro-Y or H-X-Ala-Y proteins, and is the principal enzyme responsible for the cleavage of the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 functions as a key mediator of glucose stimulated insulin secretion, and several clin. studies have shown that its administration results in antidiabetic action in subjects with type II diabetes. DPP-IV inhibition with small mols. has shown clin. promise as a novel mechanism for oral antidiabetic therapy through potentiation of GLP-1 levels. Both cis-3,4- and cis-4,5-methanoprolinenitrile dipeptide mimetics demonstrated potent DPP-IV inhibitory activity. In addition, cis-4,5-methanoprolinenitriles with increased beta-branching in the N-terminal aminoacid effectively suppressed prandial glucose elevations after an oral glucose challenge in male Zucker rats, and provided enhanced chemical stability relative to that of many known prolinenitrile-based inhibitors.

L43 ANSWER 27 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:148425 HCPLUS
DOCUMENT NUMBER: 138:304140
TITLE: Palladium-Catalyzed Microwave-Assisted Amination of 1-Bromonaphthalenes and 5- and 8-Bromoquinolines
AUTHOR(S): Wang, Tammy; Magnin, David R.; Hamann, Lawrence G.

CORPORATE SOURCE: Department of Metabolic Diseases Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA

SOURCE: Organic Letters (2003), 5(6), 897-900
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:304140

AB 1-Aminonaphthalenes and 5- and 8-aminoquinolines were readily prepared from the resp. naphthalenyl and quinolinyl bromides in good yields (46-92%) by Pd-catalyzed amination with primary and secondary amines under microwave conditions. Consistent improvements in yields over those obtained under standard conditions were observed with quinoline substrates. Moreover, amination

of 5-bromo-8-cyanoquinoline with a number of amines under standard conditions failed, whereas microwave conditions provided the desired products in good to excellent yields (72-92%).

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 28 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:117794 HCPLUS
DOCUMENT NUMBER: 138:153537
TITLE: Preparation of imidazole-containing heterobicyclic modulators of androgen receptor function
INVENTOR(S): Sun, Chongqing; Robl, Jeffrey A.; Salvati, Mark E.; Wang, Tammy; Hamann, Lawrence; Augeri, David

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:


1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011824	A1	20030213	WO 2002-US24185	20020731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003055094	A1	20030320	US 2002-209461	20020731
US 6670386	B2	20031230		
EP 1414795	A1	20040506	EP 2002-756813	20020731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2004092559	A1	20040513	US 2003-685020	20031014
US 6992102	B2	20060131		
PRIORITY APPLN. INFO.:			US 2001-309059P	P 20010731
			US 2002-209461	A3 20020731
			WO 2002-US24185	W 20020731

OTHER SOURCE(S): MARPAT 138:153537

GI



AB The invention provides imidazole-containing heterobicyclic compds. (shown as I, including all prodrug esters, pharmaceutically acceptable salts and stereoisomers thereof; variables defined below; e.g. tetrahydro-2-(4-nitro-1-naphthalenyl)imidazo[1,5-a]pyridine-1,3(2H,5H)-dione), methods of using such compds. for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and pharmaceutical compns. containing such compds. Pharmacol. assay procedures are described but results for I are not reported. For I: R1 = H, cyano, nitro, halo, heterocyclo, OR4, CO2R5, CONHR5, COR5, S(O)mR5, SO2NR5R5', NHCOR5 and NHSO2R5; R2 = H, alkyl or substituted alkyl, (un)substituted alkenyl, (un)substituted arylalkyl, CO2R5, CONR5R5' and CH2OR5; R3 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, halo, cyano, NHCOR5, NHCO2R5, NHCONR5R5', NHSO2R5 and OR4. R4 = H, (un)substituted alkyl, CHF2, CF3 and COR5; R5 and R5' = H, (un)substituted

alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted heterocycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, (un)substituted heteroaryl and cyano; W = (CR₆R_{6'})_m, CHO_h(CR₆R_{6'})_m and C:NOR₄(CR₆R_{6'})_m. R₆ and R_{6'} = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, halo, cyano, NHCO₂R₅, NHCONR₅R_{5'}, NHSO₂R₅ and OR₄; X = methylene, O, S(O)_m, NCOR₅, NCO₂R₅, NCONHR₅R_{5'}, NSO₂NR₅R_{5'}; Y = O, S and H₂; E = C:Z, CHR₅, SO₂, P(O)R₅ and P(O)OR₅; Z = O, S, NH and NR₅; A and B = H, halo, cyano, nitro, (un)substituted alkyl and OR₄; m = 0-2; and n = 1-2;. Although the methods of preparation are not claimed, 42 example preps. are included.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 29 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:758161 HCPLUS

DOCUMENT NUMBER: 138:60958

TITLE: Preparation and properties of ZSM-5 zeolite membrane obtained by low-temperature chemical vapor deposition

AUTHOR(S): Li, J.; Nguyen, Q. T.; Zhou, L. Z.; Wang, T.; Long, Y. C.; Ping, Z. H.

CORPORATE SOURCE: Department of Chemistry, Fudan University, Shanghai, 200433, Peop. Rep. China

SOURCE: Desalination (2002), 147(1-3), 321-326
CODEN: DSLNAH; ISSN: 0011-9164

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A zeolite membrane was obtained by in situ crystallization of silicalite-1 from a layer of silica species prepared by the novel method of low-temperature chemical

vapor deposition (LTCVD) on a porous cordierite support. The XRD and SEM analyses showed a three-layer membrane: a 3-5 μm-thick compact layer, a 45 μm-thick zeolite-in-pore layer and the support. The pure gas permeation data indicate that the synthesized zeolite layer is dense and pinhole-free. In water-alc. mixture pervaporation, the membrane exhibited a behavior of hydrophilic materials, with a high selectivity to water and a fair flux. This behavior can be explained by the presence of Al in the framework due to Al migration from the support. The membrane flux and selectivity decreased fairly slowly with time in the transient regime of water-ethanol pervaporation with the dry membrane, suggesting slow sorption equilibrium of water and ethanol with the dry zeolite.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 30 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:618068 HCPLUS

TITLE: De novo design and synthesis of growth hormone secretagogues: Potent, orally active heterocyclic-linked peptidomimetics

AUTHOR(S): Tino, Joseph A.; Hernandez, Andres; Chen, Stephanine; Li, James; Li, Jun; Musial, Christa; Swartz, Steve; Qu, Fucheng; Wang, Haixia; Robl, Jeff; George, Rocco; Grover, Gary; Seethala, R. Krishna; Slep, Paul; Slusarchyk, Dorothy; Smith, Mark A.; Yan, Mujing; Gordon, David; Harper, Tim; Zhang, Hongjian; Humphreys, Griff; Dickinson, Ken; Giupponi, Leah;

CORPORATE SOURCE: Stouch, Terry
 Discovery Chemistry, Bristol-Myers Squibb Company,
 Princeton, NJ, 08543-5400, USA

SOURCE: Abstracts of Papers, 224th ACS National Meeting,
 Boston, MA, United States, August 18-22, 2002 (2002),
 MEDI-216. American Chemical Society: Washington, D.
 C.

CODEN: 69CZPZ

DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB A significant factor leading to functional disabilities of the aged is the decline and eventual loss of musculoskeletal integrity. While there is no accepted therapy to prevent this decline, growth hormone (GH) replacement has shown promise in preliminary clin. trials. However, GH has significant drawbacks including parenteral administration and side effects. Growth Hormone Secretagogues (GHS), a class of orally active small mols., interact with the G-protein coupled receptor for ghrelin found in the hypothalamus and the pituitary, restoring the youthful pulsatile release of GH in the elderly without side effects. Several novel heterocyclic linked peptidomimetics were developed through de novo design. One series investigated was based on a tetrazole scaffold. Early members showed moderate GHS activity in vitro and in vivo. Employing mol. modeling techniques, analogs were designed with improved in vitro potency. The synthesis and SAR of analogs with improved physicochem. properties that led to in vivo activity will be discussed.

L43 ANSWER 31 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:540258 HCAPLUS

DOCUMENT NUMBER: 137:109267

TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094977	A1	20020718	US 2001-7407	20011204
US 6627636	B2	20030930		
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	A2 20010606

OTHER SOURCE(S): MARPAT 137:109267
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃

= H, alkyl, metal ion; R4 = H, halo, CF₃, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxy carbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

L43 ANSWER 32 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:392237 HCAPLUS
 DOCUMENT NUMBER: 136:401651
 TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061901	A1	20020523	US 2001-8154	20011204
US 6620821	B2	20030916		
US 2002028826	A1	20020307	US 2001-875218	20010606
US 2004024216	A1	20040205	US 2003-602753	20030624
PRIORITY APPLN. INFO.:			US 2000-211594P	P 20000615
			US 2001-875218	A2 20010606
			US 2001-8154	A3 20011204

OTHER SOURCE(S): MARPAT 136:401651
 GI



AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH₂CR₇(OH)CH₂CO₂R₃ or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one

of x and y is other than 0; and optionally one or more carbons of $(CH_2)^x$ and/or $(CH_2)^y$ together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF₃, OH, alkyl, alkoxy, CO₂H, (un)substituted NH₂, cyano, (un)substituted CONH₂, etc.; R7 = H, alkyl]. The compds. are HMG-CoA reductase inhibitors, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Preps. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as inhibitors of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

L43 ANSWER 33 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:97548 HCPLUS
 DOCUMENT NUMBER: 137:93700
 TITLE: A general synthesis of dioxolenone prodrug moieties
 AUTHOR(S): Sun, Chong-Qing; Cheng, Peter T. W.; Stevenson, Jay; Dejneka, Tamara; Brown, Baerbel; Wang, Tammy C.; Robl, Jeffrey A.; Poss, Michael A.
 CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
 SOURCE: Tetrahedron Letters (2002), 43(7), 1161-1164
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:93700
 AB A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted β -ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcs. or bromides. Coupling of the bromides to prepare bis-dioxolenone phosphonate prodrug esters is also presented.
 REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L43 ANSWER 34 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:923807 HCPLUS
 DOCUMENT NUMBER: 136:37587
 TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2001096347	A1	20011220	WO 2001-US18864	20010612
W:	AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, RO, RU, SD, SE, SG, SI, SK, UZ, VN, YU, ZA, ZW, AM, AZ, GH, GM, KE, LS, MW, MZ, SD, DE, DK, ES, FI, FR, GB, GR, BJ, CF, CG, CI, CM, GA, GN,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, EC, EE, ES, FI, GB, GD, GE, GH, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, SL, TJ, TM, TR, TT, TZ, UA, UG, US, BY, KG, KZ, MD, RU, TJ, TM		
RW:	GH, GM, KE, LS, MW, MZ, SD, DE, DK, ES, FI, FR, GB, GR, BJ, CF, CG, CI, CM, GA, GN,	SL, SZ, TZ, UG, ZW, IE, IT, LU, MC, NL, GW, ML, MR, NE, SN,	AT, BE, CH, CY, PT, SE, TR, BF, TD, TG	
CA 2412632	AA	20011220	CA 2001-2412632	20010612
EP 1294728	A1	20030326	EP 2001-944447	20010612
R:	AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK,	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR		
JP 2004503557	T2	20040205	JP 2002-510488	20010612
BR 2001011599	A	20041013	BR 2001-11599	20010612
NZ 523627	A	20041029	NZ 2001-523627	20010612
ZA 2002010103	A	20040312	ZA 2002-10103	20021212
NO 2002006012	A	20030203	NO 2002-6012	20021213
RITY APPLN. INFO.:			US 2000-211595P	P 20000615
			WO 2001-US18864	W 20010612

OTHER SOURCE(S) : MARPAT 136:37587

GI



AB The title compds. I [X = O, S; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl; n = 0, 1; R₁ and R₂ are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; R₃ = H, alkyl; R₄ = H, halo, CF₃, etc.; R₉, R₁₀ = H, alkyl], HMG CoA reductase inhibitors and active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis, were prepared E.g., a multistep synthesis of II is reported.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 3 ANSWER 35 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:923772 HCAPLUS


DOCUMENT NUMBER: 136:37525

TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096311	A2	20011220	WO 2001-US18868	20010612
WO 2001096311	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412979	AA	20011220	CA 2001-2412979	20010612
EP 1294696	A2	20030326	EP 2001-944449	20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011571	A	20030701	BR 2001-11571	20010612
JP 2004503541	T2	20040205	JP 2002-510454	20010612
ZA 2002010102	A	20040312	ZA 2002-10102	20021212
NO 2002006011	A	20030212	NO 2002-6011	20021213
PRIORITY APPLN. INFO.:			US 2000-211594P	P 20000615
			WO 2001-US18868	W 20010612

OTHER SOURCE(S) : MARPAT 136:37525
GI



AB The title compds. I [$Z = HOCHCH_2CR_7(OH)CH_2CO_2R_3$, 2-pyranyl derivs.; $n = 0, 1; x = 0, 1, 2, 3$ or $4; yr = 0, 1, 2, 3$ or 4 , provided that at least one of x and y is other than 0 ; and optionally one or more carbons of $(CH_2)_x$ and/or $(CH_2)_y$ together with addnl. carbons form a 3 to 7 membered spirocyclic ring; $R_1, R_2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R_3 = H$ or lower alkyl],

HMG CoA reductase inhibitors and active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis, were prepared E.g. a multistep synthesis of fused pyridine derivative II is reported.

L43 ANSWER 36 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:693281 HCAPLUS

DOCUMENT NUMBER: 135:257147

TITLE: Preparation of fused cyclopropylpyrrolidine-based inhibitors of dipeptidyl peptidase IV

INVENTOR(S): Robl, Jeffrey A.; Sulsky, Richard B.;

Augeri, David J.; Magnin, David R.;

Hamann, Lawrence G.; Betebenner, David A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068603	A2	20010920	WO 2001-US7151	20010305
WO 2001068603	A3	20020214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002019411	A1	20020214	US 2001-788173	20010216
US 6395767	B2	20020528		
CA 2402894	AA	20010920	CA 2001-2402894	20010305
EP 1261586	A2	20021204	EP 2001-918383	20010305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531118	T2	20031021	JP 2001-567699	20010305
BR 2001009115	A	20031230	BR 2001-9115	20010305
NZ 520821	A	20041126	NZ 2001-520821	20010305
EP 1559710	A2	20050803	EP 2005-5368	20010305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
ZA 2002006816	A	20031126	ZA 2002-6816	20020826
NO 2002004295	A	20021106	NO 2002-4295	20020909
PRIORITY APPLN. INFO.:			US 2000-188555P	P 20000310
			EP 2001-918383	A3 20010305
			WO 2001-US7151	W 20010305

OTHER SOURCE(S): MARPAT 135:257147

GI



AB Dipeptidyl peptidase IV inhibiting compds. I ($x = 0$ or 1 and $y = 0$ or 1 provided that $x = 1$ when $y = 0$ and $x = 0$ when $y = 1$; $n = 0, 1$; $X = H, CN$; $R1, R2, R3$ and $R4$ = same or different and independently selected from H , (un)substituted chain or cyclic components) and the pharmaceutically acceptable salts or prodrugs (no data) were prepared. Thus L-pyroglutamic acid Et ester was protected, cyclopropanated and reacted further with (S)-N-BOC-isoleucine providing an intermediate II which reacted further to yield the fused cyclopropanopyrrolidine III in 57% yield. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases by employing a title DP 4 inhibitor or a combination of DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

L43 ANSWER 37 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:124741 HCAPLUS

DOCUMENT NUMBER: 134:304970

TITLE: A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors

AUTHOR(S): Robl, Jeffrey A.; Sulsky, Richard; Sun, Chong-Qing; Simpkins, Ligaya M.; Wang, Tammy; Dickson, John K., Jr.; Chen, Ying; Magnin, David R.; Taunk, Prakash; Slusarchyk, William A.; Biller, Scott A.; Lan, Shih-Jung; Connolly, Fergal; Kunselman, Lori K.; Sabrah, Talal; Jamil, Haris; Gordon, David; Harrity, Thomas W.; Wetterau, John R.

CORPORATE SOURCE: The Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(6), 851-856
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of benzimidazole-based analogs of the potent MTP inhibitor BMS-201038 were discovered. Incorporation of an unsubstituted benzimidazole moiety in place of a piperidine group afforded potent inhibitors of MTP in vitro which were weakly active in vivo. Appropriate


substitution on the benzimidazole ring, especially with small alkyl groups, led to dramatic increases in potency, both in a cellular assay of apoB secretion and especially in animal models of cholesterol lowering. The most potent in this series, BMS-212122, was significantly more potent than BMS-201038 in reducing plasma lipids (cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 38 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:666562 HCAPLUS
 DOCUMENT NUMBER: 133:252748
 TITLE: Preparation of methylalanyl-O-benzyltyrosine derivatives as growth hormone production and/or release stimulants
 INVENTOR(S): Robl, Jeffrey; Tino, Joseph A.; Hernandez, Andres S.; Li, James J.; Li, Jun; Swartz, Stephen G.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 205 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000054729	A2	20000921	WO 2000-US5704	20000302
WO 2000054729	A3	20010111		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367461	AA	20000921	CA 2000-2367461	20000302
EP 1175213	A2	20020130	EP 2000-913733	20000302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102780	T2	20020821	TR 2001-200102780	20000302
BR 2000008937	A	20020924	BR 2000-8937	20000302
JP 2002539141	T2	20021119	JP 2000-604808	20000302
EE 200100479	A	20021216	EE 2001-479	20000302
ZA 2001006854	A	20021120	ZA 2001-6854	20010820
BG 105843	A	20020531	BG 2001-105843	20010824
LT 4958	B	20021025	LT 2001-87	20010824
LV 12752	B	20031020	LV 2001-132	20010906
NO 2001004407	A	20011108	NO 2001-4407	20010911
PRIORITY APPLN. INFO.:			US 1999-124131P	P 19990312
			US 1999-154919P	P 19990921
			WO 2000-US5704	W 20000302

OTHER SOURCE(S): MARPAT 133:252748
 GI



AB R1R1aCXaNR6COYXb [R1 = (un)substituted alkyl, (hetero)aryl(alkyl), etc.; R1a = H or (cyclo)alkyl; R6 = H, (cyclo)alkyl, alkenyl, aryl; Xa = (un)substituted heteroaryl; Xb = (di)(alkyl)amino, (un)substituted imidazolyl, etc.; Y = phenylene, (phenylene-interrupted)alkylene, alkenylene, etc.] were prepared as growth hormone production and/or release stimulants (no data). Thus, (R)-PhCH2OCH2CH(NHCO2CMe3)CO2H was amidated by H2N(CH2)3CO2Me and the product cyclocondensed with Me3SiN3 to give, after deprotection, O-benzyltyrosine derivative I (R = H, R2 = OMe) which was amidated by BocNHCM2CO2H to give, in 3 addnl. steps, I.CF3CO2H (R = COCMe2NH2, R2 = NHCH2CH2R3, R3 = 3-indolyl).

L43 ANSWER 39 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:637441 HCPLUS

DOCUMENT NUMBER: 133:363213

TITLE: The aggregation and phase separation behavior of a hydrophobically modified poly(N-isopropylacrylamide)

AUTHOR(S): Shi, X.; Li, J.; Sun, C.; Wu, S.

CORPORATE SOURCE: Institute of Photographic Chemistry, Chinese Academy of Sciences, Beijing, 100101, Peop. Rep. China

SOURCE: Colloids and Surfaces, A: Physicochemical and Engineering Aspects (2000), 175(1-2), 41-49

CODEN: CPEAEH; ISSN: 0927-7757

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To study the water solution properties of a hydrophobically modified poly(N-isopropylacrylamide) (PNIPAM) that is temperature-sensitive, the copolymer of N-isopropylacrylamide (NIPAM) and octadecyl acrylate (ODA) was synthesized. The aggregation behavior of the copolymer was studied by surface tension and fluorescent probe methods. Simultaneously, the phenomenon of LCST (Lower Critical Solution Temperature) of the copolymer in aqueous solution

with the increase of temperature was also studied by using the fluorescent probe



method. Results showed that phase separation occurred in aqueous solution of the

copolymer when the temperature was increased to its LCST. The π -A isotherms for the copolymer mols., as an insol. monolayer on the water-air interface, was determined by the Langmuir-Blodgett method. The abnormal phenomenon, which the monolayer of the copolymer mols. became more condensed and more condensed with the increase of temperature, was observed. It further indicated that phase separation of the copolymer occurred from another angle. In addition, to prove the thermo-sensitive effect of the copolymer on the release behavior of liposomes, small unilamellar vesicles entrapped with 5(6)-carboxyfluorescein (5(6)-CF) were coated with the copolymer. We found that the coating of the copolymer resulted in reduction of the release below 30°C and enhancement of the release above 30°C. It indicates that there are obvious interactions between the copolymer and liposomes.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L43 ANSWER 40 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:146885 HCAPLUS
 DOCUMENT NUMBER: 132:347877
 TITLE: N-formyl hydroxylamine containing dipeptides:
 generation of a new class of vasopeptidase inhibitors
 AUTHOR(S): Robl, Jeffrey A.; Simpkins, Ligaya
 M.; Asaad, Magdi M.
 CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research
 Institute, Princeton, NJ, 08543-5400, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2000),
 10(3), 257-260
 CODEN: BMCL8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Four primary zinc-binding pharmacophores (thiols, carboxylates, phosphorus acids, and hydroxamates) were used to generate inhibitors of Zn metalloproteases such as ACE, NEP, the MMPs, and ECE. Although compds. which inhibit the activity of both ACE and NEP (vasopeptidase inhibitors, VPIs) have been reported which incorporate a thiol, carboxylate, or phosphorus acid pharmacophore, the generation of hydroxamate based vasopeptidase inhibitors has remained elusive. The first potent vasopeptidase inhibitors, which were generated from the incorporation of conformationally restricted dipeptide mimetics to an N-formyl hydroxylamine Zn-binding group, have been prepared Compds. such as the aminobenzopyridoazepincarboxylate I and the aminobenzazepincarboxylate II are among the most potent in this series, exhibiting in vitro activity comparable to other classes of inhibitors.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:8653 HCAPLUS
 DOCUMENT NUMBER: 130:168634
 TITLE: Vasopeptidase Inhibitors: Incorporation of Geminal and Spirocyclic Substituted Azepinones in Mercaptoacyl Dipeptides
 AUTHOR(S): Robl, Jeffrey A.; Sulsky, Richard; Sieber-McMaster, Ellen; Ryono, Denis E.; Cimarusti, Maria P.; Simpkins, Ligaya M.; Karanewsky, Donald S.; Chao, Sam; Asaad, Magdi M.; Seymour, Andrea A.; Fox, Maxine; Smith, Patricia L.; Trippodo, Nick C.
 CORPORATE SOURCE: The Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
 SOURCE: Journal of Medicinal Chemistry (1999), 42(2), 305-311
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A series of 7-(di)alkyl and spirocyclic substituted azepinones I [R1 = H, R2 = H, Me; R1 = Me, R2 = H, Me; R1R2 = CH2CH2, (CH2)3, (CH2)4] were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipeptides. Clear structure-activity relationships with respect to both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) activity in vitro were observed. Dimethylated azepinone I (R1 = R2 = Me) was the best in this series, and demonstrated excellent blood pressure lowering in animal models. Compound I (R1 = R2 = Me) (BMS-189921) is characterized by a good duration of activity and excellent oral efficacy in models relevant to ACE or NEP inhibition, and its activity is comparable to that of the clin. efficacious agent omapatrilat. Consequently this inhibitor has been advanced clin. for the treatment of hypertension and congestive heart failure.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 42 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:698031 HCAPLUS
 DOCUMENT NUMBER: 130:76043
 TITLE: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
 AUTHOR(S): Wetterau, John R.; Gregg, Richard E.; Harrity, Thomas W.; Arbeeny, Cynthia; Cap, Michael; Connolly, Fergal; Chu, Ching-Hsuen; George, Rocco J.; Gordon, David A.; Jamil, Haris; Jolibois, Kern G.; Kinselman, Lori K.; Lan, Shih-Jung; Maccagnan, Thomas J.; Ricci, Beverly; Yan, Mujing; Young, Douglas; Chen, Ying; Fryszman, Olga M.; Logan, Janette V. H.; Musial, Christa L.; Poss, Michael A.; Robl, Jeffrey A.; Simpkins, Ligaya M.; Slusarchyk, William A.;


Sulsky, Richard; Taunk, Prakash; Magnin, David R.;
 Tino, Joseph A.; Lawrence, R. Michael; Dickson, John
 K., Jr.; Biller, Scott A.

CORPORATE SOURCE:
 Dep. Metabolic Diseases, Bristol-Myers Squibb
 Pharmaceutical Res. Inst., Princeton, NJ, 08543-4000,
 USA

SOURCE:
 Science (Washington, D. C.) (1998), 282(5389), 751-754
 CODEN: SCIEAS; ISSN: 0036-8075

PUBLISHER:
 American Association for the Advancement of Science
 DOCUMENT TYPE:
 Journal
 LANGUAGE:
 English

GI



AB Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B-containing lipoproteins. It was hypothesized that small mol. inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compds. identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This mol. (I) inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia. These results suggest that compound I, or derivs. thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 43 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:310078 HCPLUS

DOCUMENT NUMBER: 126:338635

TITLE: Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase

AUTHOR(S): Robl, Jeffrey A.; Sun, Chong-Qing;
 Stevenson, Jay; Ryono, Denis E.; Simpkins, Ligaya
 M.; Cimarusti, Maria P.; Dejneka, Tamara;
 Slusarchyk, William A.; Chao, Sam; Stratton, Leslie;
 Misra, Raj N.; Bednarz, Mark S.; Asaad, Magdi M.;
 Cheung, Hong Son; Abboa-Offei, Benoni E.; Smith,
 Patricia L.; Mathers, Parker D.; Fox, Maxine;

Schaeffer, Thomas R.; Seymour, Andrea A.; Trippodo,
Nick C.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research

Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Journal of Medicinal Chemistry (1997), 40(11),
1570-1577

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of 7,6- and 7,5-fused bicyclic thiazepinones and oxazepinones were generated and incorporated as conformationally restricted dipeptide surrogates in mercaptoacyl dipeptides. These compds. are potent inhibitors of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo. Compound 1a, a 7,6-fused bicyclic thiazepinone, demonstrated excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiated urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. On the basis of its potency and duration of action, compound 1a (BMS-186716) was advanced into clin. development for the treatment of hypertension and congestive heart failure.

L43 ANSWER 44 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:53720 HCAPLUS

DOCUMENT NUMBER: 126:74877

TITLE: Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP.

INVENTOR(S): Robl, Jeffrey A.; Sun, Chong-Qing

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: Eur. Pat. Appl., 43 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 743319	A1	19961120	EP 1996-107787	19960515
EP 743319	B1	20000906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5877313	A	19990302	US 1995-443278	19950517
CA 2176415	AA	19961118	CA 1996-2176415	19960513
AT 196149	E	20000915	AT 1996-107787	19960515
ES 2150613	T3	20001201	ES 1996-107787	19960515
PT 743319	T	20001229	PT 1996-107787	19960515
AU 9652302	A1	19961128	AU 1996-52302	19960516
AU 695929	B2	19980827		
JP 08325152	A2	19961210	JP 1996-123228	19960517
US 6235922	B1	20010522	US 1998-205316	19981204
GR 3034834	T3	20010228	GR 2000-402522	20001113
PRIORITY APPLN. INFO.:			US 1995-443278	A 19950517
OTHER SOURCE(S):	MARPAT	126:74877		
GI				



AB Compds. I and their pharmaceutically acceptable salts are disclosed [wherein Y₁, Y₂ = H, alkyl, aryl, halo, or alkoxy; X = O or S(O)_t; A = various acyl and other sidechains containing carbonyl, S, and/or P(:O), etc.; t = 0-2; m, n = 0-1; R = H, (un)substituted alkyl or aralkyl, etc.]. I include dual inhibitors of ACE and NEP, and selective ACE inhibitors (no data). For example, the intermediate II was prepared in 11 steps, then cyclized with CF₃CO₂H in CH₂Cl₂ (81.8%), deprotected with Me₃SiI (15%), and amidated with (S)-α-(acetylthio)benzenepropanoic acid using BOP reagent (84%), to give title compound III.

L43 ANSWER 45 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:6866 HCPLUS

DOCUMENT NUMBER: 124:45213

TITLE: Dual metalloprotease inhibitors. 6. incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme (ACE)/neutral endopeptidase (NEP) inhibitors

AUTHOR(S): Robl, Jeffrey A.; Cimarusti, Maria P.; Simpkins, Ligaya M.; Brown, Baerbel; Ryono, Denis E.; Bird, J. Eileen; Asaad, Magdi M.; Schaeffer, Thomas R.; Trippodo, Nick C.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(2), 494-502

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:45213

GI



AB A series of substituted monocyclic and bicyclic azepinones were incorporated as dipeptide surrogates in mercaptoacetyl dipeptides with the desire to generate a single compound which would potently inhibit both ACE and NEP. Many of these compds. displayed excellent potency against both enzymes. Two of the most potent compds., monocyclic azepinone I and bicyclic azepinone II, demonstrated a high level of activity vs. ACE and NEP both in vitro and in vivo.

L43 ANSWER 46 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:924328 HCAPLUS

TITLE: Dual ACE/NEP inhibitors: Synthesis and activity of mercaptoacetyl dipeptides containing conformationally restricted dipeptide surrogates.

AUTHOR(S): Simpkins, L. M.; Robl, J. A.; Cimarusti, M. P.; Ryono, D. E.; Stevenson, J.; Sun, C -Q.; Petrillo, E. W.; Karanewsky, D. S.; Asaad, M. M.; et al.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SOURCE: Book of Abstracts, 210th ACS National Meeting, Chicago, IL, August 20-24 (1995), Issue Pt. 2, MEDI-064. American Chemical Society: Washington, D. C.

CODEN: 61XGAC DOCUMENT TYPE: Conference; Meeting Abstract

LANGUAGE: English

AB Association of the hypotensive effects resulting from inhibition of angiotensin-converting enzyme (ACE) in conjunction with the diuretic and natriuretic responses due to protection of the endogenous atrial natriuretic peptide (ANP) from inhibition of neutral endopeptidase (NEP) is of current therapeutic interest in the treatment of cardiovascular diseases. Towards this goal we describe the utilization of conformationally restricted dipeptide surrogates in the generation of novel mercaptoacetyl containing ACE/NEP inhibitors. Our efforts have concentrated on

the incorporation of diversely substituted (benzo-fused, mono & bicyclic, heteroatom substituted) lactams as replacements for conventional proteinogenic dipeptides. A systematic study of analogs was undertaken to establish detailed SAR's for inhibition of both ACE and NEP in vitro and in vivo.

L43 ANSWER 47 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:137711 HCAPLUS

DOCUMENT NUMBER: 122:150815

TITLE: Dual metalloprotease inhibitors. IV. Utilization of thiazepines and thiazines as constrained peptidomimetic surrogates in mercaptoacetyl dipeptides

AUTHOR(S): Das, Jagabandhu; Robl, Jeffrey A.; Reid,

Joyce A.; Sun, Chong-Qing; Misra, Raj N.;
 Brown, Baerbel R.; Ryono, Denis E.; Asaad, Magdi M.;
 Bird, J. Eileen; et al.

CORPORATE SOURCE: Bristol-Myers Squibb Pharm. Res. Inst., Princeton, NJ,
 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1994),
 4(18), 2193-8

CODEN: BMCL8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A structure-activity study of the dual acting ACE/NEP inhibitors related
 to 1a and 1b was undertaken to determine the parameters critical for activity
 vs ACE and NEP in vitro.

L43 ANSWER 48 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:63818 HCPLUS

DOCUMENT NUMBER: 123:112024

TITLE: Dual metalloprotease inhibitors. III. Utilization of
 bicyclic and monocyclic diazepinone based
 mercaptoacetyls


AUTHOR(S): Robl, Jeffrey A.; Sun, Chong-Qing;
 Simpkins, Ligaya M.; Ryono, Denis E.; Barrish,
 Joel C.; Karanewsky, Donald S.; Asaad, Magdi M.;
 Schaeffer, Thomas R.; Trippodo, Nick C.

CORPORATE SOURCE: Bristol-Myers Squibb Pharm. Res. Inst., Princeton, NJ,
 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1994),
 4(16), 2045-8

DOCUMENT TYPE: Journal
 LANGUAGE: English

GI



AB Diazepinones I [X = O, H2; R = H, Me, Pr, R1 = H; RR1 = (CH2)n; n = 2, 3] were prepared as conformationally restricted dipeptide surrogates in mercaptoacetyl dipeptide dual-acting ACE/NEP inhibitors. A comparison was made between I as well as with the previously disclosed benzazepine analog. I [X = H2, RR1 = (CH2)3] exhibited high potency vs. both enzymes in vitro as well as in vivo.

L43 ANSWER 49 OF 52 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:44912 HCPLUS

DOCUMENT NUMBER: 122:23197

TITLE: Dual metalloprotease inhibitors. II. Effect of

AUTHOR(S) : substitution and stereochemistry on benzazepinone based mercaptoacetyl

Robl, Jeffrey A.; Simpkins, Ligaya M.; Sulsky, Richard; Sieber-McMaster, Ellen; Stevenson, Jay; Kelly, Yolanda F.; Sun, Chong-Qing; Misra, Raj N.; Ryono, Denis E.; et al.

CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ, 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(15), 1795-800
CODEN: BMCL8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A structure-activity study of dual-acting ACE/NEP inhibitor 1A was initiated in order to ascertain what parameters effect in vitro activity vs. ACE and NEP. Unlike NEP, ACE was found to be remarkably tolerant to a wide variety of permutations with respect to both the lactam nucleus and the pharmacophore side chain.

L43 ANSWER 50 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:44911 HCAPLUS

DOCUMENT NUMBER: 122:133775

TITLE: Dual metalloprotease inhibitors. I. Constrained peptidomimetics of mercaptoacyl dipeptides

AUTHOR(S) : **Robl, Jeffrey A.; Simpkins, Ligaya M.; Stevenson, Jay; Sun, Chong-Qing; Murugesan, Natesan; Barrish, Joel C.; Asaad. Magdi M.; Bird, J. Eileen; Schaeffer, Thomas R.; et al.**



CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ, 08543-4000, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(15), 1789-94
CODEN: BMCL8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



AB A series of benzo-fused lactams I ($R, R1 = H, Me$, $X = CH_2, O, S$, $m = 1, 2$) were incorporated as conformationally restricted dipeptide mimetics of Ala-Pro in dual-acting ACE (angiotensin converting enzyme)/NEP (neutral endopeptidase) inhibitors II ($n = 0, 1$). The result of this modification led to compds. possessing excellent inhibitory potency vs. ACE and NEP both in vitro and in vivo.


L43 ANSWER 51 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:324187 HCAPLUS
 DOCUMENT NUMBER: 120:324187
 TITLE: Peptidomimetic Synthesis: A Novel, Highly Stereoselective Route to Substituted Freidinger Lactams
 AUTHOR(S): Robl, Jeffrey A.; Cimarusti, Maria P.; Simpkins, Ligaya M.; Weller, Harold N.; Pan, Yolanda Y.; Malley, Mary; DiMarco, John D.
 CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
 SOURCE: Journal of the American Chemical Society (1994), 116(6), 2348-55
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:324187
 GI



AB New methodol. for the synthesis of substituted seven-membered lactams, e.g. I (R = H, allyl, cyclohexyl, R1 = H, Me, CH2Ph, CHMe2, PhtN = phthalimido), has been developed. This method allows for the stereoselective introduction of substituents R at the C-7 position of the azepinone ring as well as substituents R1 α to the acetic acid side chain. Dehydrative cyclization of dipeptidyl aldehydes e.g. OHC(CH2)4CH(PhtN)CONHCHR1CO2Et, affords the corresponding bicyclic fused lactams II in good yield and high stereoselectivity. Lewis acid catalyzed reduction of II with triethylsilane provides azepinones I (R = H) in homochiral form. Introduction of substituents at the C-7 position was effected by treatment of II with various alkyl nucleophiles. The resulting azepinones may be viewed as conformationally restricted peptidomimetic surrogates.

L43 ANSWER 52 OF 52 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:631537 HCAPLUS
 DOCUMENT NUMBER: 113:231537
 TITLE: Phosphorus-containing inhibitors of HMG-CoA reductase. I. 4-[(2-Arylethyl)hydroxyphosphinyl]-3-hydroxybutanoic acids: a new class of cell selective inhibitors of cholesterol biosynthesis
 AUTHOR(S): Karanewsky, Donald S.; Badia, Michael C.; Ciasek, Carl P., Jr.; Robl, Jeffrey A.; Sofia, Michael J.; Simpkins, Ligaya M.; DeLange, Barbara; Harrity, Thomas W.; Biller, Scott A.; Gordon, Eric M.
 CORPORATE SOURCE: Bristol-Myers Squibb Pharm. Res. Inst., Princeton, NJ, 08543-4000, USA
 SOURCE: Journal of Medicinal Chemistry (1990), 33(11), 2952-6
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A series of 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxybutanoic acids (I) such as II and III [R¹ = H, Me; R² = Me, Et, Me₂CH; p-FC₆H₄; XY = CH₂O, CH₂NH, CH₂CH₂, CH:CH, C.tplbond.C, CH₂, (CH₂)₃, OCH₂] were synthesized and evaluated in vitro and in vivo as inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase). By analogy to the enzymic reaction mechanism for HMG-CoA reduction, the hydroxyphosphinyl function of inhibitors I was proposed to interact with the protonated form of the catalytic group which normally serves to activate substrate carbonyl groups toward reduction. The most potent inhibitors were phosphinic acid analogs in which X-Y in II and III is CH₂CH₂, (E)-CH:CH or C.tplbond.C and R² was Me₂CH. These compds. exceeded the inhibitory potency of the fungal metabolites pravastatin and lovastatin. Testing of I as inhibitors of cholesterol biosynthesis from ¹⁴C-acetate in whole cells, revealed a high degree of selectivity for hepatic cells compared to other cell types. Thus, I were 50-1200 fold more potent as inhibitors of cholesterol biosynthesis in isolated rat hepatocytes than in human skin fibroblasts.

=>

THIS PAGE BLANK (USPTO)